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Aims of the Project. 
In July 1987 discussions between Hare field Hospital and Loughborough University 
led to the establishment of a project to investigate the development of a novel 
fluorescence immunoassay for the immunosuppressant drug cyclosporin A At this 
time cyclosporin levels in transplant patients were routinely monitored by 
radioimmunoassay, however, with increasing numbers of patients surviving, all of 
whom require monitoring for the rest of their lives, routine assays were becoming 
extremely time consuming and dependent on a rising number of skilled operators. 
It was therefore decided to investigate the development of a cheap, simple assay 
operated by unskilled staff and with the potential to be used in locations remote 
from transplant centres. 
A number of aims were established for the project: 
1. To overcome the environmental and safety hazards of using isotopes, new 
fluorescent derivatives of cyclosporin should be synthesised for use in 
immunoassay. 
2. The immunoreactivity of the derivatives should be evaluated with currently 
used polyclonal antibodies and monoclonal antibodies when available. 
3. Investigate the development of a fluorescence based flow injection 
immunoassay for cyclosporin capable of being fully automated. 
4. Investigate the potential of a solid surface "dip stick" immunoassay for 
cyclosporin. 
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ABSTRACT 
FLUORESCENCE IMMUNOASSAY FOR CYCLOSPORIN A 
Monodansylcadavarine (MDC) was used to synthesise a fluorescent derivative of cyclosporin A and 
the product of the reaction was Isolated by preparative thin layer chromatography (TLC) and 
purified by high performance hqmd chromatography (HPLC). The fluorescent derivative was shown 
to bind with a polyclonal antibody to cyclosponn A by submitting the derivative for analysis by 
cyclosporin radioimmunoassay (RIA). However this derivative <hd not bind with a monoclonal 
antibody used in a RIA speCific for the parent compound. To achieve this fluorescent derivatives 
were synthesised using cyclosporin-C-hemisuccmate as the staring material with MDC, 4-
bromomethyl-7-methoxycoumarin (BMMC), 4-bromomethyl-6,7-dimethoxycoumarin (BMDC) and 
tetramethyl rhodaminecadavarme (TRC) as the labels. All derivatives were isolated and purified by 
TLC and HPLC and shown to have antibody binding in the parent compound specific RIA. The 
fluorescent properties of the derivatives were investigated and the most promising, BMMC and TRC 
used in the immunoassay development 
Initial assay development work was carried using a Sephadex G-25 column to separate the antibody 
bound from the free denvative. Using th1s method •t was possible to show that both BMMC and 
TRC are capable of being used in an immunoassay and that once antibody bound they show some 
quenching of fluorescence, whilst their emission profiles remain unaltered and neither show any 
polarisation effects. Because of the lower background noise encountered at longer wavelengths TRC 
was chosen as the derivative for use m further assay development. 
A microreactor containing protein A coupled to controlled pore glass beads was used to replace the 
Sephadex column in a flow inject1on system incorporating a fixed volume loop for introducmg the 
incubation mixture onto the column. Inclusion of unlabelled cyclosporin A in the incubation mixture 
was shown to reduce the amount of TRC bound to the antibody and by using a number of standards 
of known concentration a cahbration curve was established. Optimisation of the assay over the range 
0-1500 ngfml was ach1eved by determining the appropriate values for the incubation time, reagent 
concentrations and the flow rate through the column for binding and elution. 
xii 
CHAPTER ONE 
THE CYCLOSPORINS 
1. The cyclosporins 
1.1 Immunosuppression 
1.1.1 Historical background 
A variety of immunosuppression agents have evolved to control 
transplant rejection, beginning with the physical methods of total body 
(Taliaferro et al., 1964) and more recently total lymphoid (Kaplan 1980) 
irradiation, or thoracic duct drainage (Newton 1965). The introduction 
of chemical agents such as azathioprine (Calne et al., 1962) and 
cyclophosphamide (Starzl et al., 1971), particularly in combination with 
prednisone (Marchioro et al., 1964) and/or polyclonal antilymphocyte 
sera or monoclonal anti-T cell antibodies (Cosimi 1981) enabled 
greater control over rejection episodes. However, in general these 
agents display a lack of specificity causing depression not only of 
multiple organ systems, but also of nonspecific elements such as 
polymorphonuclear leucocytes and macrophages and specific 
immunological responses. 
Although no clinical agent to date has achieved selective inhibition of 
the response towards donor histocompatibility antigens in the fashion 
of neonatal tolerance (Billingham et al., 1953) major' progress has been 
made in transplantation therapy with the introduction of the fungal 
metabolite cyclosporin A 
1.1.2 The development of immunosuppression 
The tissue cells of animals exhibit antigens that are specific for the 
species of origin and will if implanted into an animal of another 
species induce an immune response. The result is the rapid destruction 
1 
of the implanted tissue by mechanisms characteristic of the primary 
and secondary immune response. The transfer of tissue cells between 
members of the same species induces a similar response. However, the 
closer the genetic relationship between individuals the more likely are 
implanted cells to survive, as was demonstrated by the first successful 
kidney transplant, (Merrill et al, 1956) whilst with identical twins 
survival is assured 
The basis for the rejection process was established with the discovery 
of the HLA system of tissue histocompatibility antigens which led to 
the conclusion that there is a correlation between the degree of 
compatibility between two individuals in the HLA system and the 
speed and severity of rejection of tissue transplanted between them. 
The histocompatibility antigens of the HLA system are widely 
distributed in the tissue, but are absent from red blood cells. However, 
leucocytes carry all of the known HLA antigens and it is therefore 
possible to use an agglutination test for the presence or absence of 
particular antigens by incubating specific antisera for HLA antigens 
with leucocytes, if the antigen is present agglutination will be visible 
using a microscope. 
Although the use of cross matching donor and recipient for HLA 
compatibility has improved the chances for graft acceptance, the main 
reason for graft survival is the use of immunosuppression techniques 
that inhibit the mechanism of graft rejection. Initially this involved the 
use of X-rays to destroy the lymphoid tissue and abolish the immune 
response, whilst drugs such as azathioprine (Calne 1961) and 
prednisone (Goodwin et al, 1963) were used in chemotherapy. 
Immunological methods were also employed with the use of 
antilymphocyte and anti thymocyte globulin along with combinations of 
antilymphocyte serum, prednisone and azathioprine. Although these 
methods of immunosuppression undoubtedly improved survival rates 
2 
they all suffered from one or more of the problems of lack of 
specificity, toxicity and death by infection from fungi, bacteria or 
viruses. 
Although the process of graft rejection is a complex series of 
interrelated phenomena, it can be shown histologically that grafts 
undergoing rejection are heavily infiltrated with lymphocytes. This 
observation led to the realisation that it was necessary to produce 
immunosuppressive drugs that selectively acted on the lymphocytes. 
(Salaman 1979) To some extent this was possible using corticosteroids, 
and antilymphocyte and anti thymocyte antisera, but it was not until the 
introduction of cyclosporin A in the late 1970's that the value of 
selective immunosuppression was demonstrated in humans. (Calne et 
al., 1978) Survival rates for patients treated with cyclosporin on its own 
or in combination with other agents improved markedly in comparison 
to those patients treated with other therapies. 
For patients receiving a bone marrow transplant the major 
complications are graft verses host disease (GVHD), an attack on the 
recipients tissue by the donor lymphocytes, infection and pneumonitis 
(Kay 1982). Randomised studies comparing therapies using cyclosporin 
and methotrexate the traditional drug of choice showed that the 
severity of GVHD was significantly reduced in the cyclosporin group 
(Kendra 1981) as was the incidence of death as a direct consequence 
of interstitial pneumonitis (Speck et al., 1983) 
For kidney transplants the early success of cyclosporin led to a 
European multicentre trial in which cyclosporin was compared with 
conventional therapy of azathioprine and steroids. The result 
demonstrated the superiority of cyclosporin therapy with one year graft 
survival at 72% for the cyclosporin group and 52% for the control 
3 
group (European Multicentre Trial Group 1983). A similar study was 
undertaken in Canada, where cyclosporin was given along with steroids 
and compared to conventional therapy of azathioprine and steroids. 
The one year graft survival rates were fou!ld to be 72% for the 
cyclosporin group and 65% for the control group. However, not every 
study showed improvements in graft survival rates, especially when 
centres traditionally had one year graft survival rates greater than 70%, 
as was shown in the Australian trial of cyclosporin for use in renal 
transplants (Sheil1983). 
Some of the most impressive advances resulting from the use of 
cyclosporin came in the field of liver transplantation. In the early years 
this very difficult operation had one year survival rates between 30-
50% (Starzl et aL, 1982), however, with the introduction of cyclosporin 
studies showed that one year survival was better than 70% and had 
doubled compared with the previous figures obtained with azathioprine 
and steroids (Starzl1983). Similar results are also found with children 
who were previously disadvantaged by the necessary high doses of 
steroids used (Malatack et al., 1983). 
Undoubtedly the most celebrated transplant to date was carried out at 
Groote Schuur Hospital in Cape town in December 1967 when the first 
human heart transplantation was performed. (Barnard 1967). However, 
the failure of the majority of transplants encouraged by Barnards work 
meant that the operation was abandoned in all but a few centres. It 
was not until the introduction of cyclosporin at Stanford in 1980 and 
with it actuarial survival at one year of better than 80% (Oyer et aL, 
1983) that world-wide interest in the operation was reawakened. Since 
then heart transplantation has become a predictable and routine 
procedure with a success rate comparable with or superior to that 
obtained for renal transplantation from unrelated donors.(Yacoub et 
aL, 1985) 
4 
The introduction of cyclosporin therapy was accompanied by other 
factors such as improved tissue matching, blood transfusion and better 
surgical techniques, which together were producing better graft 
survival. Nevertheless, it is clear that the use of cyclosporin has still 
further improved graft survival in organ transplantation, albeit whilst 
introducing problems of its own. In its early use cyclosporin was 
frequently over dosed leading to the development of lymphomas in 
some patients ( Calne et al., 1979). Nephrotoxicity is the most 
troublesome side effect of cyclosporin treatment particularly since it is 
difficult to distinguish from rejection. Again it was often due to 
overdosage in early studies and like the incidence of lymphomas can 
be reduced by carefully controlling the dose levels (Thiel et aL, 1983). 
A particular side effect of cardiac transplants is the development in 
most patients of hypertension (Wallwork 1983) the cause of which 
remains unknown. 
In spite of these problems cyclosporin continues to be the drug of 
choice in transplantation therapy and shows considerable promise in 
the treatment of some autoimmmune diseases, (Schindler 1985) whilst 
several workers have demonstrated the antiparasitic activity of 
cyclosporin in animals infected with a range of parasites (Nilsson et al 
1985). 
1.1.2.1 Other immunosuppressants. 
Apart from cyclosporin A the only other major new 
immunosuppressant to be developed in recent years was first 
reported at the 11th International Congress of the 
Transplantation Society in 1986 ( Ochiai et aL, 1987). During 
routine screening for naturally occurring immunosuppression 
agents the Fujisawa Pharmaceutical company isolated a 
macrolide antibiotic from the fermentation broth of a strain of 
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soil fungus Streptomyces tsukubaensis (Tanaka et aL, 1987). The 
compound designated FK506 and identified as an 822 
molecular weight macrolide of the formula C44 H69 N012• H20. 
Although dissimilar in structure from cyclosporin A FK506 
exhibits similar if not identical selective antilymphocytic activity, 
although with much greater immunosuppressive potency. 
(Thomson 1989). In vitro studies showed that FK506 could 
suppress human mixed lymphocyte reactivity and the generation 
of cytotoxic T cells at concentrations 100 times lower than 
cyclosporin A (Kino et aL, 1987) However in vivo the minimum 
effective doses of FK506 are about one tenth those of 
cyclosporin A and this may reflect different rates of absorption 
and/or metabolism of the two agents (Thomson 1989) 
The first report of clinical experience with FK506 described its 
use in salvage therapy for liver transplant patients suffering 
rejection, nephrotoxicity or both whilst under conventional 
immunosuppression. 7 out of 10 patients recovered with no 
further rejection episodes or serious side effects, such as 
nephrotoxicity and hypertension, often encountered with 
cyclosporin A therapy. 
Further clinical trials are underway and are being reported 
(Thomson 1990), however, evidence concerning the toxicity of 
FK560 is still not clear and longer experience in clinical 
practice is required before more complete assessment of its 
relative merits compared with cyclosporin A can be made. 
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1.2 Discovery of the cyclosporins 
The history of the cyclosporins begins in 1970 when two new strains of 
fungi imperfecti, cylindnocarpon lucidum Booth and Tolypocladium 
injlatum Gamma were isolated from soil samples collected in Wisconsin, 
USA and in the Hardanga Vidda, Norway.(Dreyfuss et aL, 1976). In 
primary tests extr4"ts of cultures displayed a rather narrow spectrum of 
antifungal activities in vitro: however in vivo only marginal antimycotic 
effects were noticed. In response to this a partially purified extract 
preparation from T.injlatum (code number 24-556) was submitted to a 
general pharmacological screening programme in which about 50 
parameters were tested. 
These tests included a cell culture assay for inhibition of cell proliferation 
and a combination of tests for anticancer and immunosuppressive activity. 
The fungal product gave a strongly positive result in only one of the tests, 
the haemagglutination titre of the sera of the mice treated with 24-556 was 
extremely low compared to that of controls. The assay for inhibition of cell 
multiplication in vitro was negative, whilst the rest of the screening did not 
reveal any significant activity of the preparation, with the exception of a 
substantial increase in blood urea nitrogen in rats treated with very high 
doses for 1 week. (Bore! et al., 1976) (Bore! et aL, 1977) Thus these results 
obtained in the early 1970's highlighted what are now recognised as the 
three most important features of the biological effects of the active 
ingredient of this product. Namely effective immunosuppression with a 
well tolerated dose, no general inhibition of cell proliferation (in contrast 
to e.g. azathioprine or cyclophosphamide) and impairment of kidney 
function at very high doses. The active ingredient of the fungal product 
was later isolated and named cyclosporin A 
Although the cyclosporins were initially only encountered in C. lucidum and 
T.injlatum systematic screening showed that the related species 
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Tolypocladium geodes as well as several other genera of lower fungi were 
capable of synthesising these secondary metabolites (Dreyfuss 1986). 
Because of its complex structure cyclosporin is difficult to synthesise for 
commercial application (Wenger 1983) and so for large scale production 
fermentation of aerated submerged cultures of selected mutants of T. 
inflatum is used. After a fermentation time of 10-12 days the culture broth 
is extracted with organic solvents, the crude extract is then centrifuged and 
the lipid content removed to leave a complex mixture of cyclosporin 
metabolites (Dreyfuss et al., 1976). The complete separation of this 
mixture is achieved by systematic chromatography on silica gel as outlined 
in Fig 1.1. At present 25 individual cyclosporins have been isolated from 
T. inflatum and several more congeners are under investigations. (Traber 
et al., 1982) 
1.3 Structure of the cyclosporins. 
1.3.1 Structure of cyclosporin A 
The main metabolite cyclosporin A crystallises from acetone as white 
prismatic needles which easily dissolve in most organic solvents, but 
poorly in water, as shown in Table 1.1 
Ruegger et al (1976) showed that cyclosporin A is a neutral compound 
as demonstrated by microtitration and electrophoresis. 
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Fig 1.1 
(c) (b) 
Cy K 
~yY Cy I (g) 
Cy F I ,~, 
- r.----h Cy Z 
- (c) Cy M I 
Cy N Cy 0 
crude extract 
I (a) 
(b) 
Cy T Cy L Cy V I 
(d) 
Cy X 
CyV CyH 
I (e) 
Cy E c: A I C:W (f) CyS 
Cy P Cy Q 
Isolation of the cyclosporins A-Z. (a) Sephadex LH-20, methanol; (b) silica-gel, water-saturated ethyl acetate; (c) silica-gel, 
hexane/acetone (2:1); (d) silica-gel, chloroform/methanol (98:2); (e) silica-gel, diethyl ether/methanol (95:5); (0 silica-gel, methylene 
chloride/methanol (96:4); (g) LiChroprep RP-18, methanol/water (4:1) 
Table 1.1 
Solvent Amount 
dissolved mg/g 
Water 0.04 
Methanol >lOO 
Ethanol >100 
Isopropanol >lOO 
Acetone >50 
Chloroform >100 
Ethyl acetate >100 
Cyclohexane 17 
n-Hexane 5.5 
Benzene >lOO 
Solubility of cyclosporin A in various solvents at 25 ° C ± 0.01 o C after 
vibrations for 24 hours. 
Spectroscopic examination revealed the presence of a secondary 
hydroxyl group, confirmed by acylation reactions and a C=C double 
bond corroborated by hydrogenation of cyclosporin to 
dihydrocyclosporin. The high content of nitrogen characteristic bands 
for amide groups (1630 1670 cm·1) and a series of 1H and 13C NMR 
signals associated with amide protons, a-protons of amino acids and 
carbonyl groups pointed clearly to a peptide structure for cyclosporin 
A Hydrolysis with 6M HCL generated a mixture of atnino acids which 
was separated by chromatography on cellulose into the following 
components: sarcosine, DL-alanine (2mol), L-a-amino butyric acid, L-
valine, N-methyl-L-valine, N-methyl-L-Leucine (4mol) and an artifact 
of an hitherto unknown N-methylated c; amino acid. Physicochetnical 
data are summarised in Table 1.2 
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Table 1.2 
Melting point 148-151•C (crystallised from 
acetone) 
Optical rotation [a)0 20 = -224• (in chloroform) 
= -189• (in methanol) 
Elemental analysis C61.9 H9.5 N12.6 0 15.8% 
Molar mass 1201.842 ± 0.003 (mass 
spectrum) 
Formula C62 Hm Nu 012 
Molecular weight 1202.635 
Functional groups 1 double bond 
1 secondary hydroxy group 
11 amide carbonyl (13CNMR) 
Table 1.2 Physicochemical data for cyclosporin A 
1.3.1.1 Structure of the <; amino acid 
The genuine unknown amino acid, originally designated as ~­
amino acid according to its carbon skeleton contains both the 
OH group and the double bond established in cyclosporin A, 
however in the isolated artifact these functional groups were 
absent. Isolation of the dihydro-<;-amino acid in its genuine 
form from the hydrolysis products of dihydrocyclosporin A and 
analysis by mass spectrum and NMR of the corresponding N, 
0 -bis (trifluoroacetyl) methylester derivative revealed the true 
structure of the genuine ~-amino acid, as shown in Fig 1.2 
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Fig 1.2 
The stereochemistry of the molecule was confirmed by high-
resolution 1H-NMR at 360 MHz. Final proof of the absolute 
configuration emerged from x-ray analysis of cyclosporin A 
(Fetcher et al., 1976) and the c;-amino acid was designated 
( 4 R )-4-[ (E)-2-butenyl]-4,N -dimethyl-L-threonine( abbreviation-
MeBmt) 
1.3.1.2 Sequence analysis of cyclosporin A 
Characterisation of the eleven amino acids had shown that they 
all belong to the L-series except for one D-alanine and that the 
lipophilic character of cyclosporin A could be explained by the 
presence of seven N-methylated amino acids. In addition the 
absence of free amino and carboxyl groups inferred the 
structure of cyclosporin A as a cyclic undecapeptide, which 
precluded the use of conventional methods for sequence 
analysis. Attempts to open the ring by selective hydrolysis 
yielded only small fragments, however acid catalysed 
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methanolysis yielded a rearrangement product Isocyclosporin 
A, as shown in Fig 1.3 from which sequence analysis was carried 
out using a modified Edman degradation. 
Fig 1.3 
CH 
H 
Cyclosponn A 
ll.torlx:Jse 
CH 
lsocyclosponn A 
! Edmon degradation 
Fig 1.3 Acid catalysed methanolysis of cyclosporin A used to 
generate a derivative suitable for amino acid sequence 
analysis 
The methylthiohydantoin derivative of MeBmt appeared as the 
first residue followed by the other ten to reveal the sequence 
illustrated in Fig 1.4 
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Fig 1.4 
1 2 3 4 
lleBmt Abu 
--
Sar 
--
Meleu 
t t 
Val 5 11 MeVal 
t t 
Meleu 
...- Meleu ...- 0-Aia ...- Ala.._ Meleu 
10 9 8 7 6 
Fig 1.4 Amino acid sequence of cyclosporin A following 
sequence analysis by a modified Edman degradation 
Final confirmation of the correct structure of cyclosporin A and 
evidence of the shape of the molecule was obtained by x-ray 
analysis of the iododerivative (Fetcher et al., 1976). Fig. 1.5 
shows the proposed shape where the antiparallel B-pleated 
sheet conformation of residues 1-6 and the loop formed by 
residues 7-11 are apparent. Stabilisation of the molecule is 
maintained by several transanular hydrogen bonds. 
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Fig 1.5 
Fig 1.5 Three dimensional structure of cyclosporin A based on X-ray analysis of 
the iododerivative 
1.3.2 Structure of the other cyclosporins 
In addition to cyclosporin A the other natural cyclosporins have been 
sequenced and their amino acid structure is given in Table 1.3 
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Metabobte 
CyA 
CyB 
CyC 
CyD 
CyE 
CyF 
CyG 
CyH 
Cyl 
CyK 
CyL 
CyM 
CyN 
CyO 
CyP 
CyQ 
CyR 
CyS 
CyT 
CyU 
CyV 
CyW 
CyX 
CyY 
C, 
C, 
c. 
C, 
c. 
desoxy-C, 
c. 
c. 
c. 
desoxy-C, 
N-desmetbyi-C, 
c. 
c. 
MeLeu 
N-desmetbyi-C, 
c. 
c. 
c. 
C, 
C, 
C, 
C, 
C, 
C, 
2 
Abu 
Ala 
Thr 
Val 
Abu 
Abu 
Nva 
Abu 
Val 
Val 
Abu 
Nva 
Nva 
Nva 
Thr 
Abu 
Abu 
Thr 
Abu 
Abu 
Abu 
Thr 
Nva 
Nva 
3 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
Sar 
4 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
Val 
MeLeu 
Val 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
s 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Nva 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Val 
Amino acid corn ition 
6 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
Leu(?) 
MeLeu 
MeLeu 
Leu 
MeLeu 
MeLeu 
MeLeu 
Leu 
7 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Abu 
Ala 
Ala 
Ala 
8 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
D-Aia 
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MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
Leu 
MeLeu 
10 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
Leo 
MeLeu 
MeLeu 
MeLeu 
Leu 
MeLeu 
MeLeu 
MeLeu 
Leu(?) 
MeLeu 
Leu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
MeLeu 
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MeVal 
MeVal 
MeVal 
MeVal 
Val 
MeVal 
MeVal 
D-MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
MeVal 
Val 
MeVal 
MeVal 
Molecular Fonnula 
CczllmNu012 
C .. H,.NuOd 
CaHwNuO~a 
C.,H..N .. o. 
C.H.NuOd 
CaHmNuOu 
C.,H.,N.o. 
CalfwNuOil 
C.,H.,N.o. 
C.H,.,NuOu 
CaHt.,NnQIS 
C,.IImNuOa 
C..Ht..NuOu 
C .. H • ..NuOo 
C,.H..,.NuOu 
C.,H,.N.o. 
C.Ift.,NuOu 
C.H • ..NuOg 
C.H.NnOd 
c.lf...N'u012 
C.H • .NuOu 
C.fluaNuOd 
CallmNuOd 
Cy Z MeAminooctaooic Abu Sar MeLeu Val MeLeu Ala D-Ala MeLeu MeLeu MeVal C.H ... N .. O .. 
9, IS a hitherto unknown amino acul ={2S,JR,4R,6E]-3-hydroxy-4-methyl-2-methylamzno-fH>ctenoic acid; Abu = L-a-aminobutyric acid; Nva = L-norvaline; 
MeVal = N-methy/-L-va/ine; Meleu = N-methyl-L-leucine. 
Chemical structures of cyclosporins A to Z 
1.4 Structure activity relationships 
As already discussed in 1.2 cyclosporin A is produced by fermentation 
along with varying amounts of the other metabolites. However, knowledge 
of the composition and stereochemistry of cyclosporin A has allowed for 
its production by total synthesis (Wenger 1983a, 1983b, 1984) along with 
a great many synthetic analog§$ (Wenger 1985). In addition the use of 
directed biosynthesis where specific amino acids are added to the 
fermentation medium has allowed for the generation of analogues not 
occurring in nature ( Kobel et aL, 1982). The availability of a wide range 
of cyclosporin analogues has enabled detailed structure activity 
relationships to be studied ( Wenger 1983) and Table 1.4 lists the 
immunosuppressive activity of a number of these analogues. 
From these results and from further studies it was possible to establish the 
involvement of each amino acid residue in the immunosuppressive activity 
of cyclosporin A Wenger (1986) found that exchange of one or two amino 
acids in cyclosporin A results in a more or less pronounced influence on 
the immunosuppressive activity depending on the residues involved. In 
addition NMR and X-ray analyses provided information on the importance 
of conformational changes in the molecule when amino acids are 
substituted. In general conformational disturbances caused by breaking of 
existing hydrogen bonds or the formation of new ones leads to a reduction 
in immunosuppressive activity. This is also true if residues are replaced by 
bulky substituents which interfere with the binding of cyclosporin to its 
receptor. 
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Table 1.4 
TrmaJ.Name IUPACName Source ActiVIty 
I nn 
A Cyclosponn A nat +++ 
(Dihydro-MeBmt 1] CyA ps + 
[(OAc) MeBmt I] CyA ps (+) 
L [Bmt1] CyA nat + 
p [Bmt1Thr1:J CyA nat + 
F [(3l.Desoxy)MeBmt 1] CyA nat (+) 
K [(31-Desoxy) MeBmt 1, Vat 1:J CyA nat (+) 
z [N-Me-2-ammooctanoic ac1d 1] CyA nat (+) 
0 [Me Leu 1] CyA nat (+) 
[MeThr1:J CyA syn (+) 
[MeLeu (threo-3-0H) 1] CyA syn + 
[MeAbu 1] CyA syn 
B [Ata1:J CyA nat + 
c [Thr1:J CyA nat ++ 
D [Vat1:J CyA nat + 
G [Nva1:J CyA nat +++ 
[Ser1 CyA syn (+) 
[ rfdePhe ~ CyA ps (+) 
[rfdeA!a~ CyA ps + 
[MeAla~ CyA syn (+) 
[rfro~ CyA syn (+) 
[Pro~ CyA syn (+) 
Q [Vat~ CyA nat (+) 
s [Thr~ Vat~ CyA nat (+) 
M [Nva2, Nva~ CyA nat ++ 
u [Leu~ CyA nat + 
y [Nva2, Leu~ CyA nat + 
R [Leu 6(•~ Leu 10q CyA nat (+) 
V (Abu 1 CyA nat ++ 
(DAta 1 CyA syn (+) 
lo"<r~ CyA dbs +++ 
X [Nva ~ Leu ~ CyA nat + 
[vat 2, Leu 1~ Cya nat (+) 
N [Nva ~ Leu I~ CyA nat (+) 
T [Leu 1~ CyA nat ++ 
E [Vat 11] CyA nat (+) 
w [Thr2, Vat11] CyA nat (+) 
[MeLeu 11] CyA syn (+) 
[Melle 11] CyA syn + 
[aMelle 11] CyA syn (+) 
[MeA!a 11] CyA syn (+) 
H [rfde Vat11] CyA nat 
+ + + = Strong 1mmunosu~f,resstVC actMty; + + • Moderate actiVIty; + "" weak actM~ i ( + )/· = no s1gmficant actiVI y nat • natural, ps • partial syntheSIS. syn • syntheSIS, dbs • d1rected b10synthesas 
18 
From these results it was possible to establish structure activity 
relationships for each residue and it was obvious that an intact amino acid 
No.1(MeBmt) was required for full immunosuppressive activity. 
Replacement of this residue as in cyclosporins 0 and Z or modification 
such as with the deoxy analogues cyclosporins F and K result in derivatives 
devoid of significant activity. Whilst removal of the N-methyl group or 
saturation of the double bond also results in a considerable loss of 
efficacy. In contrast structural variation at position 2 (L-a-aminobutyric 
acid) are quite well tolerated and length and shape of the residue is 
important. Replacement of this residue with the similar shape norvaline 
in cyclosporin G results in a congener with similar activity to cyclosporin 
A However shortened or branched side chains as in cyclosporin B 
(alanine) and cyclosporin D (V aline) tends to result in a reduction of 
activity. Interestingly cyclosporin C which contains a polar threonine 
• 
residue at position 2 exhi!ks strong activity. 
Modification are possible in positions 5,7 and 8 without a marked decrease 
in activity whilst N-demethylated congeners in general possess little or no 
immunosuppressive activity. Like MeBmt at position 1 the adjoining N-
methyl-valine in position 11 was found to be essential for full activity. N -
demethylation, such as in cyclosporin E and W led to the formation of 
an additional hydrogen bond between valine at position 11 and D-alanine 
at position 8, this induced severe conformational changes in the molecule 
resulting in much reduced activity. 
Wenger (1986) concluded that amino acid No 7 is essential for 
immunosuppressive activity and that activity is associated with a region of 
cyclosporin A including amino acids 1,2,3,10 and 11, as shown in Fig 1.6. 
In addition the main traits of the overall shape of cyclosporin A are 
preserved in congeners displaying high activity. 
19 
Fig 1.6 
Clip of a computer generated van der Waal surface of cyclosporin showing abo 
a parL of the peptide keleton. Amino acid 1 (MeBmt) is coloured in red, amino 
acid 2 (Abu) in yellow and amino acid 11 (MeVal) in green. The white surface~ 
represent the amides. The two main black surfaces on the left and on the right 
are the clips of the N-methyl group of sarcosine in position 3 and methyl leucine 
in position 9 respectively. (Wenger 1986) 
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Significant deviation in the backbone conformation or in the space filling 
and spatial arrangement of the side chains induce a decrease in activity to 
a greater or lesser extent. 
1.5 Mode of action of cyclosporin 
The most important activity of cyclosporin A is its influence on the 
immune system manifest in a marked suppression of antibody formation 
and cell mediated immune response (Bore! et aL, 1977). Although much 
work has been done and the subject extensively reviewed (Sherach et 
aL,1988) the mode of action of cyclosporin A is still not fully understood. 
The available data from in vitro investigations strongly suggest that 
cyclosporin A acts selectively on lymphocytes, inhibiting cytotoxic T 
lymphocyte generation in response to transplantation antigens whilst 
showing a sparing effect on the activation and establishment of suppressor 
cell regulatory mechanisms. Fig 1. 7 illustrates the cyclosporin sensitive 
steps in the activation and amplification of cytotoxic T lymphocytes and 
the T cell functions which are relatively insensitive to this agent. 
Apparently cyclosporin inhibits primary T-helper cell activation and blocks 
the formation of lymphokines such as interleukin 2 (Il2). Regulation of 
T-cell derived IL-2 can be effected by blocking the biosynthesis of the 
mediator or by inhibition of precursor T-cell from acquiring functional IL-
2 receptors. Both of these events are required for the proliferation and 
maturation of cytotoxic T lymphocytes (CTL), it seems likely therefore 
that the precursor CTL fails to mature and acquire lytic function in the 
presence of cyclosporin A 
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Fig 1.7 
IL-Z 
Clonal 
Amphf•cot•on 
Schematic illustration of the effect of CyA on cell-to-cell collabration in 
the MLR. M<t> = Macrophage; T et! = cytotoxic T lymphocyte; T se = 
suppresser T lymphocyte; Th cyt = T helper-inducer lymphocytes for 
cytotoxic T cells; Th se = suppressor-inducer T helper lymphocytes; IL-l 
= interleukin 1; IL-2 = interleukin-2; p = precursor ; • = inhibition by 
CyA. 
At the sub-cellular level studies on the binding and nature of cyclosporin 
receptors and their connection to nuclear control elements of transcription 
have again failed to produce definitive results. Cyclosporin appears to 
diffuse passively through the cell membrane (Merker et al.,1984) into the 
cytoplasm where it is suggested that it binds to two cytosolic proteins, 
cyclophilin and calmodulin (Handschumacher et al., 1984, Co/ombani et a/, 
1885). Involvement of calmodulin in the mechanism of action of 
cyclosporin has largely been discounted, supported by studies showing that 
calmodulin binds equally well to cyclosporin analogues regardless of the 
immunosuppressive activity (le Grue et al., 1986). In contrast a good 
correlation was observed between the binding of nine cyclosporin 
derivatives to cyclophilin (CYP) and their immunosuppressive activity 
(Handschumacher et a/1984). From this and other work CYP has emerged 
as the leading candidate for the cellular receptor responsible for 
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cyclosporin immunosuppression. CYP is a 17,000 molecular weight 
protein and reports have suggested that it is an enzyme called 
peptidyl-propyl cis trans isomerase (Fischer et aL,1989). A mechanism of 
action involving CYP has been proposed and is shown in Fig 1.8. 
Fig 1.8 
CyA 
CYP 
ea 2• 
Protein X- CIS 
\. CYP ~ CyA-CYP~ ' 
Protein 
synthesis 
Gene activatiOn 
I + 
DNA 
synthesis 
lymphoklne release 
Antloen 
Fig 1.8 Schematic representation of the suggested role of cyclophilin in the 
I sub-cellular mode of action of cyclosporin A 
Further supporting evidence for the involvement of CYP comes from the 
finding that it binds to the region of cyclosporin involved in its 
i=unosuppressive activity (Quesniaux et aL,1987). It has been inferred 
that residues 1,2,3,10 and 11 are probably involved in the active site of 
cyclosporin (Wenger 1986) and Quesnianx et al found that with the 
exception of residue 3 the active site is identical to the binding site for 
CYP. It was concluded that the stereochemical and conformational 
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properties of cyclosporin that are required for immunosuppressive activity 
are also require for binding to CYP. 
1.6 Phannacokinetics and metabolism 
1.6.1 Phannacokinetics 
The pharmacokinetics and metabolism of cyclosporin A have been 
extensively investigated in humans and animals (Maurer et aL,1985, 
Hartman et aL, 1985). This work helped to optimise therapeutic 
regimens and because of its poor water solubility led to the use of 
oral dose cyclosporin in the form of an olive oil based solution. 
(Cavanak et a/.,1986) 
Absorption of cyclosporin A after an oral dose is slow and peak 
blood levels are reached about 3-4 hours after ingestion (Beveridge 
et aL,1981). The bioavilability of the drug is in the range of 20-50% 
although a steady increase in absolute bioavailability over the first 
few weeks post-transplant due to the induction of cyclosporin gut 
receptors has been reported (Kahan et aL,1983). 
Using biosynthetically prepared 3H-cyclosporin A (Kobel et aL,1983) 
its distribution in the body has been studied (Lanaive et aL,1983). 
The uptake by the liver is the highest and is related to its drug 
metabolising and excreting role. Although high concentrations are 
also found in fat tissue. Brain levels of cyclosporin are extremely low 
indicating that only a little crosses the blood brain barrier. Within 
the blood approximately 50% of cyclosporin is associated with 
erythrocytes, 10-20% with leucocytes and 30-40% is found in the 
plasma, predominantly bound to lipoproteins. The binding of 
cyclosporin to erythrocytes and leucocytes is concentration dependent 
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and subject to saturation, whilst the binding to plasma proteins has 
been shown to be independent of concentration between 0.02 and 20 
JJ.g/rnl. In addition the distribution of the drug between plasma and c 
blood cells depends on temperature (Wenk et aL,1983), with only 
about 50% of the initial concentration found in the plasma as the 
temperature is decreased from 37" to 21". 
1.6.2 Metabolism 
Experiments using 3H cyclosporin A have determined that 
cyclosporin is slowly but extensively metabolised. Approximately 17 
single metabolites have been detected so far, all of which are present 
in consideraby lower plasma concentrations than cyclosporin A itself 
(Wood et aL, 1983). Studies in man have shown that cyclosporin is 
metabolised in the liver to about 99%, probably involving the 
cytochrome P-450 enzyme system and is subject to liver first-pass 
elimination. (Freeman et aL, 1984). A number of ether extractable 
metabolites have been isolated from urine using preparative HPLC 
and TLC (Maurer et aL, 1984). Structural assignment of the 
metabolites was carried out using NMR, MS and amino acid analysis 
and it was discovered that the biotransformation sites are limited to 
four amino acids, those at positions 1, 4, 6 and 9, as shown in Fig 1.9 
The metabolites were all found to retain the intact cyclic 
undecapetide structure of cyclosporin A and that structural 
modifications were limited to N-demethylation, hydroxylation and 
cyclisation. No evidence of conjugation with sulphuric acid or 
glucoronic acid was found. 
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Fig 1.9 
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Proposed pathways for the biotransfonnation of cyclosporin A (Lemaire et a/1986) 
The immunosuppressive activity and nephrotoxicity of the identified 
metabolites is the subject of much debate, although the prevailing 
view appears to be that the metabolites display only low 
immunosuppressive activity. (Wartbwz von et al., 1988, Ryffel et al., 
1988, Hartman et al., 1987, Chabannes et al., 1987) 
However some disagree, concluding that some metabolites especially 
Ml7 have significant immunosuppressive activity, either alone 
(Rosano et al., 1986, Freed et al., 1987) or synergistically in the 
presence of the parent drug (Zeeri et al., 1988). Early studies on the 
toxicity of metabolites indicated that they are not related to the 
nephrotoxicity of cyclosporin A (Cunningham et al., 1984). In further 
studies it was concluded that metabolite M17 is not toxic as 
compared to cyclosporin A (Ryffel et al., 1986, Cole et al., 1988). 
1.7 Therapeutic monitoring 
1.7.1 Background 
Prior to the introduction of cyclosporin A conventional 
immunosuppressant therapy with azathioprine and steroids did not 
rely on drug concentration monitoring to optimise dosing. However, 
it was soon recognised that with cyclosporin A clinical response does 
not correlate well with administered dose. It was found that there 
exists large inter-and intrasubject variability in cyclosporin blood 
levels due to the slow, erratic and incomplete absorption of drug 
from the intestinal tract, allied with a variable elimination rate 
dependent largely on hepatic function (Atkinson et al., 1983, 
Beveridge et al., 1981, Kahan et al., 1983). In addition a number of 
coadministered drugs 
example phenytoin 
influence cyclosporin concentration, for 
(Keown et al., 1984), phenobarbital 
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(Burckart et aL, 1984) carbamazepine (Lele 1985) and rifampin 
(Van Buren et aL,1984) all decrease the concentration in blood in 
humans, whilst ketoconazole (Ferguson et aL, 1982) and erythromycin 
(Wadwha et aL, 1987) increase whole blood trough concentrations. 
For the above stated reasons it proved difficult to predict individual 
patient response based solely on the dose administered. In addition 
it has been established that cyclosporin displays concentration 
dependent nephrotoxicity (Shaw 1987) and that on the incidence of 
chronic nephrotoxicity and chronic rejection is lower if parent drug 
concentrations are maintained within a narrow therapeutic range 
(M oyer et aL,1988, Uchida et aL, 1988). 
It was obvious that to fully maximise the potential of cyclosporin 
routine therapeutic drug monitoring (TDM) is essential and a 
number of methods have been developed over the past decade. 
1.7.2 Measurement of cyclosporin 
Two methodologies have been used extensively for monitoring 
cyclosporin therapy, radioimmunoassay (RIA) and high performance 
' liquid chromatography (HPLC) and the controversy is intense over 
the acceptability of either. The last few years has seen the 
introduction of alternative methods, most notably fluorescence 
polarisation immunoassay (FPIA) but they are doing little to resolve 
the arguments. 
The use of virtually all possible combination of methods and sample 
matrix allied with the variable pharmacokinetics and metabolism of 
cyclosporin have produced a bewildering array of reported 
concentrations and made inter institutional comparison of 
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cyclosporin monitoring difficult if not impossible. In response to this 
a Task Force on cyclosporin Monitoring was established and in its 
report ( Shaw 1987) it made several recommendations to standardise 
procedures. The most important are : 
(i) to use specific assays that measure the parent compound 
only; 
(ii) that the sample matrix should be whole blood. 
Although these recommendations are largely being implemented, it 
can be seen from the following section that the issue is far from 
resolved. Because of the multitude of methods and results obtained 
a clearly defined therapeutic range for cyclosporin has not been 
established, however commercial specific assays operate between 
approximately 0-1500 ng/ml in whole blood. The report of the Task 
Force on Cyclosporin Monitoring (Shaw 1987) showed that a number 
of investigators found that the likelihood of nephrotoxicity increases 
with values above approximately 250 ng/ml as measured by specific 
assay or HPLC. It was also found that long term graft survival was 
maximised by maintaining cyclosporin parent compound levels at 
between 50 and 150 ng/ml. 
1.7.2.1 Radioimmunoassay 
The RIA method was originally developed by Sandoz 
(Donatsch et aL, 1981) the manufacturers of cyclosporin and 
involved the use of polyclonal antisera raised in rabbits or 
sheep against cyclosporin antisera raised in rabbits 6rS!ieep-
against cyclosporin tritiated by saturating the double bond on 
amino acid No.1. The assay was found to have about a 32% 
cross reactivity with the major cyclosporin metabolite M17 
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(Rosano et al, 1986). The use of liquid scintillation counting 
and the need for quench correction with whole blood samples 
stimulated the introduction of iodinated tracers. Two methods 
have been described to synthesise the tracer, in the first 
iodine was introduced by reduction of the double bond of 
amino acid No1 (Mahoney et al, 1985) and this derivative was 
used in commercial assays. In the other iodine containing 
histamine was linked to cyclosporin through amino acid No2 
(Wong et aL, 1986). Both of these tracers were for use with 
polyclonal antibodies and so had variable cross reactivity with 
the different metabolite in the patient sample. As explained 
in 1.6.2 the immunosuppressive activity of cyclosporin 
metabolites is not clear whilst the inter- and intrasubject 
variability in the pharmacokinetics and metabolism of the 
drug mean that when non-specific immunoassays are used it 
is virtually impossible to know what are the relative 
concentrations of parent compound and individual 
metabolites. In response to this Sandoz developed a 
monoclonal antibody (Quesniaux et al, 1987) which was 
characterised as being highly specific for the parent 
compound with little cross reactivity with any of 11 
metabolites (Ball et al, 1988). The introduction of this 
antibody has enabled the development of commercial assays, 
the most successful to date being from the lncstar 
Corporation in which iodinated cyclosporin A is used. In this 
assay very good agreement has been demonstrated with an 
HPLC method for the determination of parent compound in 
whole blood samples (Wolf et aL, 1989). The separation of 
antibody bound from excess cyclosporin is achieved by 
centrifugation of the primary antibody/second antibody pre-
conjugate, a much simpler procedure than the charcoal based 
separation used in the Sandoz 3H assay (Ball et al1988). 
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1.7.2.2 High performance liquid chromatography 
The HPLC analysis of cyclosporin was first reported by 
Niederberger et al (1980) and since than a great many methods 
have been published and reviewed (Schran et aL, 1986, Shaw 
1989) 
Representative examples are given in Table 1.4 
Although HPLC methods are more technically difficult and 
labour intensive than RIA techniques HPLC is considered to 
be the reference method where unequivocal values are 
required, both of parent compound and individual 
metabolites. 
The major drawback with HPLC methods is the lack of a 
chromophore in cyclosporin resulting in the need to monitor 
the column eluent at very short wavelengths, usually around 
210 nm. A great many molecules absorb energy in this part 
of the spectrum resulting in the problem of significant 
interference and high background signal. Two different 
approaches have been taken to resolve the problem, the most 
common being the use of extensive sample preparation prior 
to chromatography. Usually, this involves the extraction of the 
sample into an organic solvent either by liquid-liquid or solid-
liquid partitioning. 
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Table 1.4 
Refereoce Sample Extraction • Chromatograpluc conditions Detection Run time 
limit (min) 
(nglml) 
Mode Column, temperature Mobile phase 
Sawthuk and Cartier.1981 Plasma, blood Liquid-hquid, very long lsocratic C,., Spm, 75°C Acetonitrile-water 25 10 
Nussbaomer et al. 1982 Plasma, blood Protein precipitation, short Column switclling Cu, Spm, 70°C 6-Solveut switclling scheme 20 26 
Leyland-Jones et al. 1982 Plasma Solid phase, long lsocratic Zorbax TMS Spm, 55"C Acetonitrile-water 100 20 
Yee at al. 1982 Serum Solid phase, long Gradieut Ultrasphere ODS, Spm, 70"C Acetonitrile-water- 50 16 
trifluoroacetic acid 
Carruthers et al. 1983 Plasma Liquid-liquid, long Isocratic C., Spm, 72°C Acetomtrile-water-methanol 31 30 
Smith and Robinson. 1984 Plasma, blood ProteiD precipitation, short Column switclling C., Spm, 75°C Acetomtrile-water 8-20 15 
Kates and Latini. 1984 Serum, blood Solid phase, very long lsocratic C., tOpm, 70°C Acetonitrile-water 25-50 20 
Tukada et al. 1985 Plasma, blood Liquid-liquid, very long lsocratic CN, 40°C Acetonitrile-water 100 >15 
w Aral'ind. et al. 1985 Blood Cbarcol adsorption, very lsocratic cl., 5 pm, 75°C Atetonitril~water-methanol 50 8 N 
long 
Hamilton et al. 1985 Plasma, blood Protein preapttabon, long Column switclling c . ., 3JIID, 60°C Acetonitrile-water 2-10 15 
Lensmeyer and Fields. 1985 Plasma, blood Sohd phase, long lsocratic CN, Spm, 58°C Atetonitril~ter 111-15 10 
Sbihabi et al. 1985 Blood Solid phase long Isocratic CN, S IJDI, S6°C Acetonrtrile-water 50 >20 
Gmnr et al. 1985 Serum Protein precipitation, long Column switdung Cu, Spm, 70°C Acetomtnle-water 20 >20 
Garraffo and Lapalus. 1985 Plasma, blood Liquid-liquid, long Isocratic C.., 41UD, 75°C Acetonitrile-water- 25 10 
trilluroacetic: acid 
Kabra et al. 1985 Plasma, blood Sohd phase, sbort Isocratic CN, so•c Atetomtril&-phospllate 10 15 
bulfer 
Kahn et al. 1986 Blood Liquid-liquid, long Isocratic ~. 3pm, 73°C Acetonitrile-water- 10 8 
methanol-ammonium 
sulpllate 
• Short, protein preciptation + injection; long, extraction + evaporation; very long, additional sample mani(MIIation. 
Representatwe selectJon of HPLC methods for the analysiS or cyctosponn A 
In liquid-liquid partitioning cyclosporin and its metabolites 
are often extracted into an ether (Annesley et aL, 1986) 
sometimes followed by a wash with acid or base ( Carruthers 
et aL, 1983) to remove eo-extracted interferents. The use of 
solid phase extraction columns such as the "Sep-Pak C18", 
"BondElut C18" (Moyer et aL, 1986) and BondElut CN 
(Lensmeyer et aL, 1985) have helped to overcome some of the 
drawbacks of liquid phase extraction, namely they are less 
labour intensive in multi step extractions and the use of 
volatile solvents such as ether is obviated. However, the 
additional cost of the columns, the possible introduction of 
extraneous peaks into the chromatogram (Lawrence et aL, 
1980) and variability in extraction efficiency among various 
lots of columns may limit this technique. Nevertheless column 
extraction methods have been demonstrated to have 
extraction efficiencies and precision similar to those for the 
solvent extraction procedures (M oyer et al, 1986). In addition 
the use of extraction columns has enabled the introduction of 
semi-automated HPLC methods (Wallemacq and Lesne, 1987; 
Lachno et aL, 1990). 
The second approach to minimising background interference 
involves the use of sophisticated chromatography techniques 
and minimal sample preparation. With these methods basic 
protein precipitation is followed by either gradient elution 
(Niederberger et aL, 1980) or more complex column switching 
procedures where two or more columns are used in series to 
sequentially purify, separate and quantify cyclosporin and its 
metabolites (Smith and Robinson, 1984; Grnrr et aL, 1985). 
The main problems with this technique are the need for two 
pumps, electronic switching valves and control circuitry and 
the relatively short column life due to the lack of sample 
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clean up. All of these things add considerably to the expense 
of the procedure, nevertheless there is a major advantage in 
that all of the sample is applied to the analytical column 
thereby allowing for the use of smaller sample volumes, for 
example, from paediatric patients. In addition the reported 
methods are characterised by low limits of detection. 
Numerous columns and chromatographic conditions have 
been reported, the majority of which are reverse phase 
methods using C18 columns heated to 70-75 • C with mobile 
phases of generally acetonitrile/water (typically 70/30 v /v) or 
acetonitrile/methanol/water (typically 50/20/30 vfv). The 
problem of short column life at high temperatures has 
encouraged the use of more polar columns with a typical 
mobile phase of ethanol/hexane (10/90) operating at around 
50· C. It is necessary to use elevated temperatures because at 
room temperature cyclosporin elute as a very broad peak, the 
result of interconversion of several conformers. Raising the 
temperature speeds up the interconversion and yields a sharp 
peak corresponding to an average conformer composition 
(Bowers and Matthews, 1985). 
1.7.2.3 Fluorescence polarisation immunoassay. 
A detailed description of fluorescence polarisation 
phenomena is given in 5.1.3 
The introduction of a fluorescence polarisation immunoassay 
(FPIA) for cyclosporin (Wang et aL, 1986) by Abbott 
Laboratories, operating on their "TDx" instrument offers the 
potential of a simple assay that avoids the need for skilled 
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personnel and the hazards of radioisotopes. 
In early studies plasma samples were analysed by FPIA, 
polyclonal RIA and HPLC (Sanghvi et al, 1988, Hayashi et 
al, 1989) and the results compared. Not surprisingly there 
was poor correlation between the immunoassay methods and 
the HPLC method since they both used polyclonal antibodies. 
However, there was reasonable correlation between the RIA 
and FPIA methods although the FPIA method gave higher 
values than RIA. Further refinements saw the introduction of 
serum and whole blood assays for the "TDx" (Vogt and 
Welsch, 1988; Schroeder et al, 1989). These methods 
confirmed the good correlation between FPIA and the 
commercially available RIA kits whilst again showing that 
FPIA produces elevated results compared to RIA. However, 
in another investigation (Haven et al., 1989) it was found that 
in comparison with the polyclonal RIA's from Sandoz and 
Incstar the FPIA gave proportional results in whole blood 
(Sandoz < Incstar < IDx) with reasonable correlation but in 
plasma the values obtained by TDx and the Sandoz RIA 
differed by as much as 100%. 
Because of the considerable cross reactivity of the antibody 
used in the polyclonal IDx FPIA and the desire to use 
specific methods for parent cyclosporin A quantification a 
monoclonal antibody based IDx assay has recently been 
introduced (Wang et al., 1990). However, this assay does not 
use the same monoclonal as the specific Sandoz and Incstar 
RIA procedures and comparisons with the Sandoz RIA have 
shown that on average the TDx results are about 6% higher, 
probably because of increased cross reactivity with 
metabolites (Yatscoff et al, 1990). The same work also 
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showed that the "specific" RIA and IDx assays gave values on 
average 17% and 24% respectively higher than those 
obtained by HPLC. 
Although only recently introduced results appear to show that 
the specific FPIA operating on the Ab bott IDx offers a rapid, 
precise and accurate measurement of cyclosporin A 
concentration (Kahan et aL, 1990; Shaw et aL, 1990), although 
further studies need to address the significance of the binding 
profile of the new monoclonal antibody. 
1.7.2.4 Other reported methods. 
Because of the dominance of the RIA and HPLC methods 
the only other commercially available technique is the FPIA 
discussed in 1.7.2.3. However, the Syva Company have 
recently released for investigation an EMITR cyclosporin 
assay for whole blood samples operating on the COBAS 
MIRA analyser. The assay utilises a monoclonal antibody and 
cyclosporin A labelled with the enzyme glucose-6-phosphatase 
dehydrogenase (G6PDH). After a 175 second incubation 
enzyme activity, which is a function of drug concentration is 
monitored by following the production of NADH 
spectrophotometrically at 340 nm for 100 seconds. In a 
comparison with the Incstar monoclonal RIA a good 
correlation was found between the two assays although the 
EMIT gave lower results than the RIA, most significantly at 
values of less than 100 ng/ml (Kit Infonnation). Considering 
the widespread use of enzyme assays in clinical laboratories 
and a claimed pre-treatment and assay time of less than two 
hours for twenty samples and six calibrators it will be 
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surprising if this assay does not generate a good deal of 
interest. 
Two other methods have been reported in the literature, the 
first utilises chemiluminescence to provide the tracer signal 
(Stabler and Siege~ 1990). Cyclosporin C-hemisuccinate is 
labelled with N-(4-aminobutyl)-N-ethylisoluminol and is used 
with the Sandoz monoclonal antibody. The assay was 
compared with the Incstar monoclonal RIA and found to 
have similar sensitivity, accuracy and precision. 
Finally, a radioreceptor assay has been described in which 
unidentified cyclosporin specific receptors were isolated from 
human mononuclear leucocytes. These were then used in a 
competitive assay with extracted plasma, serum or whole 
blood samples and 3H dihydrocyclosporin. Comparisons were 
made with polyclonal and monoclonal RIA methods as well 
as with the polyclonal 1Dx and HPLC. Although the 
radioreceptor assay showed reasonable precision, correlation 
with the other methods was poor (Donnelly and Soldin, 1989). 
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CHAPTER1WO 
INTRODUCTION TO THE TECHNIQUES USED IN THE PROJECT 
2.1 Protein A. 
2.1.1 Background 
Staphylococcal Protein A (SpA), a protein component of the cell wall of 
Staphylococcus aureus was first described in 1940 (VeJWey, 1940) as a 
protein antigen present in type A Staphylococci (coagulase-positive, a-
toxin-positive, mannitol fermenting and pathogenic) but not in type B 
staphylococci (those lacking these characteristics). The systematic study 
of SpA did not begin in earnest until two decades later when it was 
demonstrated that the well recognised ability of all human sera to 
agglutinate S. aureus, which had been attributed to the universal 
presence of so-called natural antibodies did not in fact represent an 
immune reaction (Forsgren and Sjoquist, 1966). It was shown that 
purified SpA bound to the Fe fragment of the immunoglobulin molecule, 
not to the antigen binding Fab fragment. 
Although more than 90% of S. aureus strains synthesise SpA (Kronvall 
et aL, 1971} there is a marked difference in the amount present in 
different strains. The Cowen I strain synthesises relatively large amounts 
of SpA and has been used extensively for the study of the molecule, 
which comprises 1.7% of the dry weight of whole, lyophilised cells and 
6.7% of the dry weight of isolated cell walls (Sjoquist et aL, 1972a). The 
SpA molecules are densely distributed on the surface of the bacterium 
with approximately 80,000 molecules/cell as determined by Scatchard 
analysis (Kronvall et aL, 1970a). Only a small fraction of SpA is newly 
synthesised or secreted extracellularly (Movitz, 1976). Biological 
responses to SpA include activation of the complement system, 
hypersensitivity reactions, cell mediated cytotoxicity, interferon 
production, activation of polyclonal antibody synthesis and mitogenic 
stimulation of lymphocytes (Sjodahl and Moller, 1979; Romagnani et al., 
1980). 
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Purified cell wall bound SpA has a markedly extended shape with a 
relative molecular mass of 42,000 (Bjork et al., 1972) and contains few 
if any sugar residues (Sjoquist et al., 1972). The secondary structure of 
SpA has been estimated to be 31% a-helix, 13% a-structure and 56% 
random coil (Lindmark, 1982). 
Fragmentation of the protein A molecule by trypsin digestion followed 
by purification and amino acid sequence analysis of the fragments 
initially suggested three homologous Fe binding regions, each one 
containing very similar sequences of 50 amino acids (Sjodah~ 1976). 
Further work however showed that the IgG binding part of protein A 
was a tetrameric structure. A model was therefore proposed where 
protein A consists of four highly homologous Fe binding domains - D, A, 
B and C followed by a C terminal region X which anchors the protein 
to the cell wall of S. aureus. However binding studies suggested that one 
molecule of intact protein A can only bind two molecules of IgG 
(Langone et al., 1978). In the light of this a model was proposed for the 
formation of protein A-IgG soluble complexes based on the evidence 
that IgG has two functional binding sites for protein A and that protein 
A has four functional binding sites for IgG (Hanson and Schumaker, 
1984). However, this model has been brought into question by work 
done on the cloned protein A gene which revealed a fifth region E, 
homologous to the four previously identified regions (Lofdah~ 1983). In 
further work (Moks et al., 1986) isolated gene fragments encoding 
regions E and B were cloned and expressed in Escherichia coli followed 
by binding studies of the purified gene products. It was concluded that 
protein A contains the E region in the N terminus and can therefore be 
considered structurally pentameric. Binding studies on the fragments 
showed that region E can bind to the F0 portion of IgG although with an 
affinity somewhat lower than that found in the other four regions. The 
results of these studies show that the structure of protein A-IgG 
complexes is still not understood, although the binding site for SpA has 
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been shown to be located both on the CH2 and CH3 domains on the Fe 
part of human IgG (Deisenhofer et al, 1978). 
SpA binds to serum immunoglobulins of almost all mammalian species 
(Kronvall et al, 1970) however there is a greater than 1tr-fold variation 
in the affinity of SpA for the immunoglobulins of different species 
(Richman et al, 1982). Sera from amphibia, reptiles and birds were 
found to be non-reactive with the exception of two primitive birds 
(Kronvall et al, 1970). The affinity constants for the binding of SpA to 
human polyclonal IgG, rabbit IgG and guinea-pig IgG have been 
calculated to be 4.8 x 107 lfmol, 4.1 x 10S lfmol and 2.5 x 108 1/mol 
(Lindmark et al, 1981). In both humans and animals there are marked 
differences in the affinity of different classes and subclasses of 
immunoglobulins for SpA A number of studies have been published 
reviewing these differences (Kronvall and Williams, 1969; Lindmark et al, 
1983; Saltvedt and Harboe, 1976, Patrick et al, 1977, Coe et al, 1981). It 
has been found for example that with human immunoglobulins IgG1, 
IgG2 and IgG4 bind strongly whereas IgG3 does not bind to SpA lgA2 
and some IgM proteins also bind well whilst 6-9% of IgE bind to SpA 
but probably in a mauner different from that of the other 
immunoglobulins, most likely via their F.b portions (Johansson and 
Inganas, 1978). In mice IgG2a, IgG2b and IgG3 bind well, whereas IgG1 
binds less well and the majority of IgA and IgM do not bind (Kronvall 
et al, 1970c). 
Since SpA binds to the Fe portion of the immunoglobulin molecule an 
important practical consequence of this binding site is that the 
attachment of SpA to an immunoglobulin molecule does not interfere 
with antigen binding by the Fab portion. However, enhanced interaction 
between antigen, antibody and SpA may occur if complexes are 
generated with polyvalent antigens (Kessler, 1976; Sandor and Langone, 
1981). It has also been observed that SpA has enhanced binding activity 
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to antibody that is complexed to solid phase antigen compared to non-
specifically bound antibody or antibody free in solution (Kessler, 1975). 
SpA offers several potential advantages over antiglobulin, it is a well 
defined molecule that is readily available in pure form, either 
commercially or by simple laboratory preparation. It is a highly stable 
molecule that can be conjugated to a number of labels with little or no 
loss of activity (Richman, 1983). SpA's ability to bind to 
immunoglobulins of most manunalian species enables the development 
of indirect immunoassay with sera for which antiglobulins are not readily 
available. This property also permits the detection of multiple antigens 
in indirect irnmunoassays utilising antisera from several different species 
(Richman et aL, 1982). 
The problems of non-specific binding of antiglobulins are well known 
and these tendencies appear to be lower with SpA (Engval~ 1978; 
Kessler, 1975). Antiglobulin possesses several potential advantages over 
SpA, the former can be raised against certain classes and subclasses of 
irnmunglobulins such as IgG3 and IgM which may be important in a 
particular assay, whilst immunoglobulins from some species have very 
poor binding with SpA Some authors have noticed that the sensitivity 
of an assay when using labelled SpA is not as great as that obtained 
when using labelled antiglobulin ( Ghetie et aL, 1974; Dorval et aL, 1974). 
The introduction of affinity chromatography and the use of SpA-
Sepharose has provided one of the most simple and effective methods 
of purifying and concentrating immunoglobulins (Hjelm et al., 1972). The 
fraction of irnmunoglobulins bound to SpA-Sepharose is influenced by 
many factors, such as the amount of irnmunosorbent used in relation to 
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serum, the length of the column, the pH of the applied buffer and the 
buffer flow rate through the column. The first three factors have been 
found especially critical in the purification of immunoglobulins from 
species with low affinity for SpA, for example an application pH of 8-9 
has been demonstrated to enhance the binding oflgG1 in the mouse and 
goat (Ey et aL, 1978). Purifying antibody prior to conjugation with 
labelling molecules increases the specific activity of the conjugate and 
reduces non-specific labelling. Affinity chromatography is also an 
extremely effective and easy method for purifying Fab fragments from 
Fe fragments and intact immunoglobulin molecules (Goding, 1976). 
SpA is the prototype of bacterial Fe receptors but it is only one 
representative of a family of bacterial Fe receptors that have been 
identified on the bacterial cell surface (Boyle and Reis, 1987). Currently 
bacterial Fe receptors are classified based on their reactivity with 
different classes and subclasses of IgG from various mammalian species. 
To date five distinct patterns of species IgG reactivity have been 
recognised (Fig 2.1). The type Ill Fe receptor associated with certain 
group C and G streptococci has been isolated recently in a functionally 
active form and demonstrates a wider range of species reactivity when 
compared with the type I Fe receptor SpA (Eliasson et aL, 1989). This 
additional reactivity has enabled workers to use specific antibodies from 
sheep and goats, species that are frequently utilised for preparation of 
commercial antibodies (Reis et aL, 1988). The so-called protein G is the 
most widely used of type Ill Fe receptors and shows considerable promise 
as an alternative to SpA (Akerstrom, et aL, 1985; Nilson et aL, 1987; 
Eliasson et aL, 1989). 
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Fig 2.1 
Type 1 Type 11 Type lll Type IV Type V 
Human 
• • • • • 
Rabbit 
• • • • • 
Ptg 
• • • • • Mouse 
• 0 • 0 • 
Rat 0 • 0 • 
Cow • • • 0 • 
Goat • 0 • 
0 • 
Sheep • • • 
0 • 
Cat 
• 0 0 • 0 
Dog • 0 • nt 0 
Species reactivity of different bacterial Fe receptor types. The size of the 
dots is proportional to the reactivity of the receptor. nt = not tested. 
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2.1.2 The use of protein A 
2.1.2.1 Introduction. 
The use of Protein A (SpA) in immunoassays can be considered 
to fall into three major areas defmed by the way in which it is 
used. SpA can be used as an immunoadsorbent either in its 
purified form or bound to a carrier such as Sepharose or the 
intact staphylococcal cell. The SpA is then used in solution, that 
is the immunoadsorbent is mobile and generally requires 
centrifugation to remove it from the incubation mixture. The 
second group is similar to the first except that SpA is immobile 
in the assay, this is accomplished either by having the SpA-carrier 
complex packed into a column or immobilising SpA onto a solid 
surface. Finally the most common use of SpA in immunoassays 
is as a labelled binder for IgG, acting as a pseudo labelled 
anti-immunoglobulin. A whole range of labels have been used 
including isotopes, enzymes, fluorophores, metals and proteins. 
2.1.2.2 SpA as an immunoadsorbent in solution 
SpA is commercially available from a number of sources either 
in its pure form, as a recombinant product, as killed whole cells 
or covalently linked to a variety of carrier molecules. Methods for 
preparing whole killed, fixed S. aureus cells ( Goding 1978; Kessler 
1981), for isolating and purifying SpA (Hjelm et al 1972; 
Lindmark et al1977) and for conjugating SpA to Sepharose (Kato 
et al., 1981) and controlled pore glass beads (Phillips et al., 1985) 
have all been reported. 
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SpA bound to carrier molecules has been used as an 
immunoadsorbent in a whole range of assays that fall into two 
main types. In the first antibody (Ab) is bound by the SpA and 
this complex is incubated with the antigen (Ag), which must be 
large enough to have more than one recognition epitope. A 
second labelled Ab then binds the Ag and after separation the 
bound labelled Ab is monitored. This method has been used to 
measure human serum albumin (Harper et al, 1982) and PGH 
synthase (Smith and Dewitt, 1984). Alternatively the label is 
attached to the Ag which is used in a competitive assay with the 
Ab and unlabelled Ag. SpA-binder is then used to precipitate out 
bound Ag. This method has been used to develop assays for Ab 
produced in response to grass allergen components (Moran et al, 
1978), staphylococcal enterotoxins in foods (Miller et al, 1978) 
and the products of cell lysates (Kessler, 1975). In addition 
Sepharose-SpA has been used to remove endogenous anti-insulin 
Ab from the plasma of patients with insulin dependent diabetes 
prior to the determination of free insulin ( Chevenne et al, 1991). 
SpA has also been used as an immunoadsorbent in its pure form, 
acting as a bridge between specific Ab to cell surface Ag and 
labelled Ab, binding both by their Fe regions (Notani et al, 1979). 
2.1.2.3 SpA as an immobilised immunoadsorbent 
The use of SpA as an immobilised immunoadsorbent falls into 
two main groups, the first and most common involves packing a 
column with a SpA-carrier matrix and using this in a flowing 
system. This approach was used to determine the levels of serum 
Ab's to a number of analytes including insulin and human 
thyroglobulin (Kato et a~ 1981). In this assay serum was 
incubated with enzyme labelled antigen and the mixture applied 
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to the SpA column. The retained Ab complex was then eluted by 
passing PBS containing 25mM dithiothreitol down the column 
which splits disulphide bonds between SpA and the Sepharose 
carrier matrix. A drawback of this method is that SpA is removed 
from the matrix and so the column is not re-usable. Assays with 
re-usable columns are obviously more attractive and this 
approach has been used to isolate and purify membrane 
components from celllysates by preparing a number of columns 
with different monoclonal antibodies covalently bound to 
Sepharose (Schneider et al., 1982). SpA coated glass beads have 
been used in a similar way (Phi/lips et aL, 1985) with rabbit IgG 
covalently linked to the SpA beads which are then packed into a 
column and used in a HPLC system for the analysis of human 
serum albumin and human IgG. 
The second method for using immobilised SpA as an 
immunoadsorbent involves solid surfaces rather than beads as the 
carrier. This method allows for the development of biosensors as 
demonstrated by the use of a piezoelectric quartz crystal (Davis 
and Leary, 1989) which resonates at a specific frequency, 
dependent upon the mass bound to its surface. In this assay SpA 
is deposited onto one of a pair of gold electrodes attached to 
either side of the crystal which forms the base of a well in a 
Plexiglas block, when IgG is bound by the SpA the resonance 
frequency decreases by a quantity related to the mass of the IgG 
bound. The addition of anti-IgG causes an additional decrease in 
resonance frequency. Changing the buffer to O.lM sodium acetate 
pH 3.0 displaces the Ab from the PA allowing the sensor to be 
re-used. 
A biosensor based on a semiconductor and P A has been 
developed ( Colapicchioni, 1988), this sensor has an 
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immunochemical membrane of IgG or SpA bound to a support 
biopolymer matrix covalently linked to the surface of a 
semiconductor device. In the case of the SpA membrane Ag 
specific Ab is incubated with the device and the Ag is determined 
by labelling it or a second Ab with an enzyme capable of 
producing an electroactive product which is measured by the 
transducer. The electrical response will be inversely proportional 
to the quantity of Ag in solution. 
2.1.2.4 SpA as a labelled binder 
By far the most common use to date of SpA in immunoassays is 
as a labelled binder of IgG acting in a manner analogous to the 
traditional labelled second Ab or immunoradiometric methods. 
A range of labels have been used with a bias towards traditional 
isotopes and enzymes, however recently used labels have enabled 
the development of new and sometimes simpler SpA 
methodologies. 
2.1.2.4.1 Isotopes 
Although there has been some use of 3H (Wilder et aL, 
1979) by far the most popular isotopic label for SpA has 
been 1251 and a number of methods for the synthesis of 
1251-SpA have been published (Dorvall et al., 1975, 
Biberfeld et aL, 1975, Langone, 1977). 
The common theme for assays that utilise labelled SpA 
is the binding of Ab to immobilised Ag. This Ag can be 
a drug, hapten or biological molecule immobilised onto 
a polymeric support as part of an assay for free analyte 
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in the sample, or may be a cellular antigen visualised on 
or within the cell. 
In the first case the methods follow a similar protocol. 
The solid phase antigen is incubated with specific Ab 
and after removal of the unbound Ab labelled SpA is 
introduced and the bound SpA label measured. Free Ag 
in solution will reduce the amount of Ab bound to solid 
phase Ag and therefore reduce the amount of labelled 
SpA bound. 
A range of analytes have been measured by this method. 
Arachidonic acid metabolites and synthetic 
prostaglandin analogues were immobilised on activated 
polyacrylamide beads (Levine et a~ 1979) as well as 
methotrexate (Langone, 1978 and 1980), human lgM 
(Langone, 1980) and human IgE (Langone, 1980; 
Langone et al., 1979). Agarose has been used to 
immobilise human chorionic gonadotropin, human IgM, 
goat IgG (Langone, 1978)and actin (Lessard et aL, 1979). 
Although the use of polymeric bead supports gives 
reproducible and accurate results the need to repeatedly 
wash and centrifuge the beads during the assay means 
that it can become time consuming and tedious. The use 
of solid phases where unbound material is simply 
washed off overcomes these problems. Polypropylene 
tubes have been used for the determination of 
5-methyltetrahydrofolate, human IgG, lgA, I gM, IgE and 
methotrexate (Gee and Langone, 1981; 1983) whilst the 
efficiency of different blocking agents on nitrocellulose 
membrane has been studied using 1251-SpA (Baldo et aL, 
1986). 
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The study of specific receptors on the surface or within 
the structure of cells has been aided by the use of 1251 
labelled SpA The quantification of transferrin receptors 
on adult hepatocytes with both monoclonal and 
polyclonal Ab to these receptors has been accomplished 
(Rudolph et aL, 1988). Surface Ag of tumour cells have 
been visualised by determining the binding of specific 
Ab with 1251-SpA (Dyrberg and Billestmp, 1984; Brown et 
aL, 1977). 
In all of these assays where labelled SpA acts as a 
binder of IgG it is being used in a way analogous to 
methods utilising anti-immunoglobulin. There are a 
number of advantages from using SpA in this way 
including its availability and ease of use with a whole 
range of IgG's from a number of species (Langone, 
1978, Richman, 1983). However IgG from a number of 
animals including goat and sheep were found to have 
relatively low affinity for SpA (Langone, 1978), which is 
a problem since generally these animals are used when 
large volumes of antiserum are required. In spite of this 
the use of goat and sheep IgG in immunoassay has been 
demonstrated for human IgE, IgM and methotrexate 
immobilised to polymeric beads (Langone, 1980). An 
explanation has been suggested based on the 
observation that SpA has enhanced binding activity to 
Ab that is complexed to solid phase Ag, compared to 
non specifically bound Ab or Ab free in solution 
(Kessler 1975; 1976; Goding, 1978). This property would 
account for a further advantage in using 1251-SpA as a 
labelled binder since these methods give much lower 
non-specific binding and hence lower background signals 
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than anti immunoglobulin methods (Brown et al., 1977; 
Engval~ 1978). 
2.1.2.4.2 Enzymes 
Apart from isotopes enzymes are the only other label to 
have widespread use in labelled SpA immunoassays. The 
assay methods are very similar to those already 
described for isotopes and in many cases either label 
can be used. Alkaline phosphatase-SpA has been used 
to determine methotrexate, 5-methyltetrahydrofolate, 
human IgG, IgA, lgM and IgE immobilised on 
polypropylene tubes (Gee and Langone, 1981), 
ovalbumin coated onto microtitre plates (Buchanan et 
al, 1981) and rhizobia from various sources on 
microtitre plates (Ayanaba et al, 1986). SpA-Invertase 
has been prepared as a monoconjugate and used to 
determine human chorionic gonadotropin and human 
IgG coupled to nylon mesh (Pain and Surolia, 1979). 
Cell membrane and viral Ag have been visualised using 
SpA-horseradish peroxidase with antisera from five 
different species (Dubois-Dalcq et al, 1977). 
2.1.2.4.3 Alternative labels 
Fluorescein labelled SpA has been used in a number of 
assays (Ghetie et al, 1974; Biberfeld et al, 1975; Forsum 
et al, 1976) and has found to be useful in the detection 
of a variety of Ag's including cell surface and 
cytoplasmic Ag's of peripheral blood leucocytes and 
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2.2 Fluorescence 
spleen cells, tissue sections of pituitary, pancreas and 
intestine and viral Ag's of tissue culture cells (Notani et 
aL, 1979). Recently more exotic labels have been used 
including Europium (Ius et aL, 1985), Ferritin (Bachi et 
aL, 1977), Gold (Roth et aL, 1978; Muller and Baigent 
1980; Geuze et aL, 1981; Slot and Geuze, 1981; Todd, 
1988) and the photoprotein Aequorin (Zenno, 1989). 
Luminescence phenomena may be classified generally as fluorescence, 
phosphorescence, chemiluminescence, triboluminescence and 
electroluminescence. The term luminescence indicates the emission of light 
or radiant energy accompanied by little or no heat and hence is often called 
'cold light'. The luminescence in most cases represents the energy emitted 
when a substance returns from an excited or higher energy state to its normal 
or lower energy state. In the case of fluorescence and phosphorescence the 
substance is raised to a higher energy state usually by the absorption of 
radiant energy such as ultraviolet rays. If the emission of energy ceases 
around 10-S sec after the exciting source has been removed, the phenomenon 
is called fluorescence and if it persists for a longer time than this the term 
phosphorescence is used. Chemiluminescence is essentially fluorescence 
except that the excitation energy is produced by a chemical reaction. If that 
reaction occurs in a living system, the luminescence is referred to as 
bioluminescence. Triboluminescence (Greek- tribo, to rub) is produced as 
a release of energy when certain crystals, such as uranyl nitrate or sugar are 
broken. Electroluminescence is a term applied to fluorescence or 
phosphorescence produced by the direct application of an electric current to 
a substance. 
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Emission and absorption spectroscopy have been used for many years in 
analysis whilst fluorescence spectroscopy has developed since about 1945. 
Absorption and fluorescence are closely related since the absorption of light 
precedes fluorescence emission. The absorption of energy occurs in discrete 
units or quanta equivalent to the energy difference between the ground state 
of the molecule and an upper electronic state. This and the potential 
outcome can be best described with the aid of the energy diagram, m Fzg 2.2. 
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Fig 2.2 Schematic representation of the energy transitions possible when a 
molecule capable of fluorescence absorbs energy. S0 = electronic ground 
state; S1 = first excited singlet state; S2 = second excited singlet state; 
T1 = first excited triplet state; T2 = second excited triplet state 
In order to produce fluorescence a molecule must absorb energy from some 
source such as radiant or chemical energy and be raised to an excited state in 
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which the electron pair remain in their singlet state i.e. they retain opposite 
spin. In most cases absorption of energy will result in the first excited singlet 
state (S1); if the highly excited singlet states (S2, SJ> ...... ) are reached these 
rapidly (10"12 sec.) lose energy by passing on vibrational energy to other 
molecules in a process known as internal conversion. When the molecule 
drops from the S1 state back to its normal ground state, much of the absorbed 
energy may be emitted as fluorescence at a longer wavelength (and hence less 
energy) than the absorbed energy. This shift in wavelength is known as the 
Stokes shift. Apart from fluorescence the molecule in its excited singlet state 
can lose energy in other ways. A non-radiant transition may occur where 
energy is given up in collisions with other molecules, usually solvent. 
Alternatively intersystem crossing may occur where some energy is lost in spin 
inversion to give the triplet state i.e. the electron pair have their spins parallel. 
Decay from the triplet to the ground state results in phosphorescence which 
is long lived compared to fluorescence and generally of a longer wavelength. 
Unlike absorbance spectra those obtained in fluorescence measurements are 
instrument dependent and so need to be corrected if comparisons are made. 
In particular allowances need to be made for the spectral output of the source 
since fluorescence is dependent on excitation intensity. The relationship 
between fluorescence, concentration and source intensity can be derived from 
the Beer-Lambert law 
I -kcl 
- = e 
I. 
where I is the intensity transmitted. 10 the incident intensity, k the absorption 
coefficient,c the concentration and l the path length of the cell. 
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Subtract both sides from 1 and the fraction of light absorbed is found. 
and 
1 I = 1 - e-Jxl 
I. 
I0 - I is the amount of light absorbed, which is proportional to the 
fluorescence intensity F but not equal to it since we must consider the 
quantum efficiency 0 (the fraction of molecules in the excited state that 
fluoresce) and the fact that fluorescence is emitted in all directions but the 
instrument only measures in one direction. 
A geometric factor k1must therefore be applied 
Now 
for low values of kcl and in most cases 
If the intensity of the light source is constant then 
F a c since Ok; k, I are constant. 
* This equation only holds for dilute samples and it is possible to calculate 
the concentration level (CmaJ above which non-linearity is observed from 
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C = 0·05 E - molar extinction coeifjicient 
mu: El 
likewise if the sample concentration remains constant and below Cmax 
?-- ~ 
Many compounds and elements exhibit the property of fluorescence but in 
many cases the emission is in the UV region. In general visible fluorescence 
may be expected from strongly absorbing structures such as aromatic systems 
with multiple conjugation and electron donating groups. Rigidity and 
planarity are also important. For example, in Fig 2.3 fluorescein is fluorescent 
whilst phenolphthalein is not. 
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Many organic compounds which show only a slight fluorescence under normal 
conditions may fluoresce intensely if combined with metal ions to form 
chelates. Environmental factors will influence fluorescence, and the charge 
on the chromophore will be affected by pH enabling some molecules to be 
used as acid-base fluorescent indicators e.g. luminol. Quenching of the 
fluorescence can occur due to solvent effects, increase in temperature and 
dissolved 0 2 which promotes intersystem crossing. 
2.3 Antibodies 
Antibodies are glycoproteins synthesised by an animal in response to the 
presence of a foreign substance and are isolated from the gamma globulin 
fraction of serum. In the human five classes of protein with antibody activity, 
termed immunoglobulins are recognised. These classes, based on structural 
characteristics are IgG, IgM, lgA, IgD and lgE and similar classes of antibody 
exist in other species. 
Animals can make specific antibodies against virtually any foreign chemical 
group, which if a macromolecule capable of eliciting antibody formation is 
known as an antigen or immunogen. Small molecules (RMM around 100 
- 1000), known as haptens do not stimulate antibody formation until 
conjugated to a carrier molecule. 
Traditional antibody production involves the repeated injection of antigen or 
hapten-carrier complex into an experimental animal, followed by collection of 
the animals bl~od serum which contains the required antibodies. The 
recovered serum will contain a heterogeneous population of antibodies with 
varying affinity and specificity for the antigen and may be used directly in an 
immunoassay after a simple dilution. However cross reactivity with molecules 
of similar chemical structure to the antigen may severely limit the usefulness 
of the serum. 
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More recently the development of monoclonal antibody technology based on 
the cell hybridisation method (Kohler and Milstein, 1975) has revolutionised 
antibody production techniques. In this procedure antibody secreting spleen 
cells are fused with "immortal" myeloma cells to produce a hybridoma cell 
line. Unlimited quantities of antibodies with very restricted specificities can 
be prepared by this method. The method involves the immunisation of mice 
with antigen followed weeks later with a booster of the same antigen. Days 
after . the booster the spleen is removed and mouse lymphocytes 
(approximately !OS cells) are fused in the presence ofpolyethylene glycol with 
cultured mouse myeloma cells (2 x 107) that are deficient in the enzyme 
hypoxanthine-guanine ribosyltransferase (HAT). The fused cells 
(heterokaryons) are cultured in a medium containing HAT that prevents 
growth of the myeloma cells. The mouse lymphocytes normally die after a 
week, leaving only the heterokaryon colonies that posses the combined traits 
of the lymphocytes and the myeloma cells. These cultures are called 
hybridomas and are cloned and the daughter cells screened for the production 
of specific antibody by micro titre plate enzyme or radioimmunoassay methods. 
A clone of cells that secretes a specific antibody of interest is further cloned, 
mass produced in ascites and frozen away for future use. 
The use of monoclonal antibodies in immunoassay has eliminated concern 
over the use of large quantities of antibodies in immunoradiometric assay 
methods since the amount required can be reproducibly made from the cloned 
cell lines. In addition selection of an ideal pair of monoclonal antibodies that 
recognise different determinants which are sterically distinct on the ligand 
molecule has permitted rapid simultaneous addition of labelled and solid 
phase antibody to the assay reaction mixture without loss of assay sensitivity. 
As already discussed in chapter 1 the need to measure parent compound 
cyclosporin A distinct from its metabolites has only been achieved in 
immunoassay with the introduction of monoclonal antibodies (Quesniaux, et 
al., 1987). In addition to the production of antibodies for use in immunoassays 
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the work provided interesting information about the structural parameters 
involved in antibody-antigen recognition. Cyclosporin A is a neutral, 
hydrophobic, cyclic undecapeptide with a RMM of about 1200 and its size 
corresponds approximately to the generally accepted dimensions of an 
antibody binding site and so may be expected to produce antibodies that react 
with the whole molecule. In fact more than 180 monoclonal antibodies to 
cyclosporin A were prepared (Quesniaux et aL, 1987), many of which had very 
specific recognition epitopes covering clusters of amino acids. From this work 
two monoclonal antibodies were isolated and selected for potential use in 
immunoassays based on their individual recognition epitopes. The first 
antibody was an IgG2a isotype and reacted strongly with residues 1, 6 and 9 
and weakly with residue 4. These residues are the sites of chemical change 
when cyclosporin A is metabolised in the body. The antibody was shown to 
have poor binding to cyclosporin A analogues derivatised at these positions 
and so was selected for use in immunoassay kits which measure only the 
parent compound. The second antibody, an IgG 1 isotype did not interact with 
residue 6, showed weak interaction with residues 1 and 9 but reacted more 
strongly with residue 4. It was shown that this antibody recognised both parent 
compound and the majority of metabolites and was chosen for use in assays 
where their combined concentrations are required. 
2.4 Immunoassay 
The basis of all immunoassay is the interaction between an analyte, known as 
the ligand or antigen and a biological molecule showing affinity for the analyte 
called the binder. A number of different binder molecules have been used to 
develop immunoassays including tissue receptors, such as in the determination 
of P human chorionic gonadotropin in pregnancy tests (Saxena, 1981) and 
carrier proteins such as thyroxine binding globulin (Ekins, 1960). However by 
far the most commonly used binders are antibodies, both polyclonal and more 
recently monoclonal and it was the work of Berson and Yalow (1959) that 
pioneered their use in immunoassay. 
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The basis of immunoassays with antibodies can be described by equation (1) 
Ag +Ab ... Ab- Ag (1) 
Ag = antigen Ab = antibody Ag-Ab = immune complex 
If a labelled derivative of the antigen (Ag ") that also binds the antibody is 
introduced then equation (2) results and either the free or the bound labelled 
antigen is measured. 
Ag + Ag' +Ab..,. Ab-Ag + Ab-Ag' (2) 
This type of assay is known as a competitive immunoassay because the 
labelled and unlabelled antigen compete for a limited quantity of antibody. 
Traditional radioimmunoassay where the label is a radioisotope uses the 
above approach which is also known as the labelled analyte technique (Ekins, 
1981). 
An alternative approach is the immunometric assay or labelled reagent 
technique (Ekins, 1981) in which an excess of labelled antibody is used to bind 
the antigen. These methods are in principle more sensitive than competitive 
assays (Ekins, 1985) and have a number of formats: 
Ag-1 
Ag + Ab' ..,. Ag-Ab' + Ab' ..,. Ag-Ab' + Ab'-Ag-1 
where solid phase antigen (Ag-j ) removes unbound Ab' 
Ag +Ab' + Ab-1 ..,. Ab'-Ag-Ab-1 +Ab' + Ab-1 
Ab' 
Ag + Ab-1 ..,. Ag-Ab-1 ..,. Ab'-Ag-Ab-1 + Ab' + Ab-1 
where solid phase antibody binds the antigen-labelled antibody complex. 
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This two site immunometric assay has a number of limitations including the 
need for a large quantity of antibodies since if the antibody concentration 
becomes the limiting factor the immunoassay reaction behaves like a 
competitive assay and so at high antigen concentrations the response is no 
longer linear. In addition this technique can only be applied to large antigens 
with at least two distinct antibody binding sites such as polypeptide hormones 
and tumour markers. 
A convenient way to classify immunoassays is to divide them into two groups 
according to whether they utilise homogeneous or heterogeneous techniques. 
Homogeneous assays rely on the fact that the measurable property of the 
label changes once the immune complex has formed and so free or bound 
labelled antigen can be determined in the presence of the other. 
Heterogeneous assays require a separation step to remove the bound labelled 
antigen from the unbound before determining one or the other. Some of the 
most commonly used separation techniques include: 
(a) Double antibody method: a second antibody from a different species of 
animal is used to precipitate the primary antibody-antigen complex which 
is then centrifuged out of solution. 
(b) Coated tube or plate : the reaction tube or microtitre plate is coated with 
primary antibody and unbound labelled antigen is washed off. 
(c) Solid phase : antibody is bound to cellulose, sephadex, polystyrene or 
glass beads. 
(d) Adsorption : free antigen is adsorbed e.g. with charcoal leaving bound 
antigen in solution. 
(e) Column separation: Ion exchange, gel filtration and immunoaffinity. 
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Although the separation step results in additional manipulations and hence 
longer assay time it also removes interfering substances thereby tending to 
make the assay more specific and sensitive than a corresponding homogeneous 
assay, although the precision tends to be worse. Because of their relative 
simplicity homogeneous assays lend themselves well to automation and have 
shorter assay times than heterogeneous techniques. Table 2.1lists a number 
of parameters comparing the two assay methods (Chan, 1987). 
Table 2.1 
Parameter 
Specificity 
Sensitivity 
Precision 
Automation 
Analysis Time 
Technical expertise 
Cost 
Reagent/ disposal 
Instrumentation 
Correlation with 
bioactivity 
+Advantage 
Heterogeneous 
immunoassay 
+ 
++ 
+ 
0 
0 
+ 
0 
- Disadvantage 
Homogeneous 
immunoassay 
0 
+ 
++ 
+ 
+ 
+ 
0 
0 
0- Average 
A large and increasing number of labels have been used in immunoassay, a 
representative selection is listed in Table 2.2. Historically immunoassays have 
used isotopic labels because they are simple to measure, unaffected by 
chemical environment, do not suffer from background interference and are 
sufficiently small that they do not interfere with the antigen-antibody binding. 
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Table 2.2 
Label Assay method Reference 
Enzymes 
Alkaline phosphatase Amplified colourimetric Johannson et al., 1986 
Electrochemical Wehmeyer et al., 1985 
Visual assessment Anderson et al., 1986 
.8-D-Galactosidase Colourimetric Labrousse et al., 1982 
Fluorimetric Ishikawa, 1987 
Horseradish peroxidase Fluorimetric Ishikawa, 1987 
Luminometric Thorpe et a/, 1985 
Urease Colourimetric Lo et al., 1988 
Fluorophore 
Fluorescein Fluorimetric Coxon et al., 1988 
Coumarin Fluorimetric A/lain et al., 1989 
Phycoerythrin Fluorimetric Anderson & Miller, 1988 
FITC/TMRITC 
Europium Time resolved Hemmzla et al., 1987 
Samarium Time resolved Bador et a/, 1987 
Isotopic 
1251 Solid scintillation counting Hunter & Corrie, 1983 
S7co Solid scintillation counting Desai et aJ, 1988 
Ligand 
Avidin Biotinylated enzyme Ashzhara et a/, 1987 
Biotin derivative Avidin-enzyme colourimetric Ohwovonole & Willdn, 1988 
Avidin-acridinium ester Hart & Taafe, 1987 
luminometric 
Luminescent 
Acridinium ester Luminometric Weeks & Woodhead, 1984 
Isoluminol derivatives Luminometric Seitz, 1984 
Particle 
Latex Nephelometric Marre et a/, 1987 
Turbidometric Collett-Cassart et al., 1989 
Particle Counting Willans et a/, 1988 
Stained bacteria Visual assessment Shoham (Schwartz) et a/, 
1987 
Vesicle 
Lipsome Entrapped colourimetric dye O'Connell et al., 1985 
, Table 2.2 Representative selection of labels used in immunoassays 
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However radio labels have a number of limitations including a relatively short 
half life, relatively long count times to achieve a good statistical accuracy 
(10,000 counts for a 1% variation), a limited shelf life, the expense of disposal 
and concern over safety. From an analytical point of view they cannot be used 
in homogeneous assays because they are unaffected by their environment. 
Because of the reasons stated above there has been a proliferation of 
immunoassays involving a wide range of non isotopic labels and this 
development has been well reviewed (Miller, 1990; Schall and Tenoso, 1981; 
Gosling, 1990). Amongst these alternative labels the most common'include 
enzymes (Engvall, 1980), fluorophores (Hemmila, 1985), luminescent 
compounds (McCapra et al., 1989), metals (Cais et aL, 1977) and spin labels 
(Esser, 1980). The most widely accepted and used non isotopic method is 
enzyme immunoassay (EIA) which has been shown to have similar or greater 
sensitivity than isotopic methods especially when the end point of enzyme 
activity is a fluorescent product (Neurath and Stride, 1981). The limitations 
with EIA are caused by the bulky labile enzyme, its susceptibility to inhibition 
and denaturation and the additional incubation with substrate to monitor the 
enzymes activity. 
Fluoroimmunoassay (FIA) overcomes many of the limitations found with 
isotopic and enzyme based assays and so offers the potential for widespread 
use in clinical analysis. Fluorescent labelling is safe and relatively inexpensive, 
the resulting conjugate is often stable thereby not limiting the shelf life of the 
assay kit. The ease and simplicity of making sensitive fluorescent 
measurements allows for the development of rapid, simple assays and offers 
the potential for automation. 
The major drawback with FIA methods has been their inferior sensitivity, 
caused to a great extent by the high background signal of the sample matrix. 
In many cases this matrix is serum, the emission spectrum of which is shown 
in Fig 2.4. 
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Fig 2.4 Fluorescence profile of human blood serum. Excita tion 350 nm 
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The most co=only used fluorophore is fluorescein and this is susceptible to 
serum interference both from background fluorescence at its emission 
wavelength of 525 nm and light scattering due to its small Stokes shift. 
However developments such as solid phase separation systems (Curry et aL, 
1979) enable the removal of interferents prior to measurement, whilst the 
introduction of new labels with unique fluorescent properties such as 
phycobiliproteins (Kronick and Grossman, 1983) and natural macrocyclic 
compounds such as porphyrins and chlorophylls (Hendrix, 1983) enable 
measurements at wavelengths less susceptible to background interference. In 
addition time resolved measurements using labels with very long fluorescence 
lifetimes such as Europium (Hemmila et aL, 1984) and Terbium (Wilmott N.J. 
et aL, 1984) overcome problems of interference by making the analytical 
determination after the background fluorescence has decayed. 
2.5 Flow injection analysis. 
The rapid expansion over the last decade of solid phase i=unoassay systems, 
especially 96 well microtitre plate methods confirms the benefits in 
convenience and efficiency available with these techniques (Gosling, 1990). 
However, they tend to be semi-quantitative and difficult to automate (Blake 
and Gould, 1984) and often fall a long way short of the ideal qualities 
required of an i=unoassay, namely that it should be fast, reliable, specific, 
sensitive, quantitative, reusable and automated. 
Flow injection i=unoassay (f.i.a.) was first described in the early 1970's 
(Ruzicka and Hansen, 1975) and is a continuous flow method based on the 
introduction of a sample aliquot into a moving non-segmented carrier stream. 
The method has most often been used in conventional analytical chemistry 
applications to provide online, automated reaction systems (Ruzicka and 
Hansen, 1986) . 
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The development of the method since its introduction and its use in clinical 
chemistry has been well reviewed (Linares et al., 1985; Schmid and Kunnecke, 
1990; Ludi et al., 1990) whilst excellent texts covering the theory, methodology 
and applications of f.i.a. are available (Ruzicka and Hansen, 1988; Karlberg 
and Pacey, 1989). This introduction will confine itself to a brief overview of 
the application of f.i.a. techniques to immunoassay and its potential 
advantages. 
As already suggested typical solid phase immunoassays have widespread use 
however, they fall short of the ideal requirements. F1ow injection analysis on 
the other hand is easily automated and the precise control of reagent addition 
and reaction times offers the potential for fast, reliable deterrninations with 
high analytical precision. When allied to immunochemistry techniques and the 
use of monoclonal antibodies specific, sensitive and quantitative assays are 
possible. 
Basically the typical f.i.a. immunoassay system incorporates one or more 
carrier streams into which reagents are introduced and which flow through an 
immunoreactor containing the solid phase ligand binder and on which the 
immunochemistry takes place. The isolated bound analyte or labelled analyte 
is then used to produce an analytical response at a downstream detector, 
through which the carrier stream flows. Electrochemical (DeAlwis and Wilson, 
1987) and optical (Lee and Meyerhoff, 1988) detectors have been used and the 
signal is generated either by directly monitoring the labelled immune complex 
after eluting it from the reactor or in the case of enzyme based assays using 
the immune complex to generate an electro- or optoactive- product. 
Depending on the complexity of the assay the system may also require other 
features including multiple injection valves, mixing coils and post reactor 
sample processing. 
A number of solid phases have been used in immunoreactors, these include 
Sepharose (Mattiasson and Borrebaeck, 1978), non porous silica (Lee and 
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Meyerhoff, 1990), activated nylon membrane (Stocklein and Schmid, 1990) and 
polymeric beads (Shellum and Gubitz, 1989). By far the most common binders 
used on immunoreactors are antibodies (Lee and Meyerhoff, 1988; Locasio-
Brown, 1990), however, the random coupling of the antibody to the support 
may limit the antigen binding capacity. Although attempts have been made to 
overcome this problem (DeAlwis and Wilson, 1987) the reactors have only 
limited applicability, determined by the specificity of the immobilised 
antibody. These problems can be largely overcome by the use of protein A as 
the ligand binder since this bacterial membrane protein binds to the Fe region 
of antibodies. This allows for the production of immunoreactors containing 
antibodies with their antigen binding sites orientated away from the support 
material and into the carrier stream thereby maximising potential antigen 
binding. In addition, a whole range of antibodies with different specificities 
can be bound to and eluted from the reactor (Richman, 1983) making it 
extremely flexible in its use. 
A number of methods have been developed employing immobilised protein 
A in a flowing system, the majority of which are used for isolating and 
purifying antibodies (Hjelm, 1972; Goding, 1976) and labelled antibody 
conjugates (Page, 1979) although recently a method for monitoring the 
bioprocess of monoclonal antibodies has been reported (Stockhein et aL, 
1991). 
A wide range of flow injection immunoassay methods have been published, 
these include the use of enzyme (Kelly and Christian, 1982), 
immunoprecipitation (Hughes and Worsfold, 1985), liposome (Plant et al., 
1988) and fluorescence (Lim and Miller, 1980) techniques. Surprisingly, the use 
of protein A in flow injection immunoassays has been limited (Mattiasson and 
Borrebaeck, 1987) even though the flexibility of protein A immunoreactors 
combined with flow injection techniques offers so much potential. 
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CHAPTER THREE 
MATERIALS AND MEmODS 
3.1 Materials 
Names and abbreviations used in the text are given in (brackets) 
[Tris(hydroxymethyl)aminomethane 
hydrochloride] (Tris) 
Sodium chloride 
Sodium hydroxide 
Citric acid 
Di-sodium hydrogen phosphate 
Sodium di-hydrogen phosphate 
Bovine serum albumin (BSA) 
Normal human serum 
FITC labelled rabbit anti-mouse IgG 
Sodium azide 
Sodium carbonate 
Sodium bicarbonate 
Anhydrous potassium carbonate 
Anhydrous magnesium sulphate 
Anhydrous sodium sulphate 
Casein [Hammarsten grade] 
Polyoxyethylenesorbitan Monolaurate 
(Tween 20) 
Bromine 
Triethylamine 
N,N'- dicyclohexyl-carbodiimide (DCCI) 
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SIGMA 
BDH 
SIGMA 
BDH 
BDH 
BDH 
SIGMA 
SIGMA 
SIGMA 
SIGMA 
BDH 
BDH 
BDH 
BDH 
BDH 
BDH 
SIGMA 
SIGMA 
SIGMA 
SIGMA 
18-crown-6 
2-Iminothiolane (2-IT) 
Succinimidyl 4-(p-maleimidophenyl) 
butyrate (SMPB) 
Dithiothreitol 
Iodoacetamide 
5-dimethylaminonapthalene-1-[N-(5-aminopentyl)] 
sulphonamide (monodansylcadaverine )(MDC) 
4-bromomethyl-7-methoxycoumarin (BMMC) 
4-bromomethyl-6,7-dimethoxycoumarin (BMDC) 
5( and-6-)-[ {N-(5-aminopentyl)amino }carbonyl] 
tetramethylrhodamine ( tetramethylrhodamine 
cadaverine) (1RC) 
Fluorescein 
Fluorescein isothiocyanate (FITC) 
/3-phycoerythrin (/3-Phy) 
Kieselgel 60 F254 0.2mm aluminium backed 
TLC plates 
Kieselgel 60 GF254 
Sephacryl S300 
PD-10 columns 
Biodyne membranes 
lmmunodyne membrane 
Alkylamine activated and non-activated 
controlled pore glass beads - GC Porasil 
type B mesh lOQ-500 (CPG beads) 
Disposable Puradisc 25PP syringe filter 
0.45JLm rated 
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ALDRICH 
PIERCE 
PIERCE 
SIGMA 
SIGMA 
SIGMA 
SIGMA 
KODAK 
MOLECULAR 
PROBES 
SIGMA 
SIGMA 
MOLECULAR 
PROBES 
MERCK 
MERCK 
PHARMACIA 
PHARMACIA 
PALL 
PALL 
WATERS 
WHATMAN 
All organic solvents - HPLC grade FISONS 
Mouse monoclonal antibodies(MAb) and cyclosporin 
congeners were kind gifts SANDOZ 
Glass microcolumn 50mm x 3mm I.D. fitted with 
polyethylene endpieces and 251'm rated Teflon 
frits OMNIFIT 
Controlled pore glass-protein A (Pro-A) 
particle size 75-1251'm, with 5.5mg Pro-A 
per m! of settled gel and binding 40-45mg 
of mouse IgG1 per m! of settled gel OROS 
Gilson Minipuls 3 peristaltic pump ANACHEM 
Solvent resistant pump tubing 0.015mm I.D. STERIUN 
All connections made with Teflon capillary 
tubing 0.8mm I.D. OMNIFIT 
Manual sample injection valve fitted with 
a 1001'1 Teflon sample loop 0.8mm I.D. OMNIFIT 
Model 176.051-QS flow cell with 1001'1 
sample compartment HELLMA 
Polyethylene centrifuge tubes 73mm x 23mm LUCKHAM 
3.2 Methods 
3.2.1 Fluorescence measurements 
Fluorescence spectra and measurements were recorded uncorrected at 
room temperature unless otherwise stated. A Perkin Elmer model LS-50 
fluorescence spectrometer was used with data manipulation and 
processing carried out using the LS-50 Fluorescence Data Manager 
software operating on an Epson AX3 personal computer. 
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3.2.2 Absorption measurements 
Absorption measurements were made corrected for background on a 
UV /VIS LKB Ultrospec II single beam spectrophotometer. 
3.2.3 Infra red measurements 
Infra red spectra were taken in chloroform, corrected for background on 
a Perkin Elmer 1600 series FTIR spectrophotometer. 
3.2.4 pH measurements 
pH measurements were carried out using a Philips PW9420 pH meter 
fitted with a potassium chloride electrode. The instrument was calibrated 
before use with standard buffer solutions at pH 4.00, 7.00 and 10.00 ± 
0.01. 
3.2.5 Mass determinations 
Weighing operations were made using a Precisa 405M- 200A electronic 
five place balance. 
3.2.6 Water purification 
Solutions were prepared using HPLC quality water purified by the 
Liquipure Modulab system. 
3.2. 7 Pi petting 
Pipetting was carried out using Gilson Pipetman and Microman variable 
automatic pipettes except that the application of samples to TLC plates 
and membranes was done using lJ.Ii or 2JLI Boehringer fixed volume pipettes. 
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3.2.8 Centrifugation 
Centrifugation was carried out using a Clandon bench- type model T52 
centrifuge fitted with an 18 x Sml sample rotar. 
3.2.9 Buffers 
Names used in the text are given in (brackets). All concentrations are in 
mol/litre. 
3.2.9.1 Equilibration buffer (Tris) 
SOmM Tris hydrochloride, O.SM NaCl. pH to 8.8 with SM 
NaOH. 
3.2.9.2 Elution buffer (Citrate) 
0.1M citric acid, O.SM NaCl. pH to 2.5 with 2M NazHP04 
3.2.9.3 Assay buffer (PBS/BSA) 
40mM Na2HP04, 8mM NaH2P04, 150mM NaCl, 0.01% BSA, 
0.1% NaN3• pH to 7.4 with 1M HCI 
3.2.9.4 Phosphate buffered saline (PBS) 
As for the assay buffer except that there is no BSA or NaN3 
3.2.9.5 Carbonate buffer 
0.015M NazC03, 0.035M NaHC03 pH 9.6. 
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3.2.9.6 Coupling buffer 
0.1M N~HP04, 0.05M NaCl pH 6.8 
3.2.10 Radioimmunoassay measurements 
Gamma counting was carried out using a LKB 1282 
Compugamma instrument with data handling and curve fitting 
using the LKB RIACALC software. 
3.2.10.1 RIA procedure for the analysis of fluorescent derivatives 
of cyclosporin A using the 1251 lncstar Cyclo-Trac 
polyclonal RIA kit. 
(i) 100J.Il of cyclosporin standard, control or unknown 
was aliquoted into assay tubes. 
(ii) 100J.Il of 1251 cyclosporin tracer was added to each 
assay tube and to a separate total count tube. 
(iii) l.Oml of primary antibody/second antibody 
preconjugate was added to each assay tube 
except tbe total count and non specific binding 
tubes. 
(iv) l.Oml of non inmmne primary antibody/second 
antibody preconjugate was added to the non 
specific binding tube. 
(v) all tubes except tbe total count tube were vortex 
mixed and incubated for 2 hours at 20-25 • C. 
(vi) all incubation tubes were centrifuged at 1000 x g 
for 20 minutes at 20-25 • C. 
(vii) the supernatant was decanted from each tube and 
the pellet counted for 1 minute. 
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3.2.10.2 RIA procedure for the analysis of fluorescent derivatives 
of cyclosporin C hemisuccinate using the 1251 Incstar 
Cyclo-Trac SP monoclonal RIA kit. 
Extraction of standards and controls 
(i) 400).11 of methanol was dispensed into a series of 
assay tubes for each standard and control. 
(ii) 100).11 of cyclosporin standard or control was 
aliquoted into each tube. 
(iii) the tubes were capped and vortex mixed for 15 
seconds. 
(iv) the capped tubes were centrifuged at 1600 x g at 
20-25 • C for 5 minutes. 
Assay of standards, controls and unknowns 
(v) 50).11 of extracted standard, extracted control or 
methanolic unknown were added to a series of 
assay tubes. 
(vi) 100).11 of 1251 cyclosporin tracer was added to each 
assay tube and to a separate total count tube. 
(vti) l.Oml of primary antibody/second antibody 
preconjugate was added to each assay tube except 
the total count and non specific binding tubes. 
(vtii) l.Oml of non immune primary antibody/second 
antibody preconjugate was added to the non 
specific binding tube. 
(ix) all tubes except the total count tube were vortex 
mixed and incubated for 1 hour at 20-25 • C. 
(x) the incubation tubes were centrifuged at 1600 x g 
for 20 minutes at 20-25·C. 
(xi) the supernatant was decanted from each tube and 
the pellet counted for 1 minute. 
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In normal use the assay operates with whole blood 
samples extracted as in sections (i)-(ix) thereby resulting 
in a 1:5 dilution of the sample. However the fluorescent 
cyclosporin derivatives were introduced at section (v) 
and so were not diluted prior to analysis. Therefore the 
values obtained from the standard curve were five times 
greater than they should be and were adjusted 
accordingly. 
3.2.11 Size exclusion chromatography 
Size exclusion chromatography was performed using a pre-packed 
PD-10 column of Sephadex G-25 previously equilibrated by 
passing through it three column volumes of the appropriate 
buffer. 
3.2.12 Thin layer chromatography (TLC) measurements 
TLC analyses were carried out using phosphor containing silica 
and the resulting quenching was visualised using an ultra violet 
plate reader at 366nm. 
3.1.13 High performance liquid chromatography (HPLC) analysis 
HPLC analysis of the fluorescent derivatives of cyclosporin C 
hemisuccinate was carried out as described in the literature 
(Lachno et al 1990) except that a Merck-Hitachi FlOOO 
fluorescence detector was placed in series with and after the UV 
detector. The AASP (advanced automated sample processor) was 
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used only to inject the sample via the pneumatically operated 
valve and at the same time initiate data collection from each 
detector. 
3.2.13.1 Instrumentation 
The apparatus was set up as in Fig 3.1. The 
chromatography system consisted of a Varian 
Instruments AASP, a Merck-Hitachi Lichrograph L-4000 
variable wavelength UV detector and a Merck-Hitachi 
FlOOO fluorescence detector. The analytical column 
(150mm x 4.6mm I.D.) was packed with 5JJ.m CPS 
Hypersil and a lOOmm x 4.6mm I.D. saturating column 
packed with 37-53JJ.m silica gel was connected between 
the pump and the AASP. Both columns were housed in 
a LKB 2155 forced air column oven. The AASP was 
interfaced to the chromatograph via a Valco 
pneumatically operated 10 port valve fitted with a 50JJ.l 
injection loop. Samples were introduced into the loop 
using a 25JJ.l Hamilton 700 series micro syringe. Sample 
peak data was collected and integrated using a Perkin 
Elmer-Nelson Turbochrom chromatography data system 
operating on an ffiM PS/2 model 80 micro computer. 
Data collection for each sample run was initiated 
through a contact closure on the AASP. 
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Fig 3.1 
AASP Injection valve 
i 
I 
remote 
start 
I 
-: ( 
-
saturating-+-
column 
data 
collection 
pump I 
I 
I 
solvent 
reservoir 1 
L.....---.1 
fluorescence 
detector 
Column oven 
analytical 
column 
l UV detector 
Schematic representation of the HPLC system used for the analysis of the 
fluorescent cyclosporin derivatives 
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3.2.13.2 Chromatographic conditions 
MDC, BMMC and BMDC derivatives 
Mobile phase 
Column 
: Hexane:Ethanol (85:15 vlv) 
: 5J.Im CPS Hypersil 
(150= X 4.6= I.D.) 
Flow rate : 1.0 mllmin 
Oven temperature : 53· C 
UV detection : 210nm 
Fluorescence 
detection 
TRC derivative 
Mobile phase 
:MDC Ex 340nm I Em 490nm 
BMMC Ex 355nm I Em 410nm 
BMDC Ex 380nm I Em 430nm 
: Acetonitrile:Methanol:Water 
( 60:20:20 v lv) 
Column : Silica (150= x 4.6= I.D.) 
Flow rate : 1.0 mllmin 
Oven temperature : room temperature 
UV detection : 210nm 
Fluorescence 
detection : Ex 545nm I Em 580nm 
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CHAPTER FOUR 
THE SYNTHESIS AND PROPERTIES OF FLUORESCENT 
CYCLOSPORINS 
4.1 Derivatives of cyclosporin A 
4.1.1 Introduction 
The fluorescent labelling of cyclosporin A must be approached by 
considering the reactivity of the functional groups contained within the 
molecule. Cyclosporin A is a polypeptide structure, (see chapter one) 
consisting of the amide functional group formed by interaction between 
amino groups and carboxyl groups of amino acids. The amide group 
-NHCO- in peptides is referred to as the peptide linkage. 
In addition to the amide group cyclosporin A also contains a number of 
saturated carbons and two unsaturated carbons in the form of a double 
bond. By far the most reactive of these functional groups is the double 
bond and it is at this point that derivatisation should be attempted. 
The fluorescent molecules most commonly used in labelling do not 
contain functional groups that easily lend themselves to addition to 
double bonds. A reactive intermediate must therefore be formed which 
will itself be displaced by the label. 
A very useful group of compounds that undergo a wide range of 
substitution reactions are the alkyl halides, the halogen of which may be 
displaced from a molecule by any group having basic properties. 
Therefore to obtain a fluorescent derivative of cyclosporin A the double 
bond must first be reduced by the addition of a halogen, to give the alkyl 
halide followed by displacement of the halogen atom by a fluorescent 
molecule with basic properties. 
The choice of halogen is made by considering the reactivity of the 
subsequent alkyl halide to substitution. The ease of reaction is 
dependent on the nature of the leaving group, alkyl iodides reacting 
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most rapidly and alkyl chlorides most slowly. For laboratory uses alkyl 
bromides are commonly used because they are 50-100 times more 
reactive than the corresponding chlorides. Iodides are somewhat more 
reactive than bromides but are quite a bit more expensive and this 
slightly increased reactivity does not justify their additional cost. The 
reagent of choice therefore is bromine water. 
The mechanism of bromination of double bonds is wen known resulting 
in anti addition of -Br and -OH. The significance of this mechanism in 
the bromination of the double bond in cyclosporin A can be seen when 
the structure of amino acid 1 is considered. The mechanism in Fig 4.1 
is proposed 
Fig 4.1 
H 
.. ~ 
HO 
M1 
Fig 4.1 Proposed mechanism for the bromination of cyclosporin A 
The formation of the tetrahydrofuran ring will impart some rigidity to 
the amino acid side chain and may serve as a useful bridging group to 
space the fluorescent molecule away from the bulky polypeptide 
structure. The alkyl halide now formed can be reacted with a 
nucleophilic fluorescent molecule. The basic amino group is an exce11ent 
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nucleophile and so a good choice would be a fluorophore containing this 
functional group, such as monodansylcadaverine, the structure of which 
is given in Fig 4.2 
Fig4.2 
MONODANSYLCADAVERINE (MDC) 
This is a useful molecule in that it has a large Stoke's shift of approx. 
200 nm (i.e. the difference in wavelengths of the light exciting the 
molecule and the light emitted in the form of fluorescence) and the 
nucleophilic amino group is at the end of a long chain away from the 
bulk of the molecule. This should help to reduce any problems caused 
by steric hindrance, such as reduced reactivity between the functional 
groups of the two bulky molecules and quenching of the fluorescence. 
4.1.2 Experimental. 
4.1.2.1 Synthesis, isolation and identification of CyA-Br 
derivative. 
94.9 mg (7.9 x 10·5 moles) of CyA was placed in a 250 ml round 
bottom flask and dissolved in 50 ml of HPLC grade MeOH. To 
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this was added ea. 8 ml of Br2 water (100 ~1 Br2 made up to 100 
ml with H 20) to give a 2:1 ratio of Br2 : CyA The reaction 
mixture was left stirring in the dark for 1 hour at room 
temperature after which time the solvent was taken off and the 
product recrystallised from heptane to give fine white crystals of 
CyA-Br (41.6 mg). 
KBr disc infra-red spectra were obtained and compared for 
parent CyA and the CyA-Br derivative, These showed that the 
compounds differed in two ways, firstly the OH stretching peak 
at 3416 cm·1 found with CyA was absent in CyA-Br and the C-H 
out of plane deformation indicative of the double bond in CyA 
at 970 cm·1 was also absent in the CyA-Br sample. These facts 
suggest that the proposed mechanism of derivatisation has 
occurred. 
4.1.2.2 Synthesis, isolation and identification of CyA-MDC derivative. 
107 mg (8.9 x 10·5 moles) of CyA was put into a 250 ml round 
bottomed flask and dissolved in 50 ml of MeOH; to this was 
added ea. 10 ml of Br2 solution (100 JLl of Br2 made up to 100 ml 
with MeOH) to give a 2 : 1 ratio of Br2 : CyA The reaction 
mixture was left stirring for about 10 minutes. 89.7 mg (2.67 x 
104 moles) of monodansylcadaverine (MDC) was added to the 
reaction mixture to give a 3 : 1 ratio of MDC: CyA and this was 
left stirring in the dark overnight at R.T. After this time ea. 65 
JLl of triethylamine was added to mop up HBr produced in the 
preceding derivatisation. The reaction mixture was transferred 
to a separating funnel and to this was added 40 ml of 
dichloromethane. It was then washed with water (3 x 30 ml) and 
the organic layer separated and dried with anhydrous N~S04• 
The mixture was then filtered, the solvent removed under 
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reduced pressure and the product stored in the freezer. 
4.1.2.3 TLC analysis of the reaction mixture 
The product was reconstituted in MeOH and the reaction 
mixture separated on a preparative TLC plate as in 3.2.12 using 
CH03 : MeOH (98:2 v/v) as the solvent system. Three 
fluorescent bands were isolated with Rf values of: band 1 - 0.36; 
band 2 - 0.66; band 3 - 0.78, whilst cyclosporin A gave an Rf of 
0.12 and the label remained at the origin. The isolated bands 
were washed from the silica with methanol and examined 
individually by TLC using the same solvent system on analytical 
plates. Bands 1 and 3 appear as single spots with comparable Rf 
values of 0.34 and 0.66 respectively but band 2 is seen as a 
number of spots with the major fractions at Rf 0.41 and 0.81 
suggesting decomposition of this derivative. The solvent was 
removed from the products under reduced pressure and the three 
bands stored in the freezer. 
4.1.2.4 HPLC analysis of the isolated bands. 
The isolated bands from 4.1.23 were reconstituted in ethanol and 
20 1-11 aliquots injected onto the column. HPLC was carried out 
as in 3.2.13 with both UV and fluorescence detection and this 
showed that band 1 contained a single major fluorescent fraction 
that was not MDC and that had a retention time of 7.6 min, as 
seen in Fig 4.3 compared to CyA of 6.9 min, shown in Fig 4.4 
Band 2 consisted of at least 5 fluorescent fractions confirming the 
instability of this particular derivative, shown in Fig 4.5. Band 3 
showed one major fluorescent peak, as seen in Fig 4.6, however, 
this proved to have the same 
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Fig 4.3 Chromatograms of band' 1' isolated from the synthesis of 
'CyA-MDC. Detection by UV and fluorescence 
0.010 100 
~ 0.005 50 
1-r ... 
o ooo+---t-1---.---., o+---~--.---. 
-20 0 20 
"lime I mms 
40 0 5 10 
Time I mms 
Fig 4.4 Chromatograms of CyA plus internal standard CyD. 
Detection by UV and fluorescence 
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·Fig 4.5 Chromatograms of b'arid1i isolated from the synthesis of 
Cy~~~DC. Detection by UV and fluorescence 
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Fig 4.6 Chromatograms of band 3,isolated from the synthesis of 
CyA-MDC. Detection by UV and fluorescence 
retention time as the label itself. When a mixture of band 3 and 
the label was injected only one elution peak was seen. This 
suggests that the fluorescence found with band 3 is due solely to 
the presence of unconjugated label. This is surprising since by Tic 
band 3 contained a single fluorescent compound with an Rf 
value of 0.78, whilst the excess label remained at the origin. It 
is possible that this derivative breaks down on column (temp. 
53· C) to regenerate the free label as seen in Fig 4. 7 
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Fig 4. 7 Chromatograms of the MDC label, showing the same 
retention times as t!a'nd'· '3. Detection by UV and 
fluorescence 
However, no peak was detected by UV corresponding to 
regenerated cyclosporin although it could have eluted in the 
solvent front. 
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To confirm the absence of excess cyclosporin A in the extracted 
bands the samples were eo-injected with a standard solution of 
cyclosporin A The chromatograms for all three bands show no 
peaks eo-eluting with the spiked cyclosporin A 
4.1.2.5 Fluorescence spectra of band 1 
Band 1 was reconstituted in methanol, its fluorescence spectra 
were obtained and are shown in Fig 4.8 
4.1.2.6 RIA of isolated bands 
The isolated products were reconstituted in methanol and 50 ILl 
of each taken and the solvent removed under reduced pressure. 
The products were then reconstituted in 50 ILl of methanol:water 
(1:1 v/v), to this was added 950 ILl of normal human serum and 
the sample vortex mixed for 10 seconds. Each product was then 
assayed according to the protocol in 3.2.10.1 
The RIA kit generates a standard curve between 20 and 2000 
ng/ml and from this concentration values for each band were 
found to be above the range of the assay. A 1:200 dilution of the 
methanolic stock solution of each band was prepared and 50 ILl 
of this assayed as before. The concentration of each band was as 
follows: band 1 - 278 ng/ml ; band 2 - 234 ng/ml ; band 3 - 347 
ng/ml. These results show that the fluorescent derivatives 
isolated from the reaction mixture all bind with the polyclonal 
antibodies in the assay kit. The results from the HPLC analysis 
of the bands showed that none of them contained any parent 
compound and so the RIA results cannot be due to 
contamination from cyclosporin A 
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Fig 4.8 Excitation and emission spectra of MDC derivative (band 1) of 
cyclosporin A in methanol. SLITS 2.5/5.0 
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In addition to the above RIA a parent compound specific assay 
containing a monoclonal antibody to cyclosporin A was used to 
evaluate the binding of the isolated bands. Samples were 
prepared in serum as above and assayed according to 3.2.10.1 
The RIA kit generates a standard curve between 7.6 and 560 
ng/ml and includes two reference standards which should give 
values between 37.3 and 54.1 ng/ml for internal standard 1 and 
111.4 and 156.6 ng/ml for internal standard 2. The results are 
summarised in Table 4.1 
Table 4.1 
Sample [CyA] / ng/ml 
Internal standard 1 46 
Internal standard 2 150 
Band 1 - stock solution 55 
Band 2 - stock solution 49 
Band 3 - stock solution 69 
Band 1 - 1:200 dilution Below range 
Band 2 - 1:200 dilution Below range 
Band 3 - 1:200 dilution Below range 
The results show that when undiluted the three bands show some 
binding with the monoclonal antibody but when diluted there is 
no recognisable binding. Initially the results seem surprising since 
the monoclonal antibody is supposedly sensitive enough to 
distinguish between parent compound and metabolites where the 
change may only be demethylation or hydroxylation at one atom, 
yet addition of a very large fluorescent molecule does not bring 
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about complete incompatibility with the antibody. However the 
polyclonal RIA results showed that when undiluted the bands 
were above the top standard of the assay and calculations based 
on the 1:200 dilutions suggest that the stock solutions of the 
isolated bands are in the 50 - 70 JLg/ml range. At this 
concentration it is possible that a small amount of each derivative 
binds to the monoclonal antibody to give a positive result. 
However it is obvious that the monoclonal antibody shows 
markedly less binding for the fluorescent derivatives than the 
polyclonal antibodies and as such would not be suitable for use 
in an immunoassay with derivatives synthesised from 
cyclosporin A 
4.1.3 The need for a parent compound specific immunoassay 
After about one year of the project it became obvious that clinicians 
were demanding information on the levels of parent compound only 
because of the lack of information concerning the immunosuppressive 
activity and toxicity of its metabolites. At this time the American 
Association for Clinical Chemistry set up a task force to evaluate critical 
issues concerning the therapeutic monitoring of cyclosporin A In their 
report (Shaw, 1987) they highlighted the great variation in assay methods 
being used around the world and made a number of recommendations 
in order to standardise procedures. The major points concerning the 
analysis of cyclosporin A were that the sample matrix should be whole 
blood and that the analytical method should only measure the parent 
compound. Because of these recommendations it was decided that all 
further work would be concerned with the production of an 
inununoassay that utilised a parent compound specific monoclonal 
antibody. 
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4.2 Fluorescent derivatives of cyclosporin-C-hemisuccinate. 
4.2.1 Introduction. 
The synthesis of a fluorescent cyclosporin derivative that will be bound 
by the parent compound specific monoclonal antibody cannot be 
successfully carried out using cyclosporin A for the reasons demonstrated 
in 4.1. The selection of the starting material for the synthesis was 
determined by considering the method used to produce the monoclonal 
antibody (Quesniallx et aL, 1987) used in commercial assay kits and 
provided by Sandoz for this project . Although cyclosporin A was shown 
to be immunogenic when injected as a free peptide only low affinity IgM 
monoclonal antibodies were obtained (Quesniaux et aL, 1985). It was 
therefore decided to use cyclosporin-C-hemisuccinate covalently linked 
to a carrier molecule, chicken ovalbumin as the immunogen. Using this 
conjugate an IgG2a monoclonal was produced which showed a high 
binding affinity for cyclosporin A, in the range 10'10 to 10·11 !/mol 
(Quesniaux et al., 1987). The antibody had a recognition epitope covering 
residues 1,4,6 and 9 on the cyclosporin A molecule, which are the sole 
sites of metabolism (Maurer, 1985) whilst showing no recognition for 
residue 2 through which cyclosporin-C- hemisuccinate was linked to the 
carrier molecule. Because of this it was reasoned that a fluorescent label 
linked through residue 2 of cyclosporin-C-hemisuccinate would nor 
interfere with the binding of the monoclonal antibody. It was therefore 
decided to label cyclosporin-C-hemisuccinate (CyC-Hem) with a number 
of fluorophores and investigate the potential of these derivatives for use 
in immunoassay. 
Four labels with different fluorescent properties were investigated and 
their structures are shown in Fig 4.9 
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MONOOANSYLCAOAVERINE 
TURAMETHYL RHODAMINE CADAVERINE 
4-BROMOMETHYL-7-METHOXYCOUMARN 4-BROMOMETHYL -6,7,-DIMETHOXYCOUMARIN 
' 
Fig 4.9 St?u_cture of fluorophores used to label cyclosporin-C-hemisuccina~ __ 
4.2.2 Experimental 
4.2.2.1 Synthesis of fluorescent derivatives of CyC-Hem 
4.2.2.1.1 Using monodansylcadaverine (MDC) Fig 4.10 
OH Q:)""''"''•""' 
.. ., 
II()H()CWf$Yl~N[ (t.x;) 
0·1-€) 
CYC-HEt.I-MDC 
. .fig 4,10 Reaction scheme for the synthesis of the MDC 
~ derivative of cyclosporin-C-hemisuccinate 
91 
- ------------------------------------------, 
38.1 mg of MDC and 10.0 mg of 
dicyclohexylcarbodiirnide were dissolved in 40 ml of 
dried CH2Cl2 in a 100 ml round bottom flask. To this 
was added dropwise with stirring 51.8 mg of 
cyclosporin-C-hemisuccinate dissolved in 20 ml of dried 
CH2Cl2, and the mixture was left stirring in the dark 
for 24 hours. After this time the solvent was removed 
under reduced pressure and the product stored in the 
freezer. 
4.2.2.1.2 Using 4-bromomethyl-6,7-dimethoxycoumarin (BMDC) 
or4-bromomethyl-7-methoxycoumarin (BMMC) Fig 4.11 
Cy<:lospor/1\ C heml&...,dnat. 
+ 
R • 11 4-SROI.IOWETHYL-7-METHOXYCOUMARIN 
R • CH30 4-SROMOMETHYL-6 ?-OIMETHOXYCOVMARIN 
R • H CyC-HEM-BMt.IC 
R • OCH3 Cye-HEM-SMDC 
Fig 4.11.Reaction scheme for the synthesis of the coumarin 
- > derivathres of cyclosporin-C-hemisuccinate 
24.1 mg of cyclosporin-C-hemisuccinate, 3.0 mg of 18-
crown-6 and 13.5 mg of anhydrous potassium carbonate 
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were added to a round bottom flask. The constituents 
were then dissolved in 20 rnl of a solution of BMDC or 
BMMC in acetone (0.84 mg/rnl) and the mixture 
refluxed for 1 hour. After this time the solvent was 
removed under reduced pressure and the product stored 
in the freezer. 
4.2.2.1.3 Using tetramethyl rhodamine cadaverine (TRC) Fig 4.12 
0-suo:::ININIOOOX'I'SI.ICttn\. THR 2CYa.OSPORIN 
- l (C0~2-~ ---~ ~-. 
0 0 
I I 
C-of:-c:Hz-c-N-4-(CHz):;tHX: 
I 
0 
+ 
.... , 
Fig 4.12 Reaction scheme for the synthesis of the TRC 
_ _ ~ •c> derivative of 0-succinimidooxysuccinyl-cyclosporin C 
Initial attempts to synthesise a derivative from TRC and 
cyclosporin-C-hemisuccinate using the method described 
in 4.2.2.1.1 resulted in the generation of multiple 
products and so a milder synthesis was developed. This 
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involved using 0-succinimidooxysuccinyl-cyclosporin C 
in which the acid function is activated towards attack by 
primary amines under alkaline conditions. 
29.5 mg of 0-succinirnidooxysuccinyl-cyclosporin C was 
dissolved in 500 J.ll of dimethylformarnide in a 100 m! 
round bottom flask. To this was added 10 mg of TRC 
dissolved in 40 m! of O.OSM carbonate buffer pH 9.6 and 
the reaction mixture stirred at room temperature for 48 
hours. After this time a red precipitate had been formed 
which was separated from solution by centrifugation and 
then washed and centrifuged twice in 10 m! of water. 
The precipitate was then dissolved in 25 m! of 
dichloromethane and washed with 3 x 10 m! of water. 
The organic phase was then dried with anhydrous 
magnesium sulphate, filtered and the solvent removed 
under reduced pressure. The red product was stored in 
the freezer. 
4.2.2.2 Examination of the reaction mixtures by TLC 
The products were reconstituted into methanol and 3 x 1 J.ll 
aliquots applied to the analytical plates. For the BMMC, BMDC 
and MDC derivatives the developing solvent used was 
chloroform:methanol (96:4 v/v) and the plates were visualised 
using an ultra violet plate viewer at 366 nm. For the TRC 
derivative methanol was used for elution and the intensely red 
product was viewed by eye. The Rr values of the reaction 
mixtures are summarised in Table 4.2 
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Table 4.2 
Sample Rfvalues of Position of 
products excess label 
MDC 0.28, 0.41 remains at origin 
BMMC 0.31 on solvent front 
BMDC 0.39 on solvent front 
TRC 0.50 remains at origin 
4.2.2.3 Isolation of products 
For each reaction mixture the sample was reconstituted in 
methanol and subjected to preparative chromatography using the 
solvent systems described in 4.2.2.2. The appropriate bands were 
scraped from the plates and the products washed from the silica 
with methanol, dried over anhydrous magnesium sulphate and 
filtered. The solvent was removed under reduced pressure and 
the raw product weighed and stored in the freezer. Table 4.3 lists 
the mass of raw product from each synthesis. 
Table 4.3 
Sample mass/ mg 
MDC Rr0.41 2.3 
MDC Rr0.28 1.7 
BMMC 10.0 
BMDC 16.7 
TRC 8.4 
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4.2.2.4 Analysis of the two MDC products 
The two bands isolated from the MDC reaction mixture were 
reconstituted into 1 m! of ethanol and examined by HPLC using 
the conditions described in 3.2.13 except that the mobile phase 
was hexane:ethanol (91:9 v/v) and 20 td of sample was injected 
onto the column. Analysis of the chromatograms showed that the 
band isolated by TLC with an Rf of 0.41 consists of two distinct 
fluorescent derivatives with retention times of 11.31 and 22.62 
minutes. The band with Rf 0.28 showed only one fluorescent 
peak by HPLC with a retention time of 70.09 minutes. Because 
of the multiple products it was decided to discard the MDC 
product band Rf 0.41 and to carry out all further investigations 
using the Rf 0.28 product. 
4.2.2.5 Isolation and collection ofMDC, BMMC and BMDC derivatives 
byHPLC 
The crude products of synthesis were reconstituted into ethanol 
to give stock solutions of the following concentrations: MDC- 1.7 
mg/ml; BMMC - 10.0 mg/ml; BMDC - 10.0 mg/ml. 
25 ~I of each stock solution was in turn examined by HPLC using 
the conditions described in 3.2.13 The retention times of the 
eluted peaks for each sample were determined by both UV and 
fluorescence detection and the results are shown in Table 4.4 
Chromatograms from the fluorescence detector are shown in 
Fig 4.13 to 4.15 
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Table 4.4 
Sample 
CyC 
MDC 
BMMC 
BMDC 
Retention time / minutes 
UV detection Fluorescence detection 
3.71 
16.36 
11.41 
15.12 
16.48 
11.54 
15.24 
The results show that each crude product contains only one 
fluorescent derivative and it was decided to collect the pure 
product after it elutes from the column. To do this 25 JLl of each 
stock solution in turn was injected onto the column and the 
fluorescent fraction collected as it emerged from the fluorescent 
detector. The solvent was removed under reduced pressure and 
the product stored in the freezer. 
4.2.2.6 Isolation and collection of the TRC derivative by HPLC 
The crude product of the synthesis was reconstituted into 3 ml of 
methanol and 50 JLl of this was made up to 1 ml with methanol. 
10 JLl was examined by HPLC using the conditions described in 
3.2.13 and the chromatogram from the fluorescence detector 
monitored. This showed that the TRC derivative consisted of 
more than one fluorescent product as seen by shoulders on each 
side of the elution peak. 
97 
Chromatogram 
FlleN"' : C:l2700\datai\NTF009B.RAW Date: 19-1-99 16:09 Page I of I 
Start Tll!e: 0.00 11n End Tae: '30.00 11n loN Point: 5021 uV Htgh Point: 159194 uV 
Vertical St:ale Fat:tor: 1.00 Plot Offset: -3 •V Plot St:a!e: 162 1V 
(1 ~1j r 1j 0 r ID m ~ rt ~ t !!I 
t· ~~ n 1 n n 0 1 1 n~ 1'1 e 0 
1'1 1j~ ~ ~ m 0 !'i ID m ~m l'J ~ m 
r r r r re ('I N (1 
' ' " '" 
lllll 
" 
IOl 
> ) 
V 
Ql 
01 T!lll [ 
0 
(l 
01 
Ql 
a: 
ll ' 
I 
·rrnTflrr_./___________ nr--rr·.--1 - .. ~ 
5 00 10 00 15 00 20 00 25 00 
T1me (ml.n) 
Fig 4.13 Elution profile of the MDC derivative. Fluorescence detection 
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Fig 4.14 Elution profile of the BMMC derivative. Fluorescence detection 
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A number of flow rates, oven temperatures and mobile phase 
compositions were investigated but it proved impossible to 
separate the components of the elution peak and so it was 
collected ·and used as a whole. It is probable that the poorly 
resolved elution peak is due to the presence of isomers since the 
label used in the synthesis is an isomeric mixture. The solvent 
was removed under reduced pressure from the collected 
fluorescent fraction and the product stored in the freezer. 
4.2.2. 7 Fluorescence profiles of the purified derivatives 
The isolated pure derivatives were reconstituted in methanol and 
' their fluorescence spectra examined. Excitation and emission 
profiles are shown in Fig 4.16 to 4.19 and the maxima 
summarised in Table 4.5 
Table 4.5 
Sample Excitation Emission 
maxima I nm maxima I nm 
MDC 336 510 
BMMC 355 409 
BMDC 383 439 
TRC 550 580 
These values show that the coumarin derivatives, BMMC and 
BMDC have Stokes shifts (the difference between their excitation 
and emission maxima) of about 50 nm and the TRC derivative 
of only 30 nm whereas the MDC derivative has a shift of 174 nm. 
A large Stokes shift is important since interference due to 
scattered light increases if the excitation and fluorescence 
wavelengths are too similar, thus limiting the sensitivity of the 
assay. 
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Fig 4.16 Excitation and emission spectra of MDC derivative of 
cyclosporin-C-bernisuccinate in methanol. SLTTS 2.5/ 5.0 
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Fig 4.17 Excitation and emission spectra of BMMC derivative of 
cyclosporin-C-hemisuccinate in me tha nol. SLITS 2.5/ 5.0 
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Fig 4.18 Excitation and emission spectra of BMDC derivative of 
cyclosporin-C-hernisuccinate in methanol. SLITS 5.0/10.0 
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Fig 4.19 Excitation and emission spectra of TRC derivative of 
cyclosporin-C-hernisuccinate in methanol. SLITS 2.5/5.0 
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4.2.2.8 Infra red analysis of the derivatives 
The infra red spectra of each derivative was taken in CHC13 and 
showed characteristic cyclosporin peaks at 1635 cm·1 (amide 
carbonyl) and at 970 cm·1 (C-H deformation on double bond in 
~ amino acid). The fluorophore contributed a band centred at 
3020 cm·1 (aromatic C-H stretch) and a number of unidentified 
peaks in the region 800- 650 cm·1• A typical infra- red spectrum 
for CyC-hem-BMMC is shown in Fig 4.20 
4.2.2.9 Photostability of the derivatives under constant illumination 
During the course of any fluorescence measurements the sample 
is exposed to an intense light source and in some cases the level 
of incident light is sufficient to decompose it. Therefore 
investigations were carried out to compare the photo-stability of 
the derivatives with that of a solid fluorescent standard, 
(tetraphenyl butadiene in a polymer matrix) and that of 
fluorescein, a very widely used and accepted fluorophore. 
The BMMC, BMDC, MDC and TRC derivatives, along with the 
fluorescein reference were prepared in methanol at 1 JLg/ml and 
in turn placed in the fluorimeter. The fluorescence intensity of 
each derivative was monitored at its maxima over a ten minute 
period with the fluorimeter settings as in Table 4.6 
Table 4.6 
Sample Excitation Emission Slits 
polymer block 343 421 5/10 
fluorescein 495 515 5/10 
BMMC 355 409 5/10 
BMDC 383 439 5/10 
TRC 550 580 5/10 
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Ffffi spectrum in CHCI3 of the BMMC derivative of cyclosporin-C-hemisuccinate 
Intensity measurements were taken and the results plotted as a 
percentage of the original intensity Fig 4.21 
These results show that all of the derivatives have less 
photo-decomposition than fluorescein with the MDC derivative 
clearly showing the best photo-stability. It would seem from this 
evidence that photo- decomposition should not be a problem 
whilst taking readings when using these derivatives in 
immunoassays. 
4.2.2.10 Influence of pH on fluorescence intensity 
Because of the intended use of protein A methods it was decided 
to investigate the influence of pH on the fluorescence intensity 
of the BMMC and TRC derivatives. If low pH quenches the 
fluorescence as happens with fluorescein then the derivatives 
would not be suitable for use in the intended system. 
The derivatives were prepared in methanol at the following 
concentrations: BMMC - 15.6 J'g/ml; TRC - 45 J'g/ml. Citrate 
and Tris buffers were prepared as in 3.2.9 and the pH adjusted 
to give citrate buffers at pH 2.5, 3.5, 4.5 and 5.5 with Tris buffers 
at pH 6.8, 7.8, 8.8 and 9.8. 
25 J'l of derivative was added to 375 J'l of buffer and the 
fluorescence intensity measured as follows: 
BMMC 
TRC 
Ex - 325 nm Em - 405 nm 
Ex - 550 nm Em - 580 nm 
slits 5/5 
slits 10/15 
The intensity value in each buffer was determined for both 
derivatives and the results are shown in Fig 4.22 
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Fig 4.21 Change from the initial fluorescence intensity with time. 
Influence of constant illumination on the fluorescence output of the 
derivatives compared to a solid fluorescence standard and fluorescein 
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Fig 4.22 Influence of pH on the fluorescence intensi ty of the BMMC and TRC 
derivatives of cyclosporin-C-hemi uccinate 
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From the plots it can be seen that the BMMC derivative suffers 
virtually no quenching at low pH and is remarkedly unaffected 
across the whole pH range. The fluorescence intensity of the 
'IRC derivative does show some pH dependence with a reduction 
of about 25 % when the pH is reduced from 4.5 to 2.5, however 
this is not a major quenching problem. These results show that 
pH dependent quenching should not be a significant drawback in 
using the BMMC and 'IRC derivatives for immunoassay 
development. 
4.2.2.11 Long term stability of the derivatives 
Twelve months after their synthesis the BMMC, BMDC and 'IRC 
derivatives were removed from the freezer and their fluorescence 
and infra red spectra taken and compared with those obtained 
when they were newly synthesised. None of the derivatives 
showed any spectral changes. 
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CHAPTER FIVE 
IMMUNOREACTMTY OF FLUORESCENT DERIVATIVES OF CyC-Hem 
5.1 Assessment of antibody binding to derivatives 
As previously discussed in 2.3 and 4.2.1 the fluorescent derivatives should be 
compatible with the parent compound specific monoclonal antibody since its 
recognition epitope does not include residue 2, through which the 
fluorophores are linked. A number of techniques were used to investigate the 
binding between the monoclonal antibody and the different fluorescent 
derivatives. 
5.1.1 Radioimmunoassay 
It was decided to take the purified derivatives from 4.2 and submit them 
as samples into a parent compound specific RIA for cyclosporin A which 
utilises the same monoclonal antibody as used in this project. 
5.1.1.1 Assessment of the TRC derivative 
The TRC derivative isolated by HPLC in 4.2.2.6 was 
reconstituted into 5 ml of ethanol and duplicate 50 J.£1 aliquots 
submitted for RIA analysis as in 3.2.10.2. The RIA gave a result 
of 781 ng/ml showing that the TRC derivative binds with the 
monoclonal antibody. By working backwards it was possible to 
calculate the concentration of immunoreactive TRC in the crude 
stock solution. The collected fraction was reconstituted into 5 ml 
and the RIA determined this at 781 ng/ml. The collected fraction 
therefore contains 3905 ng which was injected onto the column 
in 10 J.ll. This sample was a 1:20 dilution of the stock solution 
and so 10 J.ll of the stock contains 78.10 J.lg which is equivalent to 
7.81 mgfml. However as explained in 3.2.10 samples are not 
diluted prior to RIA analysis and so the actual concentration was 
calculated to be 1.56 mg/ml, or 4.68 mg in total, of 
immunoreactive TRC in the stock solution. 
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5.1.1.2 Assessment of the MDC, BMMC and BMDC derivatives 
The MDC, BMMC and BMDC derivatives isolated by HPLC in 
4.2.2.5 were reconstituted into 10 ml of ethanol and 50 % serial 
dilutions into ethanol were made. Duplicate 50 1'1 aliquots of 
each dilution were taken and submitted for RIA as in 3.2.10.2 the 
results are shown in Table 5.1 
Table 5.1 
Sample Dilution Factor Conc/ng/ml 
MDC1 0 458 
MDC2 1:1 111 
MDC3 1:2 43 
MDC4 1:4 43 
MDC5 1:8 30 
MDC6 1:16 16 
MDC7 1:32 10 
BMMC1 0 3318 
BMMC2 1:1 2783 
BMMC3 1:2 1162 
BMMC4 1:4 487 
BMMC5 1:8 232 
BMMC6 1:16 97 
BMMC7 1:32 58 
BMDC1 0 2586 
BMDC2 1:1 2488 
BMDC3 1:2 815 
BMDC4 1:4 410 
BMDC5 1:8 199 
BMDC6 1'16 88 
BMDC7 1:32 49 
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The calibration curve for the RIA is at its most reliable between 
100-500 ng/rnl (private communication - Harefield Hospital). The 
above results show that all three derivatives exhibit binding with 
the antibody and that for the BMMC and BMDC derivatives the 
serial dilutions are represented in the results within the 
calibration range. The MDC derivative shows poor results, 
although for the most part they are outside the optimum 
calibration range. The low values may be due to low binding 
affinity with the antibody. In further studies the concentration of 
each stock solution was calculated as in 5.1.1.1 using the RIA 
results and compared with those obtained by dry mass 
calculations stated in 4.2.2.3. The results are summarised in Table 
5.2 
Table 5.2 
Derivative "Dry mass" (x) "RIA mass" (y) yx 100 
/mg /mg X 
MDC 1.70 0.18 106% 
BMMC 10.00 7.80 78.0% 
BMDC 16.70 10.95 65.6% 
TRC 8.40 468 55.7% 
From the above results it can be seen that a much smaller 
percentage of the crude MDC product is detected by RIA than 
that detected with the coumarin and TRC derivatives supporting 
the suggestion of lower affinity of the MDC derivative with the 
monoclonal antibody. 
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Using concentration values determined by RIA some estimation 
of the overall yield of each synthesis was possible. For the MDC 
derivative the reaction gave less than 1% yield, reflecting the 
generation of multiple products. For the coumarin derivatives the 
overall yield was approximately 33% and 46% for the BMMC 
and BMDC products respectively, whilst the 1RC derivative gave 
a yield of approximately 12%. These values might be further 
improved by changing the reaction conditions, though in 
determining the yields it has been assumed that the monoclonal 
antibody has the same affinity for all derivatives, an assumption 
that would appear not to be valid. 
5.1.2 Purification of the stock solutions 
The crude stock solutions of all the derivatives were purified by HPLC 
as in 3.2.13 by repeated injections, collection of the fluorescent fraction 
and combining of the extracts. The pure derivatives were submitted for 
RIA as in 3.2.10.2 and the results used to calculate the quantity of 
purified immunoreactive derivative. The results are summarised in Table 
5.3 
Table 5.3 
Derivative 
MDC 
BMMC 
BMDC 
1RC 
Purified mass / mg 
0.16 
7.58 
10.21 
4.50 
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These values compare well with those obtained prior to purification of 
the whole crude stock solutions. The solvent was removed from the 
purified stock solutions under reduced pressure and the derivatives 
stored in the freezer. 
Because of the very low yield from the MDC synthesis and the apparent 
lack of binding affinity with the monoclonal antibody the MDC 
derivative was not considered for use in the inununoassay development. 
This decision was vindicated when after three months the derivative was 
reconstituted in methanol and the fluorescence found to have decayed 
to zero at 510nm. After scanning the excitation and emission spectra 
only slight fluorescence was detected at 360nm when exciting at 240nm. 
These findings suggest that the MDC derivative is chemically unstable 
and further proves its unsuitability for use in immunoassay. 
5.1.3 Fluorescence polarisation 
5.1.3.1 Introduction 
As already discussed in 2.2 fluorescence phenomena are 
environment dependent and this offers the potential for the 
development of homogeneous methods. The most widely used in 
fluorescence analysis is the polarisation assay (Watson et al., 
1976) in which the labelled analyte is excited by vertically 
polarised light and the emission measured alternatively through 
a vertically and horizontally oriented second polariser. The 
fluorescence polarisation value pis determined from equation (1) 
Equation 1 
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where Iv and IH refer to the fluorescence intensity with the 
emission polariser vertical and horizontal respectively. 
This result is sufficient when comparisons are being made 
between polarisation values obtained on the same instrument, as 
happens with immunoassay measurements. However if absolute 
polarisation values are required then a correction must be made 
to account for the optics of the emission monochromator which 
causes unequal transmission of the components of the polarised 
light. The corrected polarisation value p' is given by equation (2) 
Equation 2 
where I and subscripts are as in equation (1) and I1 refers to the 
fluorescence intensity when the excitation polariser transmits 
horizontal polarised light. 
It is found that p is close to zero for molecules with low relative 
molecular mass. The plane polarised light only excites those 
molecules whose excitation vector is correctly oriented, however 
because of their size the molecules rotate rapidly and lose their 
orientation during the lifetime of the fluorescent label. The 
resulting emission is therefore unpolarised and Iv = IH. If the 
small molecule is bound by antibody it now rotates much slower 
in solution and so after excitation a much larger proportion of 
the excited molecules retain their orientation and the resulting 
emission is polarised and P' > 0. 
It was decided to investigate the potential of the BMMC, BMDC 
and TRC derivatives for use in a polarisation assay, the MDC 
derivative was not considered for reasons stated in 5.1.2. 
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5.1.3.2 Experimental. 
Purified derivatives isolated in 5.1.2 were reconstituted into 
methanol and dilutions made into PBS to give the following 
concentrations: 
BMMC 
BMDC 
TRC 
1700, 850, 212 nglml 
1300, 650, 162 nglml 
1000, 500, 125 ng/ml 
Monoclonal antibody was prepared in PBS at 48 and 4.8 J.l.glml 
Fluorimeter settings 
derivative 
BMMC 
BMDC 
TRC 
Ex 
320nm 
340nm 
540nm 
Em 
390 nm 
440nm 
580nm 
slits 
5 / 10 nm 
5 I 10 nm 
5 I 10 nm 
0.1 ml of derivative, 0.1 ml of MAb and 0.8 ml of PBS were 
added to a small glass bottle and the mixture incubated overnight 
at room temperature. This was repeated for each derivative 
concentration with both MAb concentrations and the corrected 
polarisation value for each mixture determined. The results are 
given in Table 5.4 
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Table 5.4 
Sample Polarisation value 
MAb I 48J.£glml MAb I 4.8J.Iglml 
BMMC 1700 nglml 0.281 0.287 
BMMC 850 nglml 0.287 0.310 
BMMC 212 nglml 0.292 0.291 
BMDC 1300 nglml 0.377 0.447 
BMDC 650 nglml 0.484 0.494 
BMDC 162 nglml 0.528 0.585 
TRC 1000 nglml 0.426 0.442 
TRC 500 nglml 0.505 0.540 
TRC 125 nglml 0.523 0.607 
Polarisation values were also obtained for the unconjugated 
derivatives alone using the highest concentration sample of each 
derivative and were found to be: 
BMMC - 0.161 ; BMDC - 0.103 ; TRC - 0.349 . 
The BMMC derivative incubation mixtures all give very similar 
polarisation values which is in contrast with the results obtained 
for the other samples. The BMDC and TRC derivatives both 
show the same trends, that is an increase in polarisation values 
as derivative concentration decreases for both the 48 and 4.8 
J.lglml MAb solutions. In addition for each derivative 
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concentration the polarisation value obtained with incubations 
containing MAb at 4.8 p.g/ml is higher than for incubations 
containing MAb at 48 p.gfml. However the results are 
questionable since in a number of cases the polarisation value 
exceeds the theoretical maximum of 0.5 and for all of the 
derivatives extremely high polarisation values are found with the 
unconjugated derivatives free in solution. This is surprising since 
the relative molecular mass of the derivatives should ensure that 
they show very little polarisation. 
The above polarisation measurements were made in a 0.5 cm 
silica cell rather than the usual 1.0 cm cell because of the need 
to conserve materials. In order to establish whether the 0.5 cm 
cell contributed to the unusual results incubations were carried 
out and polarisation measurements made in both the 0.5 cm and 
the 1.0 cm cells. 
Derivatives were used at the following concentrations: BMMC -
1700 ng/ml ; BMDC- 1300 ng/ml ; 1RC- 1000 ng/ml. MAb was 
prepared in PBS at 4.8 and 48 p.gfml. Fluorescence 
measurements were made as above. 
0.2 ml of derivative, 0.2 ml of MAb and 1.6 ml of PBS were 
incubated overnight at room temperature. This was repeated for 
each combination of derivative and MAb concentration. The 
corrected polarisation value of each incubation mixtures was 
measured in both the 0.5 cm and 1.0 cm cells. The results are 
shown in Table 5.5 
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Table 5.5 
Sample Polarisation value in each cell 
MAb I 48!Lglml MAb I 4.8/Lglml 
0.5 cm 1.0 cm 0.5 cm l.Ocm 
BMMC 0.31 0.03 0.33 0.02 
BMDC 0.41 0.03 0.44 0.03 
TRC 0.53 0.04 0.59 0.04 
The above results seem to confirm that the 0.5 cm cell gives false 
positive results for polarisation measurements and that when 
measured in a 1.0 cm cell there is no polarisation observed for 
the BMMC, BMDC and TRC derivatives. These false results may 
be due to an increase in scattering of the incident light from the 
0.5 cm cell, either because it is not positioned optimally in the 
sample compartment or because the bandwidth of the excitation 
beam is too wide. It was concluded that none of the derivatives 
showed any promise for use in a fluorescence polarisation assay. 
5.1.4 Size exclusion chromatography 
5.1.4.1 Introduction 
Size exclusion or gel chromatography is based on the principle 
that as a solute passes down a chromatographic bed its 
movement depends upon the bulk flow of the mobile phase and 
upon Brownian motion of the solute molecules which causes their 
diffusion both into and out of the stationary phase. The 
separation in gel chromatography depends on the different 
abilities of the various sample molecules to enter pores which 
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contain the stationary phase. Very large molecules which never 
enter the stationary phase move through the chromatographic 
bed fastest, smaller molecules which can enter the gel pores 
move more slowly through the column since they spend a 
proportion of their time in the stationary phase. Molecules are 
therefore eluted in order of decreasing size. 
Although binding between the MAb and the fluorescent 
derivatives had been demonstrated using radioimmunoassay it 
had not been confirmed using fluorescence techniques. It was 
decided to investigate this binding by applying an incubation 
mixture to a size exclusion column and monitoring the eluent. 
5.1.4.2 Experimental 
A PD-10 disposable colunm pre-packed with Sephadex G-25 
was used for the separation. This has a fractionation range of 
1000 to 5000 relative molecular mass and so antibody bound 
derivative with a RMM of greater than 160,000 should appear in 
the void volume of the column with unbound derivative eluting 
some time after. The PD-10 was connected to a flow cell in the 
LS-50 fluorimeter as in Fig 5.1 and according to 3.2.11. The 
colunm was equilibrated with PBS, the pump set at 0.4 ml/min 
and the eluent monitored at the following wavelengths: 
Sample 
BMMC 
BMDC 
TRC 
Excitation 
325 nm 
340nm 
550nm 
Monochromator 
Emission 
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405nm 
440nm 
580nm 
Slits 
10/15 nm 
10/15 nm 
10/15 nm 
data 
collection 
LS-50 
waste 
pump 
Buffer 
reservoir 
PD-10 
column 
Fig 5.1 Gel chromotography system for the analysis of the derivative incubation 
mixtures 
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The MDC derivative was not investigated for the reasons stated 
in 5.1.2 
The derivatives were prepared in PBS/BSA at the following 
concentrations : 
BMMC - 54 !'g/ml ; BMDC - 44 !'g/ml ; 'IRC - 11 !'g/ml 
The MAb was prepared in PBS/BSA at 0.5 mg/ml 
100 1'1 of derivative, 100 1'1 of MAb and 200 1'1 of PBS/BSA were 
incubated together for 30 minutes at room temperature. After 
this time the whole mixture was applied to the top of the PD-10 
column, the pump started and the data collection initiated. The 
eluent was monitored at the appropriate wavelengths and a 
typical profile for each derivative is given in Fig 5.2 to 5.4. These 
traces all show a similar pattern with a sharp peak corresponding 
to elution of antibody bound derivative in the void volume 
followed by a broad peak of excess derivative. 
Although these results show the expected profile the elution 
volume for each excess derivative is greater than predicted. The 
manufacturers instructions suggest that material entering the gel 
pores should be completely eluted off the column after one 
column volume of buffer has been passed through. In the case of 
the PD-10 the bed volume is 9.1 ml and so after passing 9.1 ml 
of elution buffer there should be no free derivative left on the 
column. However in all cases it was found that excess derivative 
was not completely removed from the column until approximately 
30 ml of buffer had been passed through. 
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Fig 5.2 Elution profile of the MAb-BMMC incubation mixture from the PD-10 
column, eluting with 0.2M PBS buffer pH 7.4 at 0.4 ml / min. Fluorescence 
detection, Ex 325 nm / Em 405 nm 
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Fig 5.3 Elution profile of the MAb-BMDC incubation mixture from the PD-10 
column, eluting with 0.2M PBS buffe r pH 7.4 at 0.4 ml/ min. Fluorescence 
detection, Ex 340 nm / Em 440 nm 
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Fig 5.4 Elution profile of the MAb-TRC incubation mixture from the PD-10 
column, e luting with 0.2M PBS buffer pH 7.4 at 0.4 ml/min. F luorescence 
detection, Ex 550 run / Em 580 nm 
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As already explained size exclusion chromatography does not rely 
on chemical interaction to achieve separation, however several 
workers have reported that aromatic compounds are liable to 
undergo non-specific interactions with the column packing 
material (lanson, 1967; Williams, 1972). This phenomena would 
explain the retarding of the elution peaks for the unbound 
derivatives since in all cases the fluorescent labels are conjugated, 
planar, aromatic systems. The influence of the label however 
would be overcome by the size of the antibody when the 
derivative is antibody bound and so does not retard the elution 
of the immune complex. 
Although the elution volumes for the excess derivative are not as 
expected the size exclusion method has demonstrated binding 
between the MAb and each derivative using the fluorescence of 
the label to follow the reaction. 
5.2 Displacement of derivative from the MAb by unlabelled cyclosporin 
It was decided to use the size exclusion method to follow the displacement of 
derivative from the MAb by adding unlabelled cyclosporin to the incubation 
mixture. 
Cyclosporin C was prepared at 15!-lg/ml in PBS/BSA by a 1:100 dilution from 
a methanolic stock solution. All materials and conditions were the same as in 
5.1.4.2 except that when 100 JLl of unlabelled cyclosporin was added to the 
incubation mixture only 100 JLl of PBS/BSA was added. Each derivative was 
incubated both with and without unlabelled cyclosporin C and the areas of 
the antibody bound and excess derivative peaks were measured as in 5.1.4.2 
The results are shown in Table 5.6 
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Table 5.6 
Sample 
BMMC 
BMMC + CyC 
BMDC 
BMDC + CyC 
TRC 
TRC + CyC 
Peak area 
Bound 
29282 
23856 
8677 
6183 
3446 
377 
Excess 
13002 
25281 
53492 
142213 
46631 
53792 
Change in peak area 
Bound 
N/A 
-5426 
N/A 
-2494 
N/A 
-3069 
Excess 
N/A 
+ 12279 
N/A 
+ 88721 
N/A 
+ 7161 
The results show that for all the derivatives the addition of unlabelled 
cyclosporin C to the incubation mixture causes a reduction in the bound peak 
area and an increase in the area of the free derivative. This demonstrates that 
unlabelled cyclosporin C displaces labelled cyclosporin from the antibody in 
a competitive manner. This reaction is the basis of competitive immunoassays 
and these results show that it should be possible to use any of the derivatives 
in an immunoassay for cyclosporin A 
The values obtained suggest that all of the derivatives undergo a degree of 
quenching when bound to the MAb. The chromatograms for the BMMC and 
TRC derivatives, Fig 5.5 and 5.6 respectively show similar results in that the 
derivative displaced from the antibody by the unlabelled cyclosporin C causes 
an increase in the free peak that is about twice as large as the decrease in the 
bound peak. However for the BMDC derivative the chromatogram in Fig 5. 7 
shows that the increase in the free peak is thirty five times as great, as the 
reduction in the bound peak, suggesting that this derivative undergoes 
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Fig 5.5 Elution profiles of the BMMC incubation mixtures showing displacement 
on adding unlabelled cyclosporin from the PD-10 column, eluting with 
0.2M PBS buffer pH 7.4 at 0.4 ml / min. Fluorescence detection, 
Ex 325 nm / Em 405 nm 
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Fig 5.6 Elution profiles of the TRC incubation mixture showing displacement 
on adding unlabelled cyclosporin from the PD-10 column, eluting with 
0.2M PBS buffer pH 7.4 a t 0.4 ml/min. Fluorescence detection, 
Ex 550 nm / Em 580 nm 
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Fig 5. 7 Elution profiles of the BMDC incubation mixtures showing displacement 
on adding unlabelled cyclosporin from the PD-10 column, eluting with 
0.2M PBS buffer pH 7.4 at 0.4 ml/ min. Fluorescence detection, 
Ex 340 nm / Em 440 nm 
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considerable quenching when bound to the MAb. The large difference in 
quenching between the two coumarin derivatives is surprising considering the 
structural similarities of the labels, as shown in Fig 5.8 
Fig5.8 
H 
0~ 0 ~0 
BDMC 
Bt.IMC 
Fig 5.8 Comparison of the structures of the BMMC and BMDC fluorophores 
The fact that the BMDC derivative suffers significant quenching when bound 
to the MAb suggests that it may lack sensitivity if used in the protein A 
format, since with this method the analytical measurement is made as the 
antibody bound derivative elutes from the protein A column, as described in 
2.1. Because of this it was decided not to utilise the BMDC derivative in the 
protein A assay development. However the quenching phenomena does mean 
that this derivative may lend itself for use in a homogeneous assay, making 
use of the enhancement in fluorescence intensity when the derivative is 
displaced from the antibody. Given the benefits of homogeneous assays, as 
described in 2.4 the potential of the BMDC derivative should be investigated 
in any future work. 
5.3 Investigation into the generation of a calibration curve 
It was decided to investigate the possibility of generating a calibration curve 
using the size exclusion method described in 5.2 The 1RC derivative was 
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chosen as the tracer in this experiment because the emission wavelength of 
this label gives a very low background signal in buffer. 
Cyclosporin C standard solutions were prepared in PBS/BSA as in 5.2 at 15, 
150, 1500 and 15000 ng/rnl. The TRC derivative and the MAb were prepared 
in PBS/BSA at 11 J-~g/rnl and 0.5 mg/rnl respectively. The assay procedure 
and monitoring were carried out as in 5.2 The antibody bound peak area was 
measured as in 5.2 and the results are shown in Fig 5.9 
It can be seen from the plot that it is possible to establish a calibration curve 
across the therapeutic range of cyclosporin using the method described in 5.1.4 
and 5.2. However this assay format is very crude and labour intensive and 
would be difficult to use routinely since the application of samples to the top 
of the column by pipette would surely lead to problems with reproducibility. 
In addition the run time of approximately 35 minutes is far too long for 
routine analysis. Although these problems may be solved it was decided that 
the development of an immunoassay based on size exclusion chromatography 
would not be practical. With real samples all endogenous proteins in the 
sample would co elute with the antibody bound derivative and considerably 
increase the background signal. The effect of this would be to reduce the 
sensitivity of the assay. 
Although the method was not developed further the size exclusion 
chromatography assay has proved the viability of using fluorescent cyclosporin 
derivatives in an immunoassay utilising a flowing system. It was therefore 
decided to investigate the potential of a flow injection immunoassay based on 
a protein A microreactor, a monoclonal antibody and the BMMC and TRC 
derivatives. 
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Fig 5.9 Calibration curve for the TRC derivative using the PD-10 column 
CyC standards in PBS/ BSA, the T RC derivative at 11 J..Lg/ ml and MAb at 
0.5 mg/ ml 
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CHAPTER SIX 
DEVELOPMENT OF A FLOW INJECfiON IMMUNOASSAY FOR 
CYCLOSPORIN A 
6.1 Introduction 
Beause of the advantages discussed in chapter 2 and the results in chapter 5 
it was decided to investigate the development of a flow injection immunoassay 
for cyclosporin A using a protein A immunoreactor. 
6.2 Experimental 
6.2.1 Preparation of the immunoreactor 
The glass microcolurnn was filled with controlled pore glass-protein A 
using a Pasteur pipette and then Tris buffer pumped through at a flow 
rate of 0.64 ml/min to compact the beads. The process was repeated 
until the column was fully packed. 
6.2.2 Design of the now injection manifold 
The flow injection system was set up as in Fig 6.1 and incorporated a 
100 1'1 sample loop and a flow cell with a volume of 100 1'1. In order to 
minimise peak broadening due to dispersion the distance between the 
column and the flow cell was kept to a minimum. 
6.2.3 Calculation of now rate through the column 
The two channels of the peristaltic pump were fitted with 0.015mm 
internal diameter solvent resistant pump tubing. Each channel in turn 
was switched to pump buffer through the column and flow cell and the 
time taken for 10 drops to be collected was found along with their mass. 
Table 6.1 sununarises the results. 
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TRIS BUFFER 
pH 8.8 
PUMP 
CITRATE BUFFER 
pH 2.5 
INJECTION 
Vfl.LVE COLUMN 
SWITCHING 
Vfl.LVE 
WASTE 
DATA 
HANDLING 
~o 
DETECTOR 
WASTE 
Fig 6.1 Flow injection manifold for the determination of cyclosporin A 
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Table 6.1 
(a) Channel1 Tris buffer 
Nominal pump Time I sec 
speed (n = 3) 
10 116 
20 58 
30 39 
40 30 
48 25 
Mass of 10 drops (n =3) 0.2662 ± 0.0005 g 
Assume density = 1.0 
Volume of 10 drops = 0.2662 ml 
(b) Channel 2 Citrate buffer 
Nominal pump 
speed 
10 
20 
30 
40 
48 
Time I sec 
(n = 3) 
117 
59 
39 
30 
25 
Mass of 10 drops (n = 3) 0.2667 ± 0.0005 g 
Assume density = 1.0 
Volume of 10 drops = 0.2667 ml 
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Calculated flow 
rate I mllmin 
0.1377 
0.2754 
0.4095 
0.5324 
0.6389 
Calculated flow 
rate I mllmin 
0.1368 
0.2712 
0.4103 
0.5334 
0.6401 
6.2.4 Binding and elution of antibody to the protein A column 
A range of concentrations between 6.25 and 100 JLg/ml of monoclonal 
antibody were examined for their binding to the protein A 
immunoreactor. 50 JLl of antibody solution was diluted with 150 JLl of 
PBS/BSA and used to fill the sample loop. The sample was then 
introduced onto the colunm in the Tris buffer stream at 0.53 ml/rnin. 
After the non bound material had been washed through the antibody 
was eluted by switching the citrate buffer through the colunm at the 
same flow rate until the elution peak returned to the base line. The 
colunm was then re-equilibrated by flowing Tris buffer through for 10 
minutes before the next antibody sample was introduced. The elution 
peak area was determined for each antibody concentration with the 
fluorimeter set at :Ex 280 nm Em 340 nm SLITS 5/10. The results are 
shown in Fig 6.2 along with a typical elution profile in Fig 6.3. 
6.2.5 Investigation into the binding of antibody-derivative conjugates to 
protein A 
Because of the problems with the BMDC and MDC derivatives 
discussed in 5.1.2 and 5.2 the binding of the immune conjugates to 
protein A was limited to the BMMC and TRC derivatives. 
6.2.5.1 BMMC 
BMMC was prepared at 250 JLg/ml in 50% vfv MeOH:PBS 
whilst the monoclonal antibody was used at 200 JLg/ml in the 
incubation mixture as follows: 
1. 25 JLl BMMC + 50 JLl MAb + 125 JLl PBS Incubate 60 min 
2. 25 JLl BMMC + 50 JLl MAb + 125 JLl PBS Incubate 30 min 
3. 25 JLl BMMC + 100 JLl MAb + 75 JLl PBS Incubate 30 min 
4. 0 BMMC + 50 JLl MAb + 150 JLl PBS Incubate 30 rnin 
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Fig 6.2 Change in elution peak area with increasing antibody concentration 
applied to the protein A column in a 100 J.Ll a liquot, in the Tris buffe r stream at 
0.53 ml/min. Fluorescence detection, Ex 280 nm j Em 340 nm 
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Fig 6.3 Antibody elution profile showing large peak of non-bound material and 
elution of protein A bound antibody from the column. Fluorescence 
detection Ex 280 nm / Em 340 nm. 
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The fluorimeter was set at:Ex 325 nm Em 405 nm SUTS 10/15 
Incubation mixtures were bound and eluted from the colunm and 
the peak areas measured as in section 5.1.4. The results are 
summarised in Table 6.2 and show that the BMMC-MAb 
conjugate is bound by protein A 
Table 6.2 
Sample Number 
1 
2 
3 
4 
Elution peak area 
583 
491 
1412 
164 
An increase in incubation time from 30 to 60 minutes brings 
about a 20% increase in elution peak area whilst doubling the 
MAb content increases the area by more than 150%. It can be 
seen from sample 4 that the antibody alone contributes 33% to 
the elution peak thereby making the background signal relatively 
high. 
6.2.5.2 TRC 
TRC was prepared at 45 ~g/ml in 1% v /v MeOH:PBS whilst the 
monoclonal antibody was prepared at 100 and 200 ~g/ml and the 
incubation carried out as follows: 
50 ~1 TRC + 100 ~1 MAb + 50 ~1 PBS Incubate 30 min 
The fluorimeter was set at: Ex 550 nm Em 580 nm SUTS 10/15 
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This incubation was repeated for both the 100 and 200 J.lg/ml 
antibody concentrations and they gave elution peak areas of 271 
and 650 respectively. An antibody blank showed no sign of an 
elution peak. 
6.2.6 Choice of TRC as derivative for use in immunoassay development 
Because of the high background obtained with the BMMC derivative 
and the reduction in light scattering at longer wavelengths the lRC 
derivative was chosen for further assay development. 
6.2.7 Preparation of unlabelled cyclosporin standards 
In order to maintain the same percentage of methanol in each working 
standard methanolic stock solutions were prepared at 150, 75 and 15 
J.lg/ml. From these 1:100 dilutions with PBS gave buffer standards of 
1500, 750 and 150 ng/ml for use in immunoassays. 
6.2.8 Inclusion of unlabelled cyclosporin in the incubation mixture 
To confirm the viability of the protein A flow injection system unlabelled 
cyclosporin at 1500, 750 and 150 ng/ml was included in the incubation 
mixture as follows with lRC used at 45 J.lg/ml and MAb at 50 J.lg/ml. 
50 J.lllRC + 50 J.ll MAb + 100 J.ll PBS or standard 
After a 30 minute incubation the samples were injected onto the column 
and the bound peak areas determined. The results are summarised in 
Table 6.3 
143 
Table 6.3 
[Cy) added 
ng/ml 
0 
150 
750 
1500 
Peak area 
(n = 3) 
1104.1 
510.2 
468.7 
278.1 
100 
46.2 
42.4 
25.2 
Results are normalised by calculating the B/B0 value expressed as a % 
as follows: 
B (-)% 
BD 
= elution peak area at stated [drug] x 100 
elution peak area at zero [drug] 
The results show that inclusion of unlabelled cyc!osporin across the 
range 150 - 1500 ng/ml results in good displacement of TRC from the 
antibody thereby forming !Pe basis of an immunoassay. 
6.2.9 Stability of TRC in solution 
It was noted that over a period of days the elution peak area of zero 
standards decreased when using the same TRC solution ( 45 JLg/ml in 
1% MeOH:PBS) and so the stability of the derivative was investigated. 
20 ILl of a methanolic stock solution of TRC (4.5 mg/ml) was made up 
to 2 ml with PBS and divided into two 1 ml aliquots in glass bottles. One 
was covered in foil and both were left in the open at room temperature 
and their fluorescence intensity measured at time intervals. The results 
are shown in Fig 6.4 
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Fig 6.4 Stability profile of the TRC derivative in PBS (45 1-Lg/ml) under subdued 
light ana with light excluded. Results normalised by plotting the change in 
initial fluorescence with time. Fluorescence detection Ex 550nm /Em 580nm 
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To normalise the values the results were plotted as the percentage of the 
initial fluorescence intensity with time. They show that both the covered 
and uncovered samples follow the same trend and so photobleaching 
would not appear to be a problem in normal daylight. There is a rapid 
loss of fluorescence followed by a slight recovery and then relative 
stability over many hours. However these results do not give any 
information about the immunoreactivity of the derivative and so an 
aliquot of 1RC was prepared as above to give a concentration of 
45 p.gfml and samples taken at time intervals and incubated for 30 
minutes with MAb at 50 !Lg/rnl as follows : 
50 p.l 1RC + 50 ILl MAb + 100 p.l PBS 
The results are plotted in Fig 6.5 and show a similar trend to the change 
in intensity values although the overall loss in immunoreactivity is 
greater. These trends can be explained by considering the HPLC results 
from section 4.2.2.6. These showed that the 1RC derivative consists of 
at least two very similar components that could not be resolved. This is 
not surprising since the label used in the synthesis is an isomeric mixture 
of5 ( and-6-)-[ (N -( 5-arninopentyl )amino )carbonyl]tetramethylrhodamine. 
It may be that the products of the synthesis have differing stabilities in 
aqueous solution and that over a period of time the more unstable 
derivatives suffer a loss of fluorescence. Although in a minority these 
derivatives may also be the most immunoreactive and this would explain 
why the percentage of i~tial fluorescence intensity is much higher than 
the percentage of initial immunoreactivity after 160 hours. 
The above results show that the preparation of a solution of 1RC for 
use in an immunoassay would not be appropriate since it appears that 
the concentration of immunoreactive derivative declines with time. 
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Fig 6.5 Change in immunoreactivity of the TRC deriva tive in PBS with time 
50 J • .Ll aliquots removed at time intervals and incubated with MAb 
(50 J..Lg/ml) for 30 minutes. Results normalised by plotting the change in 
initial immunoreactivity with time. 
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6.2.10 Preparation or dried TRC 
In an attempt to overcome the decay problems found with aqueous TRC 
it was decided to dispense methanolic aliquots into incubation tubes, 
remove the methanol under reduced pressure and store the tubes in the 
freezer until required. TRC was prepared at 112 ~g/ml in MeOH and 
20 pi aliquots transferred into each tube. This provides 2.25 ~g of TRC 
per incubation, the same quantity as used with the aqueous TRC 
method. 
6.2.11 Assessment or dried TRC in incubation mixtures 
Tubes were removed from the freezer at time intervals and allowed to 
stand at room temperature for 10 minutes, 150 ~1 of PBS was added and 
the tube left for a further 10 minutes. After this time 50 ~1 of MAb (50 
~g/ml) was added and the incubation mixture left for 30 minutes before 
being determined in the usual way. A graph of elution peak area with 
time from preparation can be seen in Fig 6.6 and although there is still 
a loss of immunoreactivity over 100 hours the reduction in elution peak 
area to 86.3% of the initial value is a considerable improvement on 
using TRC in solution. 
6.2.12 Recovery or dried TRC 
The reproducibility of recovery of the dried TRC into the incubation 
mixtures was examined by testing ten sample tubes in succession by the 
method described in section 6.2.11. The mean elution peak area was 
found to be 1612 ± 48.9 which was smaller than when fresh liquid TRC 
was used and so it was decided to check the percentage recovery of the 
dried TRC. A range of recovery solvents were prepared with an 
increasing percentage of MeOH in PBS. 
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Fig 6.6 Cb~ge in immunoreactivity of the dried TRC derivative wi th time 
TRC reconstituted into 150 J .. Li of PBS and incubated with 50 J .. Ll MAb 
(50 J .. Ll/ ml) for 30 minutes. Results normalised by plotting the change in 
initial immunoreactivity with time. 
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A complementary range of equilibration solvents was prepared with an 
increasing percentage of PBS in MeOH. Sample tubes were removed 
from the freezer, allowed to stand for 10 minutes and then 150 J'l of 
recovery buffer added. After 10 minutes 100 J'l was removed and added 
to 100 J'l of equilibration buffer so that the sample contained 100 J'l of 
PBS and 100 J'l of MeOH. This was then made up to 2 ml with Tris 
buffer and the fluorescent intensity measured. Fluorimeter settings were 
: excitation 550 nm, slit 10 nm / emission 580 nm, slit 15 nm. The 
recovery obtained with MeOH was considered to be 100 % and the 
results are summarised in Table 6.4 
Table 6.4 
Recovery Fluorescence Recovery 
solvent (n = 4) % 
PBS 86.64 ± 3.85 56.15 
2% MeOH/PBS 82.58 ± 1.01 53.52 
5% MeOH/PBS 88.86 ± 1.05 57.59 
10 % MeOH/PBS 87.63 ± 5.73 56.80 
20 % MeOH/PBS 96.21 ± 2.93 62.35 
MeOH 154.30 ± 8.30 100.00 
These results show that up to 10 % MeOH in PBS has no effect on the 
recovery of dried TRC in the tube, 20 % MeOH does increase the 
recovery but at this value the overall concentration of MeOH in the 
incubation mixture becomes prohibitive. Only just over half the TRC is 
recovered with buffer but this and the previous experiment show that the 
recovery is reproducible and so it should be possible to use the dried 
TRC in the immunoassay. 
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6.2.13 Storage of dried TRC tubes 
Because of tbe time needed to bring the tubes to room temperature it 
was decided to investigate storing them in a dessicator cabinet. Twelve 
tubes were prepared as before, six were stored in tbe freezer and six in 
a dessicator cabinet at room temperature for five days. The tubes were 
tested for recovery as in section 6.2.11 except tbat those in the dessicator 
were not left for 10 minutes prior to addition of recovery buffer. The 
results are shown in Table 6.5 and demonstrate that freezer storage is 
not necessary. 
Table 6.5 
Sample tubes 
stored in freezer 
stored in dessicator 
Peak area 
(n = 6) 
1248.2 ± 68.3 
1205.8 ± 79.6 
6.2.14 Assay method for cyclosporin standards 
Methanolic cyclosporin standards were prepared at 150, 75, 32.5, 7.5 and 
1.5 J.l.g/rnl as described in section 5.2 and from these dilutions were 
made witb PBS to give working standards of 1500, 750, 325, 75 and 15 
ng/rnl. Using these standards duplicate incubations were carried out with 
the dried 1RC at 2.25 J.l.g/tube and MAb at 50 J.l.g/ml as in section 
6.2.13. Peak areas were measured and a calibration curve was 
established by plotting (B/B0 ) % against standard [Cy) as shown in 
Fig 6.7 
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Fig 6. 7 Calibration curve for cyclosporin using the dried TRC derivative 
(2.25 J.Lg/tube) reconstituted with 150 ~-£1 CyC standard in PBS and incubated 
with MAb (50 J.Lg/ ml) for 30 minutes 
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These results show that it is possible to set up a calibration curve across 
the therapeutic concentration range of cyclosporin A However the curve 
Js not optimised under these conditions since the lowest standards are 
not greatly differentiated from zero and appear on the least sensitive 
part of the curve whilst the top standard does not give sufficient 
displacement and seems to be on a linear part of the curve. 
6.2.15. Optimisation of assay conditions 
6.2.15.1 Concentration of TRC 
When using the TRC dried in the incubation tubes at 2.25 
t~g/tube the resulting elution peak is large and easily measured 
and so to preserve materials it was decided to half this amount 
and optimise the assay on 1.12 t~g/tube. 
6.2.15.2 Concentration of MAb 
Using dried TRC at 1.12 t~g/tube the concentration of MAb used 
in the incubation mixtures was optimised. MAb was prepared at 
100, 50, 25, 12.5 and 6.25 tJg/ml in PBS by serial dilution. 30 
minute incubations were carried out in duplicate for each 
antibody concentration as follows: 
50 t~l MAb + 150 t~l PBS 
50 t~l MAb + 150 t~l cyclosporin standard (325 ng/ml) 
Values of (B/B0 ) % for each antibody concentration were 
calculated and plotted as in Fig 6.8 
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Fig 6.8 Displacement of the TRC derivative with cyclosporin taodard (325 ng/ml) 
at increasing antibody concentrations. 
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The 325 ng/ml standard was chosen because this value is central 
in the calibration range and should appear near to the most 
sensitive part of the curve. From the above results it can be 
seen that maximum displacement is achieved with an antibody 
concentration of 12.5 J.Lg/rnl however the measured peak area is 
small and gives a much poorer signal to noise ratio than when 
using 25 p.g/rnl which may prove limiting at higher cyclosporin 
concentrations. Therefore it was decided to chose 25 p.g/ml as 
the optimum antibody concentration for use in incubations with 
dried 1RC at 1.12 p.g/tube. 
6.2.15.3 Flow rate 
Optimisation of the flow rate for maximising the binding of 
antibody to the protein A column was carried out using the MAb 
at 25 p.g/rnl as follows: 
50 p.l MAb + 150 p.l PBS 
The antibody solution was injected onto the column at different 
flow rates and eluted off at 0.53 rnl/min. The elution peak area 
was measured by monitoring at the antibody wavelengths, 
excitation 280 nm , slit 5 nm / emission 340 nm, slit 10 nm and 
the results are summarised in Table 6.6 
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Table 6.6 
Binding flow rate 
ml/min 
0.14 
0.27 
0.41 
0.53 
Elution area 
(n = 3) 
6118.8 ± 102.6 
6119.5 ± 88.5 
6007.1 ± 133.1 
5539.3 ± 91.6 
The results show that for an approximate 400 % increase in flow 
rate the antibody binding is decreased by only 10 % from the 
maximum at 0.14 ml/min. This reduction in binding capacity is 
negligible compared to the benefits obtained by reducing the run 
time at higher flow rates. Therefore it was decided to set the 
flow rate at 053 ml/min for both the binding and elution. 
6.2.15.4 Incubation time 
All incubations to date have been for 30 minutes which is by far 
the major component of the assay time and where savings could 
be made. It was decided to investigate the possibility of using 
shorter incubation times with MAb at 25 JLg/ml and dried TRC 
at 1.12 JLg/tube. Triplicate incubations were carried out as in 
section 6.2.15.3 and the results are summarised in Table 6.7 
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Table 6.7 
Incubation time Elution area 
min (n = 3) 
5 1044.9 ± 121.6 
10 1055.0 ± 41.1 
15 1094.4 ± 31.1 
20 1356.6 ± 27.9 
30 1359.6 ± 50.1 
The results show that reducing the incubation time to 5 minutes 
causes an approximate reduction of 20 % in the elution area, 
however there is considerable variation in the value of the 
replicates. For this reason it was decided to chose 10 minutes as 
the optimum incubation time. 
6.2.15.5 Calibration standards 
The previously described calibration curve used 15 ng/ml as the 
lowest calibrant but this proved difficult to accurately distinguish 
from zero. For this reason the lowest calibrant was changed to 
32.5 ng/ml, which was prepared from a methanolic stock solution 
as in section 5.2 along with a 100 ng/ml calibrant which was 
included as a possible replacement for the 75 ng/ml standard. 
6.2.16 Assay procedure for cyclosporin analysis 
A calibration curve was established using the optimised assay 
conditions and the following protocol: 
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The sample tube was removed from the dessicator cabinet and 
the dried 1RC was reconstituted by adding 150 J.ll of PBS or 
cyclosporin working standard, shaking and then leaving for 10 
minutes at room temperature. After this time 50 J.ll of antibody 
solution was added, the tube shaken and then left to incubate for 
10 mins. The mixture was then drawn up into a 1 rnl syringe and 
used to fill the sample loop, taking care to avoid the introduction 
of bubbles. In the meantime the colunm had been equilibrated 
with Tris buffer. The sample was injected and simultaneously the 
data collection initiated and used to time subsequent actions. 
After about 200 seconds the next sample was removed from the 
dessicator and reconstituted. At 400 seconds the flow through the 
column was switched to the citrate buffer to elute the bound 
sample and at 700 seconds switched back to Tris. After about 800 
seconds (600 seconds after the 1RC was reconstituted) antibody 
was added to the next sample and the whole process repeated 
until duplicates of zero standards and all calibrators had been 
assayed. By overlapping each assay as described above the total 
time from injection to injection was reduced to 22 minutes. 
Elution peak areas were used to calculate (B/B0 ) %values which 
are summarised in Table 6.8 
Table 6.8 
[Cy] Elution area (B/Bo) 
ng/rnl (n = 2) % 
0 486.0 100.0 
32.5 408.5 84.0 
75 402.9 82.9 
100 359.8 74.0 
325 259.0 53.3 
750 163.1 33.6 
1500 99.0 20.4 
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It can be seen that the 32.5 and 75 ng/ml calibrants give very 
similar values and since an extra standard will increase the total 
assay time by 44 minutes it was decided to omit the 75 ng/ml 
standard in favour of the one at 100 ng/ml for all future assays. 
6.2.17 Reproducibility of standard curves 
Day to day variance in standard curves was studied by carrying 
out assays on four subsequent days as described in section 6.2.16 
The calibration curves are shown in Fig 6.9 and the mean of the 
four curves in Fig 6.10. It can be seen that there is reasonable 
reproducibility from day to day, although the variability is quite 
high with the 325 and 750 ng/ml standards. Problems with 
variability may in part be due to poor reproducibility in 
aliquoting small volumes, whilst binding of the conjugates to the 
protein A seems to be a function of the number of runs the 
column has performed. For true evaluation of day to day 
variability each calibration run should be performed on a new 
column so that the condition of the protein A is the same on 
each day. Unfortunately for reasons of cost this could not be 
done. 
6.2.18 Limit of detection of the assay 
Using the calibration curve generated on 13.3.91 the limit of 
detection (LO.D.) of the assay was determined by subtracting 
three standard deviations from the mean of the B0 value. 
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Fig 6.9 Comparison of calibration curves generated on different days. 
All conditions identical [TRC] 1.2 J.Lg/ tube; [MAb] 25 J.Lg/ rnJ (50 J.Ll / inc); 
150 J ..Ll buffer or standard; 10 rnin inc 
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Fig 6.10 Mean calibration curve from four gene rated on: 
13.3.91, 15.3.91, 17.3.91, 18.3.91 
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10000 
Mean area of B0 (n=4) = 486.0 
S.D. = ± 16.4 
C. V. = 3.4% 
3 X S.D. = 49.2 
Area giving LO.D. = 436.8 
B/Bo = 89.9% 
From the calibration curve the limit of detection of the assay in 
PBS/BSA was found to be 9.0 ng/ml as shown in Fig 6.11 
6.2.19 Recovery and precision study 
Whilst generating the standard curve on 13.3.91 a recovery study 
was carried out by spiking the 32.5 ng/ml cyclosporin standard to 
give samples at 82.5, 132.5 and 532.5 ng/ml in PBS/BSA Each 
sample was assayed five times and the results are given in 
Table 6.9 
From the results it can be seen that all three spiked samples are 
assayed with reasonable precision and that for the 100 and 500 
ng/ml samples the recovery is good. However the 50 ng/ml 
sample gives quite high recovery and considering that the %C. V. 
value is significantly higher than the other samples the poor 
recovery results may be due to the fact that measurements are 
being made on the least sensitive part of the calibration curve. In 
any further work this study should be repeated with a larger 
number of replicates. 
Unfortunately because of a lack of time a within run precision 
study was not carried out. 
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Fig 6.11 Calibration curve used to establish tbe limit of detection of the assay 
Determined from three standard deviations of the mean B
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Table 6.9 
Sample (Cyc]/ ngfml % % 
Recovered CV 
Added measured SD Recovered 
1 325 
SQ 968 8.8 645 1286 91 
2 325 
100 1355 76 1030 1030 56 
3 325 
soo 5246 317 4921 984 60 
6.2.20 Column lifetime 
Because of the nature of the assay a maximum of about 35 runs 
could be performed in any one day and it was obvious from early 
results that the column life was dependent not only on the 
number of samples injected but also on whether the buffer flow 
was repeatedly stopped and started. Initially to save materials the 
pump was stopped whenever the column was not in use (e.g. at 
lunchtimes). However it was found that binding reproducibility 
and column lifetime improved significantly if the pump was left 
running all day. 
The columns were capped and stored in Tris buffer overnight in 
the fridge and doing this along with ensuring continuous buffer 
flow through the column enabled 70-80 samples to be injected 
over two days without column deterioration. On occasion a 
column would perform acceptably on the third day, enabling over 
100 samples to be injected but in most cases it was found that the 
column performance had significantly deteriorated. 
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The poor binding reproducibility found when the buffer stream 
was repeatedly stopped and started may be due to a combination 
of inefficient column packing and poor column design. When 
packing the column the CPG- ProA material was introduced and 
packed down at high flow rates until the column bed was stable 
and no more material could be added. The column was used by 
flowing buffer from bottom to top and it was sometimes noticed 
that after using the column all day a small amount of settlement 
occurred when the pump was switched off. It is reasonable to 
assume that although it was only seen occasionally settlement 
occurs to a greater or lesser extent, depending on the efficiency 
of the column packing each time the buffer flow is switched off. 
The result of this is that the CPG-ProA at the head of the 
column, where the sample is introduced is continuously being 
disturbed as the buffer flow is switched on and off, resulting in 
variable binding of the sample. 
The design of the column did not allow for any adjustment of the 
endpieces and so the frits were fixed, butted up against the 
column ends. The problem of settlement could be solved by 
incorporating an adjustable endpiece which would allow the frit 
to be screwed into the column ensuring that the bed was 
compacted. 
6.2.21 On-line incubation 
As a further refinement and in an attempt to reduce the run time 
' it was decided to investigate the potential of carrying out the 
incubation step on the column. To this end 50 J£1 of MAb was 
made up to 200 J£1 with PBS and 100 J£1 injected onto the column 
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so that the amount of antibody introduced was equal to that 
normally used in a test tube incubation. For the same reason 
TRC at 2.25 Jig/tube was reconstituted in 200 t~l of PBS or 
standard and after 10 minutes injected onto the column and the 
sample eluted as before. 
A comparison with the test tube method showed that for the 
same zero standard the run time for the on-line method was 
approximately two minutes shorter at 20 minutes whilst the 
eluted peak area was only 30 % of that obtained when incubating 
prior to injecting. This reduction in eluted peak area is probably 
caused by much reduced binding due to the very short contact 
time between antibody and derivative. This is understandable 
since at a flow rate of 0.53 ml/min the linear velocity through the 
column is 7.5 cm/min. However reduction of the flow rate to 
increase the binding would lengthen the assay time and so defeat 
the object of the exercise. The small difference in run times 
between the two methods is due to the fact that the time 
consuming test tube incubation can be carried out whilst the 
previous sample is still running. The benefits of reducing each 
run must be weighed against a 70 % loss in signal which may 
cause signal:noise problems at high cyclosporin concentrations. In 
addition more complicated sample handling steps are required 
with the on-line method whilst in order to prevent cross 
contamination it may be necessary to use different injection loops 
for the antibody and derivative mixture. This increase in 
complexity makes automation of the assay more difficult. 
For these reasons it was decided not to pursue the on-line 
incubation method, although with optimisation and suitable 
solutions found to the above mentioned problems this method 
may have considerable potential. 
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6.2.22 Assay of whole blood samples 
To check that the assay would work with whole blood samples it 
was decided to use the spiked standards from an Incstar 
Cyclo-Trac SP whole blood radioimmunoassay for cyclosporin. 
The zero and 1244 ng/ml whole blood standards were extracted 
as follows: 
200 JLl of blood was added to 400 JLl of MeOH and the sample 
vortexed for 15 seconds after which it was centrifuged at 1600 x g 
for five minutes. Duplicate 50 and 100 JLl aliquots were removed 
from the methanolic supematant and added to tubes containing 
1RC at 1.12 JLg/tube. The solvent was then removed under 
reduced pressure and the tubes stored in a dessicator cabinet. 
Each tube was assayed as in section 6.2.16 and the results are 
summarised in Table 6.10 
Table 6.10 
Sample Aliquot Elution area (B/Bo) 
JLl (n = 2) % 
zero blank 50 502.1 
1244 ng/ml 50 410.1 81.7 
zero blank 100 479.0 
1244 ng/ml 100 335.1 70.0 
The displacement obtained with the whole blood samples appears 
much less than with equivalent buffer standards, however this can 
be explained when the dilution factor from the extraction process 
is considered. 200 JLl of whole blood was taken and made up to 
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600 ~tl with MeOH, after centrifugation 100 ~tl of this was 
aliquoted into the incubation tubes. The extraction has therefore 
caused only 1/6 of the sample to appear in the incubation, 
likewise for the 50 ~tl aliquot only 1/12 of the sample is available. 
In the case of the 1244 ng/ml standard a 200 ~tl aliquot 
containing 249 ng of cyclosporin has resulted in 41 ng being 
present in the incubation tube. On reconstitution in 150 ~tl of 
PBS this results in a concentration of 273 ng/ml of unlabelled 
cyclosporin in the incubation and not 1244 ng/ml as would have 
been the case had a buffer standard been used. Similarly for the 
50 ~tl methanolic aliquot the concentration in the incubation 
mixture was 137 ng/ml. If the (B/B0 ) % values for 273 and 137 
ng/ml are read from the buffer calibration curve the results are 
found to be 68 and 76 %respectively, which compare favourably 
with the whole blood values of 70 and 82 % for the 100 and 50 
~tl extracts. 
It would seem from these results that it is possible to assay whole 
blood samples using this method, however the sample extraction 
step is unsuitable because of the large dilution factor. For the 
assay to work routinely with whole blood samples alternative 
extraction processes should be investigated including solid phase 
extraction cartridges where the whole of the sample can be 
collected. Alternatively it may be possible to optimise the reagent 
concentrations for the assay to work successfully with the existing 
extraction process. 
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CHAPfER SEVEN 
INVESTIGATION OF THE POTENTIAL OF SOLID PHASE 
IMMUNOASSAY FOR CYCWSPORIN A 
7.1 Introduction 
Iu addition to the development of a flow injection immunoassay for 
cyclosporin A it was decided to investigate the potential of a number of solid 
phase separation systems for eventual use in a solid surface "dip-stick" type 
assay. The reagents synthesised in 4.2 were used with the cyclosporin A 
specific monoclonal antibody to evaluate a number of solid phases for use in 
a competitive immunoassay. 
Classically the separation of bound label from free in radioi=unoassay 
(RIA) was achieved by adsorbing the free label with a suspension of charcoal 
(Bourque, et al., 1986), or by precipitating the antibody bound label with a 
second antibody (Power, et al., 1989). In each case the actual separation was 
achieved by centrifugation and generally the antibody bound label was 
determined. Although such liquid phase separation methods are still co=on 
use solid phase procedures predominate in new assays because of their 
convenience. 
7.2 Solid ph a se systems. 
A survey of new assays or assay systems described in Clinical Chemistry over 
the last decade (Gosling 1990) shows that a relatively constant 10-20% of them 
are homogeneous. Of the remainder about 70% utilise some form of solid 
phase separation step and a wide range of solid phases have been employed. 
Some examples are listed in Table 7.1 
Solid Phase methods used in i=unoassay can be classified into two distinct 
groups based on mobile solid phase reagents, in which the solid phase is free 
to move in solution and stationary solid phase reagents where it is not. 
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Table 7.1 + 
Separation Method 
Solid Phase Adsorption 
Solid Phase 
Glass fibre membrane, Nylon membrane, Nitrocellulose 
membrane, Microtitre plate, Plastic tubes. 
Solid Phase 
Adsorption 
Indirect Biotin·antibody, Solid phase-avidin, FITC-antibody, 
Solid Phase Precipitation 
+ Goslmg 1990 
Solid phase -anti FITC, Microtitre plate-second antibody. 
Porous Glass Bead-Pro A 
Ferromagnetic bead-antibody, Microbead-antibody, Microbead-
second antibody, Microbead-Protein A. Staphylococcus aureus-
ProteinA. 
7 .2.1 Mobile solid phase reagents. 
Multiple polysaccharide particles or "microbeads" such as agarose 
(Hamilton et aL,1980), cellulose (Light et aL,1977) and dextran (Wzde et 
aL,1966) have been employed in solid phase immunoassays. These 
carbohydrate particles are readily activated with cyanogen bromide to 
covalently couple proteins. In some solid-phase assays the use of first or 
second antibody conjugated to "microbeads" acts largely to accelerate 
precipitation of the immune complex. However, mainly because of the 
need to carry out a centrifugation step the use of multiple polysaccharide 
particles in new solid phase assays has fallen from a peak of 40% in the 
mid 1980's to less than 10% today. In an attempt to overcome this 
drawback ferromagnetic microbeads have been developed which 
sediment with an electromagnet (Sturgess et aL,1986). These particles 
which also offer large surface to volume ratios have had continual 
popularity over the decade, being found in about 10% of new solid 
phase assays. A number of other particles including precision moulded 
plastic balls (Helenius et aL,1986), liposomes (Kung et aL,1984), latex 
particles (Masson et al1983) and red blood cells (Boros et al., 1983) have 
had limited use as solid phases. A group of binders that are becoming 
more widely used as solid phase reagents are the bacterial Fe receptors 
(Boyle et aL,1987), most notably protein A and Protein G. These 
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receptors bind the Fe region of many immunoglobulins, some with high 
affinity as explained in 2.1. This specific binding to immunoglobulins 
permits their extraction from the fluid phase incubation mixture of an 
immunoassay by protein A bound to microbeads (Moran et aL,1978) or 
intact Staphylococcus cells (Harper et aL, 1982). 
7 :1.:1.. Stationary solid phase reagents. 
Stationary solid phases have been introduced in an attempt to eliminate 
centrifugation, simplify the chemistry of the binding reaction and 
automate the assay. Microtechniques of coating antibody on capillary 
tubes (Zick et aL, 1980), glass rods (Hamaguchi et al,1976) or 
chromatography tubes (Pick et aL, 1980) have not been widely employed. 
Antibody coated plastic tubes (Schwartz et aL, 1985) were used in about 
15% of new solid phase assays in the early 1980's but their use has 
declined to about 5% today. The cause of this decline and the reduction 
in use of most other solid phase reagents has been the widespread use 
of 96 well plates and strips of similar wells (Sataguchi et fll., 1989). The 
growth in the use of microtitre wells has been steady, increasing from 
about 15% in the early 1980's to about 70% of new solid phase assays 
at the end of the decade and reflects the move to increased automation. 
More recently membranes, either activated for covalent binding or 
inactivated for adsorption of antibody or antigen have become more 
important, particulary in immunoassays formulated for over-the-counter 
sale, such as pregnancy testing kits (Brown 1987). Glass fibre (Brown 
. 
1987), nitrocellulose (Pappas et aL, 1983) and nylon (Anderson, et al., 
1986) are the most commonly used membranes materials. 
In addition, to the stationary solid phase reagents, mobile solid phase 
reagents have been used in an immobilised manner. Microbeads or 
porous glass beads with antibodies (Locascio-Brown et aL,1990) or 
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protein A (Phi/lips et aL, 1985) immobilised on their surface have been 
packed into chromatography columns and used to capture analytes 
flowing through the column. 
7.3 Selection or solid phases for investigation. 
It was decided to investigate two approaches to a solid phase assay, the first 
would involve the laying down of antibody onto a membrane and then using 
the fluorescent cyclosporin conjugates synthesised in 4.2 in a competitive 
immunoassay. Secondly, it was decided to immobilise cyclosporin onto 
activated control pore glass beads and then use fluorescently labelled 
antibodies in a competitive immunoassay for free and solid phase cyclosporin. 
7.4 Studies on a membrane immunoassay. 
Four types of porous nylon 66 membrane were chosen for investigation, each 
of which had different protein binding properties based on the surface 
chemistry characteristics of the membrane. 
Biodyne A - 0.45J.Im pore size 
An unmodified nylon 66 membrane with amphoteric surface chemistry due to 
an equal distribution of amine and carboxyl groups. 
Biodyne B - 0.45J.Im pore size 
A surface modified nylon 66 membrane with cationic surface chemistry due 
to a high density of quartenary anunonium groups. 
Biodyne C - 0.45J.Im pore size 
A surface modified nylon 66 membrane with anionic surface chemistry due to 
a high density of carboxyl groups. 
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Irnmunodyne - 0.45~m pore size 
A nylon 66 membrane with a chemically preactivated surface showing a high 
density of covalent binding sites. The primary reactivities are with amine 
groups at alkaline pH, carboxyl groups at acid pH and hydroxyl groups at 
neutral pH. 
All four membranes have intrinsic hydrophobicity, near uniform pore size, 
compatibility with a wide range of solvents and a 5000:1 ratio of reactive 
surface area to total volume. 
7.4.1 Uptake of MAb by the immunodyne membrane. 
Preliminary investigations were carried out to study the uptake of MAb 
on the Irnmunodyne membrane and to optimise the antibody loading for 
use in an immunoassay. It was decided to spot load the MAb onto the 
membrane and visualise the bound material with FITC labelled anti-
mouse IgG. 
MAb was prepared in PBS at 5 mg/rnl for spot wetting of MAb onto the 
membrane. The manufacture recommends 1 /.lg applied in 1-3 1-11. 
Therefore 2 ~1 applies 1 ~g of MAb. 
FITC-IgG was obtained with a protein content of 15.7 mg/rnl and a 
FITC:IgG ratio of 3:1. Dilutions of the stock solution were made into 
PBS to 10 rnl aliquots of 1:20, 1:32 and 1:64 dilution. 
Blocking of non-specific binding was achieved using a 0.5% casein in 
PBS solution that had been passed through a 0.45 ~m rated filter to 
remove aggregates. 
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Three strips of membrane were prepared with dimensions of 6 cm x 1 
cm, each strip was divided into six 1 cm squares and labelled as follows: 
S1RIP A (B or C) .__I A_o__._l_1 ___._12_..._13____,_1_4 ___._Is____. 
Using a 2 JLl fixed volume micropipette aliquots of MAb were applied 
to each square as follows: 
Square Label 
0 1 2 3 4 5 
PBS applied/ JLl 10 8 6 4 2 0 
MAb applied I JL1 0 2 4 6 8 10 
MAb applied / JLg 0 1 2 3 4 5 
Aliquots of PBS were applied as required to ensure that each square 
received the same volume of liquid. After the strips had been loaded 
with MAb they were allowed to air dry for 60 minutes and then placed 
in 15 ml of 0.5% casein solution and agitated on a rotary shaker for 30 
minutes at room temperature. After this the strips were washed in three 
changes of PBS for one minute each wash and then allowed to air dry. 
One strip was then placed in each of the FITC-IgG dilutions prepared 
above and agitated on a rotary shaker for 60 minutes at room 
temperature. After this they were removed and washed in two changes 
of 0.1% Tween 20 in PBS for 10 minutes each wash. The tween solution 
was then replaced with two changes of PBS and finally two changes of 
distilled water, all for 10 minutes each wash. The membrane strips were 
removed, air dried and the bound fluorescence measured. 
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Fluorescence measurements were made using a bifurcated fibre optic 
attachment with the fibre held just above the membrane. The 
fluorimeter settings were as follows: 
Ex 495 nm Em 525 nm Slits Ex 10/Em 15 nm 
The fluorescence intensity of each square was measured with the signal 
being integrated over a five second period. The results are shown in 
Fig Zl 
From the results it can be seen that for squares with 0-4 J.lg of MAb 
applied the 1:20 and 1:32 dilutions of FITC-IgG give very similar results 
but the 1:20 dilution gives a significantly higher value when 5 J.lg of MAb 
are applied. The 1:64 dilution follows the same trend as the other 
dilutions but with lower values for each square. The results for the 1:20 
and 1:32 dilutions of FITC-IgG seem to show that for squares with 
between 0-3 J.lg of MAb applied there is a linear relationship between 
the amount of MAb on the membrane and the measured fluorescence. 
This suggests that the FITC-IgG is in excess for both dilutions and able 
to saturate the membrane bound MAb and that all of the MAb applied 
to the membrane has been bound. When 4 J.lg of MAb is applied to the 
membrane the 1:20 and 1:32 dilutions still give the same fluorescence 
values suggesting that all of the MAb is being bound by the FITC-IgG 
but the increase in intensity has fallen below linearity. This implies that 
the amount of MAb being bound by the membrane is no longer 
increasing in a linear fashion, suggesting that the membrane is beginning 
to become saturated. At 5 J.lg of MAb applied the fluorescence value of 
the 1:32 dilution is not as high as for the 1:20 dilution suggesting that 
the 1:32 dilution is no longer in excess of the membrane bound MAb. 
The 1:20 dilution still shows an increase in fluorescence and is probably 
still in excess of the membrane MAb however, again the increase is no 
longer linear and seems to confirm the trend towards saturation of the 
membrane. 
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Fig Zl Uptake of MAb on immunodyne membrane. Vi ualisation with FITC-IgG 
at varying dilutions. 
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7.4.1.1 Calculation of signal:noise ratio. 
Using the zero square as the blank signal it was possible to 
calculate a signal:noise ratio for each quantity of MAb applied 
and for each FITC-IgG dilution. The values are shown in 
Table 7.2 
Table 7.2 
I Strip FITC-IgG 1 Signal:Noise Ratio for Each Square 
Dilution ~-------r-------r-------r-------r-------r-------
0 1 2 I 3 4 5 I 
A 1:20 1.5 2.0 2.7 2.8 3.2 
B 1:32 1.5 2.0 2.7 2.9 3.0 
c 1:64 1.5 1.9 23 2.3 2.7 
The results show that no real benefit is obtained by using the 
1:20 dilution in preference to 1:32 although both do appear 
superior to the 1:64 dilution. The poor values found are due to 
the high background signal caused by non-specific binding of 
FITC-IgG to the membrane, suggesting that the casein solution 
is not an effective blocking agent. 
7.4.1.2 Comparison of antibody binding on both sides of the 
membrane. 
It was decided to monitor the fluorescence intensity of both sides 
of the membrane and see how the uptake of MAb changes with 
increased quantity applied. It was reasoned that when the 
membrane becomes saturated with MAb the fluorescence 
intensity should be the same on each side. The strips prepared in 
7.4.1 were monitored on both sides of each square and the results 
are shown in Figs 7.2 to 7.4. 
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Fig 7.2 Uptake of MAb on immunoodyne membrane. Visualisation of both sides 
of the membrane with FITC-IgG 1:20 dilution. 
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Fig 7.3 Uptake of MAb on immunodyne membrane. Visualisation of both sides 
of the membrane with FITC-IgG 1:32 dilution. 
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Fig 7.4 Uptake of MAb on immunodyne membrane. Visualisa tion of both sides 
of the membrane with FITC-IgG 1:64 dilution. 
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As can be seen from the plots each FITC-IgG dilution follows a 
similar pattern with the fluorescence intensity of the reverse side 
equal to that of the top side when between 3 and 4 J.lg of MAb 
have been applied to the membrane. Unlike the fluorescence 
values on the top side the reverse side fluorescence does not 
increase in a linear manner. The increments up to 3 J.lg all show 
a progressively larger increase in fluorescence intensity, reflecting 
the increasing amount of MAb able to penetrate through to the 
reverse side of the membrane. At values above 3 J.lg the trend 
seems to suggest that a plateau is being reached indicating that 
the membrane is becoming saturated. These results for the 
reverse side of the membrane support the conclusion reached 
from the results of the top side, namely that there is a linear 
uptake of MAb when up to 3 J.lg is applied in 3 x 2 J.ll aliquots. 
Above this quantity not all of the applied MAb is being bound. 
It would therefore appear that for this application method 3 J.lg 
of MAb should be applied to the membrane since any more 
would lead to a waste of scarce material. In addition at this level 
all of the MAb should be covalently bound in a reproducible 
manner but at higher levels some variable binding to less 
accessible sites or non-specific adsorption may occur. This latter 
phenomena may explain the non-linear increase in binding when 
greater than 3 J.lg of MAb is applied to the membrane. 
7.4.2 Uptake of MAb by the biodyne membranes A, B and C. 
It was decided to investigate the uptake of MAb by adsorption onto 
three nylon membranes with different surface chemistry. Biodyne A has 
an amphoteric surface, Biodyne B has a positive potential and Biodyne 
C a negative potential as described in 7.4. It was decided to compare the 
uptake of MAb by these membranes with that of the immunodyne 
membrane which relies on covalent binding. 
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Experimental procedures were carried out as in 7.4.1 except that only 
the 1:32 dilution of FITC-IgG was prepared. The fluorescence intensity 
of the squares were measured as in 7.4.1 and the results are shown in 
Fig 7.5 
From the resnlts it can be seen that Biodyne B has very significant non-
specific binding which can be explained by charge attraction between the 
positively charged membrane and negatively charged protein. The high 
non-specific binding and negligible signal:noise ratio makes it unlikely 
that Biodyne B could be used in a solid phase immunoassay. From the 
graph it can be seen that Biodyne A reaches its maximum loading when 
2 ~g of MAb have been applied whereas Biodyne C still has increasing 
loading up to 5 ~g although the membrane appears to be saturating 
when greater than 3 ~g of MAb are applied. 
In order to compare these membranes with Immunodyne the signal: noise 
ratio of each was calculated as in 7.4.1.1. The results are shown In 
Table 7.3 along with the values for the Immunodyne with a 1:32 dilution 
of FITC-IgG. 
Table 7.3 
Membrane I 1 Signal:Noise for Each Square 
~--------r--------r--------r-------~-------
1 2 I 3 I 4 I 5 I I I 
Biodyne A 2.2 2.6 2.6 2.6 2.7 
Biodyne B 1.0 1.0 1.0 1.0 1.0 
Biodyne C 1.8 2.2 2.8 3.2 3.3 
Immunodyne 1.5 1.0 2.7 2.9 3.0 
With the exception of Biodyne B the results show that all of the 
membranes give very similar results at the optimum MAb loading of 3 
~g. although Biodyne A could be used with only 2 ~g of MAb applied. 
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Fig Z5 Uptake of MAb on biodyne membrane A, B, C. Visua lisation with 
FITC-IgG 1:32 dilution. 
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Both Biodyne C and Irnmunodyne give better signal:noise ratios above 
3 J.Lg of MAb applied, however the increases are not proportional and 
probably do not outweigh the disadvantage of using extra scarce MAb. 
From this point of view Biodyne A has an advantage but the naturally 
higher non-specific binding of this membrane may prove limiting. 
From the results it would seem that there is little to chose between 
Biodyne A. Biodyne C and lrnmunodyne, however, it is often advised 
that whenever possible covalent coupling of antibodies to a surface 
should be carried out (Chan 1987). This should avoid problems 
associated with poor absorption onto surfaces due to steric hindrance 
and electrostatic charge mismatching and should maximise the binding 
capacity of the solid phase. For this reason it was decided to use the 
Irnmunodyne membrane in further work to investigate the potential of 
a solid phase immunoassay for cyclosporin A 
7.4.3 Binding of derivatives to MAb immobilised on immunodyne. 
It was decided to use the fluorescent cyclosporin derivatives synthesised 
in 4.2 and investigate their binding to MAb immobilised on Irnmunodyne 
membrane. 
MAb was applied to the lrnmunodyne membrane as in 7.4.1 except that 
4 strips of Irnmunodyne membrane, dimensions 3 cm x 1 cm were cut 
and divided into 1 cm squares. On each strip 3 J.Lg of MAb were applied 
to two squares and the other left blank. 
Fluorescent conjugates were prepared in methanol at the following 
concentrations: BMDC - 13 J.Lg/ml; BMMC - 17 J.Lg/ml and 1RC - 9 
J.Lg/ml. For each derivative 250 J.Ll was taken and made up to 2 m! with 
PBS, this solution was then incubated with a membrane strip for 60 
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minutes on a rotary shaker at room temperature. The strips were then 
washed and dried as in 7.4.1 and fluorescence intensity values measured 
with fluorimeter settings as follows: 
&./nm Em/nm Slits 
BMMC 325 395 5/5 
BMDC 340 450 5/5 
1RC 545 585 5/5 
The results are summarised in Table 7.4 
Table 7.4 
Fluorescene Intensity on Square 
0 1 2 
BMMC 24.7 '28.5 27.6 
BMDC 21.6 25.5 24.1 
1RC 30.1 41.6 43.4 
The results show that for each derivative the non-specific binding values 
are almost as high as the sample values. Calculation of the signal:noise 
ratio for the derivatives gave the following values: BMMC- 1.1; BMDC 
- 1.1; 1RC - 1.4. From these results it would seem that the 1RC 
derivative shows the most promise for use in a solid surface assay. This 
is not surprising since interference due to light scattering and 
endogenous fluorescence is more significant at the wavelengths of the 
BMMC and BMDC derivatives. The poor signal:noise ratios observed 
again illustrate the problems of successfully blocking the membrane 
against non-specific binding. 
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7.4.4 The use of new immunodyne membranes. 
7.4.4.1 Introduction 
The Immunodyne membrane used in 7.4.1 was approximately 20 
months old and according to the manufacturer unless it is stored 
in a desiccator the functional groups involved in the covalent 
binding of proteins become hydrolysed by atmospheric water. 
This results in a reduction in binding capacity of the membrane. 
It was therefore decided to repeat the experiment of 7.4.3 using 
new Immunodyne membrane except that only the TRC derivative 
would be used. In addition, it was decided to investigate two 
methods of dissolving the 0.5% casein into solution. In the 
experiments reported in 7.4.1 and 7.4.3 the casein is dissolved 
into solution by heating to 50· C with stirring, however, the 
membrane manufacturer suggested that this method leaves 
relatively large casein aggregates in solution. As an alternative 
they suggested the following method. 
7.4.4.2 Preparation of 0.5% casein in PBS by adjustment of pH. 
A dispersion of 0.5% casein in PBS was prepared and stirred at 
room temperature, the pH was raised to pH 12 by dropwise 
addition of SM NaOH. When the solution cleared the pH was 
immediately lowered to pH 7.4 by dropwise addition of 2M 
NaH2P04• The casein solution was then filtered through a 0.45 
1-1m filter. 
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7.4.4.3 Experimental. 
MAb was applied to the new Immunodyne membrane as in 7.4.1 
except that of the four strips prepared two were blocked with 
casein prepared using the heat method and two with casein 
prepared with the pH method. 
The 1RC fluorescent conjugate was prepared in methanol at 9 
and 45 J.lg/ml and 250 J.ll of each was removed and made up to 
2 ml with PBS. One membrane strip from each of the blocking 
methods was placed in the 9 J.lg/ml 1RC solution and this was 
repeated for the 45 J.lg/ml solution. The solutions were then 
agitated on a rotary shaker for 60 minutes at room temperature 
after which the strips were removed, washed and monitored as in 
7.4.3. The results are summarised in Table 7.5. 
Table 7.5 
Membrane Strip : Fluorescence Intensity on Square 
~-------------r--------------r----------------
: 0 1 2 
H9 29.7 39.7 38.4 
H45 37.5 46.4 48.1 
P9 23.6 37.8 39.5 
p 45 30.4 45.1 47.6 
where H and P refer to blocking by the heat and pH methods 
respectively, and 9 and 45 refer to the concentration of 1RC used 
in the incubation of the membrane. 
The results show that an increase in concentration of 1RC results 
in increased non-specific staining of the membrane, regardless of 
which blocking method is used. However, the pH method does 
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result in lower non-specific binding values at both TRC 
concentrations. The signal:noise ratio for each membrane was 
calculated and found to be : H9 - 1.3; H45 - 1.3; P9 - 1.6 and P45 
- 1.5. These values show that a small improvement can be gained 
by using the pH method for preparing the casein blocking 
solution although in practical terms it is not really significant 
since a signal:noise ratio of 1.6 is less than adequate. The results 
also show that no advantage is gained by incubating with a higher 
concentration of TRC because higher sample signals are 
accompanied by a proportional increase in non-specific binding. 
Although the results are not encouraging the work has shown 
that it is possible to bind MAb to Immunodyne membrane in a 
reproducible manner and to use this bound MAb to capture 
fluorescently labelled cyclosporin. This interaction provides the 
basis of an immunoassay and suggests that a solid surface assay 
for cyclosporin should be possible. However, the major limiting 
factor in this development is the significant problem of non-
specific binding. Attempts to prevent this by blocking the 
membrane with casein appear unsuccessful and further work 
should investigate other blocking agents and different 
membrane/blocking agent combinations. 
7.5 Investigation of controlled pore glass beads as a solid phase for use in 
immunoassay. 
It was decided to investigate the use of controlled pore glass (CPG) beads as 
a solid phase in immunoassay by covalently linking 0-succinimidooxysuccinyl 
Thr cyclosporin to the bead surface and using fluorescently labelled 
antibodies in a competitive reaction between free and bound cyclosporin. As 
discussed in 4.2.2.1.3 this cyclosporin derivative forms covalent bonds with 
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amines in carbonate buffer. 
Alkylamine activated CPG beads were chosen as the solid phase to be loaded 
with cyclosporin, however, o-succinimidooxysuccinyl Thr cyclosporin has no 
chromophore and so it would be difficult to follow its binding to the CPG 
beads. It was therefore decided to use fluorescein isothiocyanate (FITC) as a 
model compound since it also undergoes covalent bonding to amines in 
carbonate buffer and is highly fluorescent. FITC was prepared in carbonate 
buffer at the following molar concentrations: 10""3M, 1o-'M, 10""5M, 10-6M, 10 .. 
7M and 10-aM. Non activated CPG beads were used to determine non specific 
binding values. The FITC solutions were measured as follows: 
[FITC]/M Measurement 
10-aM Fluorescence Ex 495 nm, Em 525 nm, Slits 2.5/2 .. 5 
10""7M Fluorescence Ex 495 nm, Em 525 nm, Slits 2..5/2 .. 5 
10-6M Absorbance 
10""5M Absorbance 
104 M 1:10 dilution then 
Absorbance 
10""3M 1:100 dilution then 
Absorbance 
Because of the extremely wide range it was not possible to use fluorescence 
detection for each FITC concentration without making very large dilutions to 
overcome quenching problems. In order to avoid the errors resulting from 
making very large dilutions it was decided to use absorbance measurements. 
However, the 10""7M and 10-SM solutions were too dilute to give absorbance 
values and so they were measured by fluorescence. In addition, the 1o-'M and 
10""3M solutions required 1:10 and 1:100 dilutions respectively in order to bring 
them into the absorbance range. 
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7.5.1 Labelling of the CPG beads with FITC. 
Initial measurements of each FITC concentration were made and then 
1.5 ml of each was added to 100 mg of activated CPG in a small glass 
bottle. The bottles were agitated on a rotary shaker at room temperature 
and the uptake of FITC was monitored by removing and measuring 
aliquots at time intervals. Non activated CPG beads were treated in the 
same way to monitor non-specific binding . Measmements of each 
aliquot were made according to 7.5 and the results are smmnarised in 
Table 7.6. 
Table 7.6 
Sample 1 Values ~---------,------------------------,----------------------
; 1
0 ~---------,:~~----------~------,--~~~---------1 I NSB I Acttvated I NSB I Actwated 
to -!M 9606 6.37t 0733 5727 0802 
to-\!: 97B7 75.59 33t0 5072 3464 
10~ 0086 0090 00t6 0092 0020 
to--\1: 0830 0842 Ot67 0867 0 t89 
to-\! 0835 0833 Ot78 0835 02t3 
to-\.! 0854 09t0 Ot94 0898 0245 
It can be seen from the results that using the more sensitive fluorescence 
measmement at 10-7M and 10-SM there is significant non-specific 
binding, although the uptake of FITC even after 20 hours is considerably 
less than with the activated beads. However, at higher concentrations 
there is no measurable non-specific binding suggesting that there is only 
a very small amount of FITC non-specifically bound to the beads and 
this is too small a difference to be seen using absorbance measurements. 
It was decided to calcnlate the percentage change from the initial value 
of each solution in order to normalise the results. The values are shown 
in Fig 7.6. 
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Fig 7.6 Uptake of FITC by activated (A) and control (C) CPG beads with time. 
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The plot shows that for every FITC concentration the alkylamine 
activated beads covalently bind considerably more FITC than the non 
activated beads absorb. In addition it would appear that maximum 
binding to the activated CPG occurs within two hours for all FITC 
concentrations. In contrast the 10-7M and 10-SM solutions show an 
increase with time for the non-specific binding of FITC to the control 
beads. The results seem to suggest that at concentrations above 10-7M 
the non-specific binding of FITC to CPG beads is negligible. 
Assuming a linear relationship between a percentage change in 
measured quantity and a percentage change in concentration it was 
possible to calculate the concentration of FITC in the incubation mixture 
at two and twenty hours. The results are shown in Table 7.7. 
Table 7.7 
Sample : Concentration of FITC at Time, t f moljl 
~---------------------------r---------------------------1 I 
1 2hr 1 20hr 
~-------------r------------~-------------r-------------
: Control : Activated Control : Activated 
10-SM 6.63 X 10-9 7.6 X 10-10 5.96 X 10-9 8.3 X 10-10 
10-7M 7.72 X 1o-S 3.4 X 10-9 5.18 X 10-S 3.5 X 10-9 
1Q-6M 1.05 X 1Q-6 1.86 X 10-7 1.07 X 10-6 2.32 X 10-7 
10-5M 1.01 X 10-S 2.01 X 10-6 1.04 X 10-S 2.28 X 10-6 
104 M 9.98 X 10-S 2.13 X 10-S 1.00 X 104 2.25 X 10-S 
10-3M 1.07 X 10-3 2.27 X 104 1.05 X 10-3 2.87 X 104 
From these results the amount of FITC bound per 100 mg of CPG 
beads can be calculated as follows: 
[ FITC Bound] = [ Fl7t:']1' - [ FITC]' 
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This can be converted to JJg of FITC bound per 100 mg of CPG beads 
as follows: 
FITC bound = [Fl7C bound] x 1.5 x 389.4 x 106 
1000 llg 
The values were calculated for each FITC concentration and the results 
are plotted in Fig 7. 7. 
These results show that the alkylamine activated CPG beads bind FITC 
in a linear manner across the FITC concentration range. This suggests 
that the beads do not become saturated at these concentrations and that 
there are covalent binding sites available. 
To confirm the results obtained from the supernatant measurement it 
was decided to monitor the fluorescence of the CPG beads themselves. 
The FITC was decanted from each bead solution and the beads then 
washed in three changes of deionised water on a rotary shaker for 
fifteen minutes each wash. Each of the bead samples were then 
resuspended in 1 m! of carbonate buffer and transferred to a well in a 
microtitre plate. 
The excess buffer was then aspirated so that no fluid was above the 
beads. Each sample was then measured for fluorescence with a fibre 
optic probe fixed just above the surface of the beads. Fluorimeter 
settings were as follows: 
Ex 495 mn, Em 525 mn, Slits 10/10. 
In addition, pseudo absorbance measurements were taken by setting 
both excitation and emission monochromator at 495 nm and measuring 
the reflectance from the beads. The values obtained are plotted in Figs 
7.8 and 7.9. 
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Fig 7. 7 Uptake of FITC on activated CPG beads with varying FITC concentration 
and time. 
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Fig 7.8 Uptake of FITC on activated and control CPG beads. Determination by 
fluorescence. Ex 495 nm / Em 525 nm 
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Fig 7.9 Uptake of FITC on activated and control CPG beads. Determination by 
"absorbance". Ex 495 nm / Em 495 nm 
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From the plots it can be seen that the fluorescence measurements 
increase rapidly for those activated beads incubated with FITC over the 
range 10-SM to 10"5M. However, with FITC above 10"5M the fluorescence 
from the beads declines with increasing concentrations of FITC. This 
reduction in intensity is probably due to an increase in quenching, 
possibly caused by inner filter effects and an increase in steric 
hinderance as the density of FITC increases on the beads with higher 
loading. Although it is not possible to correlate the uptake of FITC with 
fluorescence intensity across the whole FITC range the very crude 
reflectance measurements seen in Fig 7.9 do seem to suggest an 
approximately linear trend. The reduction in reflectance values with 
increasing FITC concentration can be explained by an increase in 
absorbance at 495 nm as more and more FITC is loaded onto the beads. 
These direct measurements on the beads seem to support the results 
obtained above where the uptake of FITC by the alkylamine activated 
CPG beads was followed by monitoring the incubation liquid. 
Using the fluorescence intensity values it was possible to determine the 
signal:noise ratio at 10"5M FITC using the signal on the non activated 
CPG beads as the non specific binding, or noise value. 
The fluorescence signal on the activated beads was 416.3 whilst the non 
activated beads gave a value of 7.3 resulting in a signal:noise ratio of 
57:1. This value emphasises the excellent binding properties of the 
alkylamine activated CPG beads and the extremely low non specific 
binding characteristics. 
7.5.2 The binding and visualisation of cyclosporin to the activated CPG 
beads and visualisation using a fluorescent labelled antibody. 
Having established the binding properties of the alkylamine CPG beads 
using FITC it was decided to attempt to label the beads in a similar 
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fashion using 0-succinirnidooxysuccinyl 'fhr cyclosporin and to establish 
the success of this labelling using the cyclosporin specific monoclonal 
antibody conjugated to a fluorophore. 
7.5.2.1 The synthesis of fluorescently labelled antibody. 
7.5.2.1.1 Introduction 
It was decided to label the MAb with the fluorescent 
label .B-phycoerythrin which belongs to a class of 
proteins called the phycobiliproteins. These proteins 
contain bilin prosthetic groups which act as efficient 
light gathering centres in a wide variety of red algae, 
blue-green algae and cryptomonads (Glazer 1981). When 
released from their natural environment and purified 
phycobiliproteins are highly fluorescent and can exhibit 
quantum yields approaching unity (Oi et aL, 1982). In 
addition to high quantum yields the phycobiliproteins 
exhibit a number of other properties that encourage 
their use as a fluorescent label. 
It has been shown that phycobiliproteins can exhibit an 
extinction coefficient as much as thirty times that of 
fluorescein (Hemmila 1985). In general, they are acidic 
and carry a negative charge at neutral pH which along 
with their generally hydrophobic character helps to 
minimise non-specific binding problems. The bilins in 
phycobiliproteins are isolated from their external 
environment by a framework of polypeptide chains. This 
isolation results in fluorescence being independent of 
pH over a range of approximately pH 5 to pH 9 and 
being immune to collisional quenching. Finally, the 
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spectral properties of the phycobiliproteins enable 
measurements to be made at the red end of the 
spectrum, minimising the interference from endogenous 
fluourophores. 
For the above stated reasons and because of its wide 
absorption spectrum enabling large Stokes shifts it was 
decided to chose B-phycoerythrin to label MAb. 
7 .5.2.1.2 Experimental. 
Coupling buffer pH 6.8 was prepared as in ??. A 
solution of B-phycoerythrin (B-Phy) was prepared by 
exchanging 1.0 mg into 0.5 ml of coupling buffer. 
Similarly a solution of MAb, 1.0 mg in 0.5 ml of 
coupling buffer was prepared. 3 mg of 2-Iminothiolane 
hydrochloride (2-IT) was dissolved in 0.3 ml of coupling 
buffer and 2.5 mg of succinimidyl 4 -(p-
maleimidophenyl) butyrate (SMPB) was dissolved in 0.1 
ml of DMF immediately prior to the synthesis. 
To the B-Phy solution was added 50 tLl of a freshly 
prepared solution of 2-IT and the mixture stirred at 
room temperature for one hour. A the same time 8 tLl 
of a freshly prepared solution of SMPB was added to 
the MAb solution and the mixture stirred for two hours 
at room temperature. After each mixture has stirred for 
its respective time the thiolated B-Phy and the activated 
MAb were isolated by passing each mixture down a PD-
10 column and collecting the appropriate fraction. The 
two isolates were then mixed together and stirred at 
room temperature for eight hours. After this time 37 tLl 
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of 1 M dithiothreitol was added to quench the SMPB 
and after 30 minutes 25 mg of iodoacetamide was added 
to block remaining sulphydryl groups. The mixture was 
left stirring for fifteen minutes after which it was passed 
down a PD-10 column and the red fraction collected. 
1.5:1.:1. Isolation of B-Phy-MAb conjugate. 
The fraction collected from the PD-10 column contains excess B-
Phy and MAb in addition to the required conjugate and so to 
isolate this the mixture was applied to a Pharmacia XK16 
chromatography column, 88 x 1.6 cm packed with Sephacryl S300. 
The separation system was set up as in Fig 7.10 with the pump 
set at 0.3 ml/min, an injection loop of 150 ~1 and the fluorimeter 
set at : Ex 545 run, Em 575 run, Slits 10/15. The elution of 
conjugate from the column was monitored by passing the eluent 
through a flow cell in the fluorimeter and a typical profile is 
shown in Fig 7.11. 
Sephacryl S300 is a size exclusion gel and so the largest materials 
elute first, therefore the chromatogram shows that there appears 
to be three components in the conjugate fraction which is 
followed by the excess B-Phy. Although it does not show on the 
trace the excess MAb would elute after the excess B-Phy because 
of its size. The three conjugate peaks suggest that multiple 
conjugation has occurred with non-stoichiometric ratios of B-Phy 
and MAb. The profile of the chromatogram shows that the 
largest conjugate has the greatest fluorescence and that the 
smaller the conjugate the lower the fluorescence. 
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Fig 7.10 Chromatographic ystem fo r the eparation of the B-Phy-MAb incubation 
mixture. 
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Fig Zll Elution profile of tbe 13-Phy-MAb incubation mixture. 
Chromatographic conditions: Sephacryl S300 column; eluent 0.2M PBS pH 
7.4; flow rate 0.3 ml/min. Fluorescence detection Ex 545 nm / Ex 574 run 
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An estimation of the retention times of the conjugate peaks 
shows that each differ from next by 2000 seconds and that the 
smallest conjugate differs from the excess B-Phy by 2500 seconds. 
It may not be unreasonable to suggest that the smallest conjugate 
is a 1:1 ratio of B-Phy-MAb and that the addition of one MAb 
molecule to the B-Phy reduces its elution time by 2500 seconds. 
The fact that each conjugate elutes almost exactly 2000 seconds 
faster than the previous smaller one suggests an equal increase 
in size is occurring. If one MAb molecule, RMM 160,000 
decreases the elution time by 2500 seconds then, assuming no 
chemical interaction, the equal reduction in retention times 
between the conjugates may be due to there being a difference 
of one B-Phy molecule between each subsequent conjugate. This 
would mean that the conjugates would have a B-Phy:MAb ratio 
of 3:1, 2:1 and 1:1. It may also be possible that there are other 
conjugates, with excess MAb:B-Phy ratios for example which are 
underneath the elution peaks in Fig 7.11. However, it was not 
possible to increase the resolution of the chromatography to 
investigate this. The fraction of the mixture containing the 
conjugate peaks was collected as it emerged from the flow cell 
and stored in the fridge. 
7.5.2.3 Fluorescent profile of B-Phy-MAb conjugate. 
Using absorbance measurements at 545 nm the B-Phy-MAb 
conjugate solution was calculated to have a B-Phy concentration 
of 0.17 p.g/ml, however, because of the variable conjugate 
stoichiometry it was not possible to relate this to conjugate 
concentration. A 1:100 dilution of the conjugate mixture was 
made into PBS and the excitation and emission spectra obtained. 
These are shown in Fig 7.12 
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Fig 7.12 Excitation and e mission spectra for B-Phy-MAb in PBS pH 7.4. 
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7.5.2.4 The preparation and examination of cyclosporin labelled 
beads. 
Solutions of 0-succinimidooxysuccinyl Thr cyclosporin were 
prepared at 104 M, 10"5M and 10-6M by 1:20 dilutions into 
carbonate buffer from stock solutions prepared in dimethyl 
formamide. The B-Phy-MAb solution was used at 0.17 ~g/ml and 
0.017 ~g/ml in PBS. 
1.5 ml of cyclosporin solution was placed into a small glass bottle 
and to this was added 100 mg of alkylamine activated CPG 
beads, this was repeated for each cyclosporin concentration. Into 
a fourth bottle was placed 1.5 ml of a 104 M FITC solution in 
carbonate buffer and 100 mg of activated beads. Each bottle was 
agitated for two hours on a rotary shaker at room temperature, 
after which the supematant was aspirated and the beads washed 
with three changes of 5 ml of deionised water, 15 minutes each 
wash. After washing the supematant was removed and 1.5 ml of 
B-Phy-MAb added to each set of beads which were then agitated 
on a rotary shaker for two hours at room temperature. The whole 
experiment was repeated for each B-Phy-MAb solution and the 
fluorescence intensity of the supematant in each incubation was 
measured initially and after two hours. The results are 
summarised in Table 7.8. Fluorescence measurements were made 
as follows: Ex 545 nrn, Em 575 nm, Slits 10/15 for B-Phy-MAb 
at 0.017 ~g/ml and 10/10 for B-Phy-MAb at 0.17 ~g/ml. 
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Table 7.8 
Fluorescence intensity at time t 
I Sample 1 t0 t = 2 hours I I 
~------------r-------------1f------------r-------------
l I I I 
1 0.17mg/ml 1 0.017 mg/ml 1 0.17 mg/ml 1 0.017 mg/ml 
I I I I 
Control 425.1 125.2 18.16 10.62 
10~ 425.1 125.2 3.44 1.38 
425.1 125.2 5.93 2.80 
425.1 125.2 7.06 5.24 
These results show that although the supernatant fluorescence 
reduces considerably for the cyclosporin labelled beads it also 
does for the FITC labelled beads. This suggests that conjugates 
undergo considerable non-specific binding with the CPG beads 
and the results show that this is true at both B-Phy-MAb 
incubation concentrations. It can be seen that with increasing 
loading of cyclosporin onto the beads there is a slight reduction 
in the uptake of conjugate from solution. Although this is only 
minimal, it may help to suggest a reason for the poor results. It 
may be that the conjugation of the large B-Phy molecule or 
molecules to the MAb inhibits the binding site of the antibody 
and thereby reduces its affinity for cyclosporin. Therefore most 
of the binding of the conjugates to the CPG beads is non-specific. 
As the uptake of cyclosporin by the beads increases this acts to 
block the beads and so reduce non-specific binding of the 
conjugate. 
It would seem from these results that the use of activated CPG 
beads in the above format does not show much potential for 
incorporation into an immunoassay. The main problem again is 
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non-specific binding, although this may be minimised with 
efficient blocking procedures. Although the results suggest that 
it is possible to produce phycoerythin labelled MAb further work 
needs to be done to establish whether the antibody retains its 
avidity. In addition the reaction conditions should be optimised 
to maximise the production of conjugates with a 1:1 ratio of 
B-Phy: MAb 
207 
\ 
\ 
-----------------------------------------------
CHAPTER EIGHT 
CONCLUSIONS 
------------------------------------------
Quantitative analytical methods with antibodies (i.e. immunoassays) are integral 
to many clinical, pharmaceutical and basic scientific investigations. For numerous 
clinically important analytes, such as many hormones, lipoproteins, oncoproteins, 
pathogen antigens and specific antibodies, there are as yet no viable alternatives. 
With a continually growing requirement for better limits of detection, often at pg 
rn1·1 or lower levels and the presence in complex matrices, such as biological 
fluids, of a large number of possible interferents there is a demand for highly 
selective and sensitive analyses. 
Traditional chromatographic techniques are often seen as the alternative to 
immunoassays and generally are more specific, each analyte being identified by 
its characteristic retention time in the colunm. The greatest advantage of 
chromatography over immunoassay is the ability to determine multiple analytes 
in the same analytical run. However, chromatographic methods are not as 
sensitive as immunoassays, but even when this criteria is not a problem 
immunological methods are often used because of their speed, simplicity and 
relatively low cost. This trend has been greatly encouraged by the availability of 
convenient reliable commercial kits. 
The need for routine therapeutic drug monitoring of cyclosporin has led to the 
development of a number of analytical methods for its determination. These 
methods must overcome a number of problems caused by the nature of the drug 
and its use. The therapeutic window - those concentrations of parent drug in the 
blood required to give immunosuppression but which produce minimum toxicity -
is narrow. Methods must therefore be accurate, reproducible and capable of 
routine use. The toxicity of the drug and attempts to overcome this has meant 
that blood levels of the drug have been reduced, especially so when cyclosporin 
is used together with other immunosuppressants. This requires the methods to 
have good sensitivity, perhaps even down to pg rn1·1 levels. 
The rapid and extensive metabolism of cyclosporin and the inconclusive evidence 
concerning the ImmunosuppressiVe activity and toxicity of the metabolites, has led 
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to the suggestion that analyses should be specific for the parent compound. 
However, because of the lack of information methods that isolate and quantify 
individual metabolites, plus the parent compound would be desirable. 
Finally, because of the nature of the immune response and the improved success 
of immune therapy an ever increasing number of patients are requiring 
monitoring over a prolonged lifetime. Consequently the rising demand for routine 
monitoring means that methods should be capable of handling high sample 
throughput, have the potential for automation and not be too technically 
demanding. 
When the project was established a number of aims were set out, these were: 
1. To synthesise and characterise novel fluorescent derivatives of cyclosporin. 
2. To evaluate their use with polyclonal and monoclonal antibodies. 
3. To investigate the possibility of an automated flow injection immunoassay 
for cyclosporin. 
4. To evaluate the potential of a "dip stick" type assay that ultimately could 
be used in out patient clinics and G.P. surgeries. 
To a large extent the first three aims of the project have been successfully 
fulfilled. Initial work to synthesise derivatives for use with polyclonal antibodies 
was showing good progress until it became obvious that the clinical requirements 
were for a parent compound specific assay (Shaw et aL, 1987). Nevertheless 
experience gained with this work helped in the rapid production of four novel 
fluorescent derivatives. Cyclosporin-C-hemisuccinate was chosen as the starting 
material to ensure compatibility with the monoclonal antibody and this was 
labelled with monodansylcadaverine (MDC), 4-bromomethyl-7-methoxycoumarin 
(BMMC), 4-bromomethyl-6,7-dimethoxycoumarin (BMDC) and tetramethyl 
rhodamine cadaverine (TRC). Of these the MDC derivative, because of its 
instability, and the BMDC derivative, because of its fluorescence quenching when 
antibody bound, were not used in the assay development. However, the 
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anomalous quenching effects seen with the BMDC derivative open up the 
possibility of a homogeneous assay relying on the thirty five fold increase in 
fluorescence when the derivative is displaced from the monoclonal antibody. 
Although both the BMMC and TRC derivatives showed promise only the TRC 
derivative was used in the assay development because of the advantages found in 
its spectral properties. 
The isolation and characterisation of the derivatives showed that the BMMC and 
BMDC conjugates were produced in good yields with high purity and that they 
were stable over a period of twelve months. In contrast the TRC derivative was 
shown to consist of at least two inseparable congeners and that although stable 
for twelve months when dried and frozen it deteriorated over a period of hours 
when in solution. These problems may well be solved by refining the method of 
synthesis, particulary by replacing the isotopic starting material with a pure 
compound when and if available. 
The problem of instability in solution was overcome by aliquotting the TRC into 
incubation tubes, removing the solvent and storing the tubes in a dry environment. 
Although intended as a remedial measure this method may have a number of 
advantages if incorporated into an assay kit. Firstly, the number of manipulations 
are reduced since the aliquotting of tracer into each incubation tube is not 
necessary. Secondly, the accuracy and precision of aliquotting the tracer should 
improve since this would be done automatically by the kit manufacturers. Whilst 
finally the convenience of part prepared incubation tubes and the reduction in the 
number of manipulations should reduce assay time. A natural continuation would 
be to include lyophilised antibody in the tube, perhaps in the form of a pre-
conjugate with the derivative which would then be displaced by the patient sample 
cyclosporin. 
As explained in chapter 2 flow injection analysis is a technique that is easily 
automated and lends itself well to immunoassays. The flow injection immunoassay 
for cyclosporin developed in this project was found to have a limit of detection 
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of 9.0 ng/ml and recovery at 50, 100 and 500 ng/ml added of 128.6, 103.0 and 
98.4% with coefficients of variations for the same samples of 9.1, 5.6 and 6.0% 
respectively. These results compare reasonably well with commercial cyclosporin 
assays although the values are for spiked cyclosporin standards in PBS/BSA For 
a true comparison more work needs to be done with whole blood samples, 
including patient samples containing metabolites and other interferents. To this 
end it may be necessary to utilise extraction procedures such as those used in 
HPLC analysis described in chapter 2, especially solid phase cartridge systems. 
However, the preliminary experiments described in chapter 6 suggest that the 
assay of whole blood samples by the reported method is possible. 
The flow injection immunoassay developed in this project and those methods 
currently available for routine monitoring of patient cyclosporin levels meet the 
above stated requirements with varying degrees of success. The methods divide 
into two basic techniques, immunoassay and HPLC, and in general terms each 
suffers from fundamental problems in the determination of cyclosporin. 
HPLC is a technically demanding and complex technique requiring extensive 
sample preparation prior to injection into the column. In addition most methods 
have run times in excess of 15 minutes, which when taken with the lengthy sample 
work up means that sample throughput is quite poor. Even when semi-automated 
methods are used (Lachno et al1990) only 50-80 whole blood samples can be 
processed in any working day, which is far short of the requirements of a busy 
monitoring centre. In comparison RIA analysis of whole blood samples using the 
Incstar, Cyclo-Trac monoclonal kit and a multiwell gamma counter allows for 200 
determinations in any working day (Harefield Hospital- private communication). 
The monoclonal TDx autoanalyser has a similar sample throughput to RIA with 
multiwell counting whilst the Emit enzyme assays claims to process 26 whole 
blood samples in two hours. In a typical working day this would approximate to 
100 samples processed. In contrast to these commercially produced immunoassays 
the flow injection immunoassay suffers from poor sample throughput, with only 
about 20 samples processed in any working day. Indeed this value will be even 
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less when extracted whole blood samples are used. However, because all of the 
immunoassays require a siiTillar preparation step this should not greatly influence 
relative sample throughput. 
The main difference between the non-isotopic assays is that the flow injection 
assay is a manual method whilst 'the commercial kits utilise automated sample 
handling and reagent addition. This enables them to incorporate very short 
incubation periods (75 seconds for the Emit assay), compared to the 10 minute 
incubation used with the flow injection immunoassay. In addition the commercial 
assays are homogeneous and so do not require a separation step prior to 
measurement. In contrast the flow injection immunoassay requires about 12 
minutes for a sample to be determined. 
It is obvious from these figures that for sample throughput to be increased to the 
levels of the commercial assays the time taken to process the extracted sample 
must be reduced. Work reported in section 6.2.15.4 showed that a five minute 
incubation between MAb and derivative gave adequate binding but with poor 
reproducibility. This problem may be due to errors in the timing of manipulations, 
which with short incubation times become increasingly more relevant. The use of 
an automated sample handling system should greatly reduce these errors and 
allow for the use of short incubation times, perhaps down to one or two minutes 
as with the Emit system. 
The other major contributor to the lengthy analysis time is the 12 minutes 
required to run the sample through the column and make a determination. 
Increasing the flow rate may significantly shorten this time, although this may be 
at the expense of sensitivity since work reported in 6.2.15.3 showed that the 
binding of antibody to the column decreased as the flow rate increased. An 
alternative approach would be to use a technique termed perfusion 
chromatography (Reneair 1990) in which high flow rates are combined with 
columns packed with polymeric beads of large surface area. It is claimed that 
protein A perfusion chromatography systems give a ten-fold reduction in run time 
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over other systems. If this method could be incorporated into the flow injection 
immunoassay system times of well under two minutes would be possible, which 
combined with two minute incubations should give a sample throughput well in 
excess of 100 per working day. 
A further fundamental problem with HPLC analysis for cyclosporin is related to 
the fact that the molecule lacks a chromophore and functional groups necessary 
for derivatisation. The absence of these features requires the use of short 
wavelengths for detection, usually around 210 nm but so many molecular species 
absorb in this region of the spectrum that background signals limit sensitivity. 
Thus many HPLC methods are characterised by poor limits of detection and few 
reach single figure ng/ml levels. With the trend towards combined immune 
therapy and hence lower blood levels of cyclosporin HPLC methods may be 
operating at the limits of their sensitivity. 
The commercial immunoassay kits have similar limits of detection in whole blood, 
the Cyclo-Trac SP RIA claims 13.8 ng ml-1 (Cyclo-Trac SP infonnation leaflet), the 
m. assay claims 25 ng ml-1 (Wang et al1990) and from only limited evaluation 
the Emit assay claims a limit of detection of 12-31 ng ml-1• In this respect the flow 
injection immunoassay compares favourably with a limit of detection of 9 ng ml'1, 
Although this was determined using standard solutions the design of the assay 
ensures that measurements are always made against the same buffer background 
and so the sample matrix should not adversely effect the sensitivity of the assay. 
Although the immunological methods do not show significantly better sensitivity 
than the HPLC methods quoted in 1.7.2.2 there is no doubt that immunoassays 
in general are capable of pg/ml detection limits and optimisation at these levels 
should be possible. However, the m. and Emit assays may not have detection 
limits as good as the RIA and flow injection immunoassay methods since in 
general homogeneous methods are not as sensitive as those incorporating a 
separation step. 
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The TD, RIA and flow injection immunoassay all operate over a calibration 
range of about 0-1500 ng/ml, whereas, the Emit assay only works between 0-500 
ng/ml. In most cases, where patients have stable cyclosporin levels or are on 
maintenance doses this is not a problem but in the period immediately post 
transplant and for crisis management during rejection episodes cyclosporin levels 
may well be above 500 ng/ml. This narrow working range may well limit the 
usefulness of the Emit assay in a clinical environment. 
A comparison of the accuracy and precision of the four immunoassay methods 
shows that the flow injection immunoassay performs only marginally less well than 
the commercial kits. The accuracy of the assays as determined from recovery 
studies, are remarkably similar. For the TD. recovery was 99.8% and 100.8% at 
100 ng and 250 ng added respectively (Yatscoff et at 1990), for the RIA for the 
results were 100.6% and 107.2% at the same values (Cyclo-Trac SP infonnation 
leaflet) and for the Emit method recovery was 99.0%, 94.8% and 99.2% at 75 ng, 
250 ng and 400 ng added respectively (Emit infonnation leaflet). In comparison the 
flow injection method gave recoveries of 128.6%, 103.0% and 98.4% of 50 ng, 100 
ng and 500 ng added respectively. The poor recovery of the 50 ng sample suggests 
that the assay performs less well at low cyclosporin concentrations perhaps 
because of poor optimisation of the calibration curve. In addition recovery studies 
for the commercial assays were carried out with 10 replicates compared to 5 for 
the flow injection immunoassay, which would be expected to improve the accuracy 
of the commercial assays relative to the flow injection immunoassay. 
Intra assay precision studies again show that the flow injection immunoassay 
performs almost as well as the commercial assays. The TD. assay shows% C. V. 
values of 2.1, 1.0 and 1.0 for ten replicates with mean values of 145, 393 and 785 
ng/ml (Yatscoff et a/1990), the RIA has % C. V. values of 10.0, 4.7 and 3.4 for 
twenty five replicates with mean values of 49.8, 188 and 728 ng/ml. (Cyclo-Trac 
SP infonnation leaflet). The Emit assay reports% C. V. values of 6.8, 5.0 and 7.1 
for twenty replicates with mean values of 82.3, 187.3 and 372.2 ng/ml (Emit 
infonnation leaflet) whilst flow injection immunoassay there are% C. V. values of 
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9.1, 5.6 and 6.0 for five replicates with mean values of 64.5, 103.0 and 492.1 
ng/rnl. Once again the relatively small number of replicates may well account for 
the differences in % C.V. values between the commercial and flow injection 
immunoassays. 
The fundamental problem with all of the immunoassay methods is their lack of 
specificity for the parent compound and on this point HPLC is the method of 
choice for absolute parent compound values. The RIA, Emit and flow injection 
immunoassays all share the same monoclonal antibody and so should not show 
any significant differences in specificity. The m. assay utilises a different 
monoclonal which shows rather higher cross-reactivity with metabolites, especially 
Ml7, Ml and M21 resulting in the m. giving relatively higher values (Yatscoff 
et al1990). 
It can be seen from these comparisons that the flow injection immunoassay has 
very similar performance characteristics to the commercially produced assays. The 
only major failing is the poor sample throughput, but incorporation of automated 
sample processing and more a rapid separation step should improve this 
dramatically. In addition, automation should improve precision and accuracy 
values as well as make the assay less labour intensive and more sUitable for 
routine use. 
A short project has recently been carried out (Jetha 1991) to investigate the 
feasibility of automating the assay. In this work a Drew Glycomat autoanalyser, 
which normally determines glycolated haemoglobin levels by ion exchange 
chromatography on miniature columns was adapted for use with protein A 
columns and set up for cyclosporin analysis. Preliminary results show that it is 
possible to assay for cyclosporin on the autoanalyser although some optimisation 
will be necessary and more work is required to fully assess the system. 
The final aim of the project, to investigate the potential of a solid surface "dip 
stick" assay for cyclosporin has not resulted in much success. In part this is due 
215 
----------------------------------
to the progress made with the flow injection method and the desire to produce 
a working assay. However, the problems of non specific binding to solid surfaces 
are notoriously difficult to solve, especially with small analytes such as drug 
molecules. 
The work carried out using nylon membranes showed that it is possible to 
immobilise antibodies and use these to detect cyclosporin in solution. However, 
the ratio of specific signal to background signal was found to be at a maximum 
of 1.6:1 for the covalent binding Immunodyne membrane; This value is very low 
and highlights the significance of the non-specific binding since the actual 
fluorescence detected was far from the limits of sensitivity of the instrument. 
The investigation onto the use of cyclosporin immobilised on glass beads and 
phycoerythrin labelled antibody was even less successful and indeed no specific 
binding could be detected. However, it may well be worth pursuing this approach, 
perhaps by immobilising cyclosporin on a membrane or other surface, since it is 
generally easier to synthesise fluorescent derivatives of antibodies than those of 
drug molecules. In addition the fluorescent properties of phycobiliproteins may 
lead to sensitive assays less susceptible to background interference whilst it is 
easier to block against non-specific binding when the object to be blocked is a 
large antibody molecule. More careful control of the antibody-label synthesis 
should also result in conjugates with higher avidity. 
Although the work investigating the potential of a solid surface assay did not 
produce very promising results it is an area that deserves further investigation. 
Different blocking agents and membrane/blocking agent combinations should be 
examined. The potential of a dip stick assay, allied with a cheap, portable 
fluorimeter would be enormous, allowing cyclosporin monitoring for those 
patients in the community on maintenance therapy to be carried out locally. In 
addition, such a test would allow for an expansion in the numbers of transplants, 
and the resultant cyclosporin therapy in developing countries where budgets and 
infrastructure make the currently available methodologies impractical. 
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